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Abstract 
Metabolic syndrome is a group of co-morbidities that, when combined, raise the risk 
of cardiovascular disease and type 2 diabetes. The syndrome is characterised by 
visceral obesity, hypertension, dyslipidaemia, fatty liver, impaired glucose tolerance 
and insulin resistance. A healthy diet is paramount to lowering these risks, including 
the consumption of whole foods, such as oats and coconut, to provide a multitude of 
nutrients that can achieve this. While understanding how individual nutrients impact 
health is important, when consumed these nutrients are taken together, so it is also 
important to understand how they work in synergy with each other, the food matrix 
that they are found in and other foods that are consumed with them. 
Methods: Male Wistar rats fed either a diet containing either cornstarch or a 
combination of high carbohydrate and high fat was supplemented with either 5% 
wholegrain oat groats, oat bran or β-glucan powder, 20% wholegrain oat groats, or had 
the saturated fat component replaced with coconut oil or coconut Nourish for the final 
8 weeks of a 16-week protocol. Cardiovascular, metabolic and physiological 
parameters were then measured to determine whether these products improved 
cardiometabolic biomarkers of metabolic syndrome. As oats contains prebiotic 
compounds that are beneficial to gastrointestinal health, the morphology of the small 
intestine and colon were also measured in the oat studies as was faecal short-chain 
fatty acid concentrations to quantify changes in the structure and function of the 
gastrointestinal tract. 
Results: Oats and coconut as whole foods attenuated metabolic syndrome markers. 
Wholegrain oat, oat bran and β-glucan powder improved glucose tolerance, systolic 
blood pressure and abdominal circumference. β-glucan powder also decreased 
triglyceride concentrations. All oat products improved duodenal morphology and 
wholegrain oat groats and β-glucan powder increased faecal short-chain fatty acid 
concentrations. Virgin coconut oil and coconut Nourish improved blood pressure. 
Virgin coconut oil decreased abdominal circumference and fasting glucose 
concentrations and coconut Nourish decreased total cholesterol concentrations. 
Conclusions:  The studies in this thesis provide evidence that different types of whole 
foods from the same cereal crop or fruit produce similar results in improving 
cardiometabolic biomarkers in this model of diet induced metabolic syndrome. They 
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also provided evidence that modulation of the gastrointestinal tract plays an important 
role in improving health parameters. The most likely mechanisms of these whole food 
components are through cardioprotective and hepatoprotective effects produced by 
anti-inflammatory responses and alterations to short-chain fatty acid production within 
the colon.   
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 – Whole foods as an intervention to prevent 
metabolic syndrome and gastrointestinal disorders. 
 
1.1 Introduction  
A healthy diet is the cornerstone of preventing cardiovascular disease and type 2 
diabetes, which together with hypertension, insulin resistance, dyslipidaemia and 
obesity make up metabolic syndrome (O'Neill and O'Driscoll, 2015). The benefits of 
consuming whole foods with a wide range of nutrients has been well studied (Tapsell 
et al., 2016, Sikand et al., 2015), as has the effect that processing has on bioactive 
components of food (Tosh and Chu, 2015, Decker et al., 2014, Marina et al., 2009b). 
The regular consumption of fruit, vegetables and wholegrains is advocated in 
Australian Dietary guidelines (National Health and Medical Research Council, 2013b) 
and is negatively correlated with the risk of developing chronic diseases (Liu, 2013b). 
Functional foods modulate biological processes such as regulating lipid metabolism 
through lowering LDL-C and triglycerides and increasing HDL-C (Sikand et al., 
2015).  While understanding how individual nutrients can impact health is important, 
when consumed these compounds are taken together, so it is also necessary to 
understand how they work in synergy with each other in a whole food. The additive 
and synergistic effects of phytochemicals and macronutrients within whole foods 
target numerous signalling pathways that reduce inflammation, decrease energy intake 
and target satiety hormones (Liu, 2013a).  
Isolated bioactive ingredients in human clinical trials have not given consistent results 
in the prevention of cardiovascular disease, due to loss of bioactivity or not behaving 
the same as when in a food matrix (Liu, 2013a). There is a complex mixture of 
phytochemicals in vegetables, fruits and grains and no single phytochemical can 
replace the combinations that are available. Each phytochemical or macronutrient 
differs in molecular size and solubility which affects its bioavailability and distribution 
in different macromolecules at cellular, organ and tissue levels (Liu, 2013a). The 
balanced combinations of these micro- and macro- nutrients that are found in 
functional foods cannot be mimicked by pills or tablets. It is generally considered safe 
to obtain antioxidants and phytochemicals from whole foods and not likely to result 
in toxic quantities as is possible with consumption of tablets or capsules of pure 
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phytochemical supplements (Liu, 2013b). For example, studies comparing tomatoes 
and one of its bioactive compounds, lycopene, show that tomatoes are more effective 
at decreasing LDL-C oxidation and lipid oxidation that lycopene supplements 
(Burton-Freeman and Sesso, 2014). Also eggs are high in cholesterol, which is 
typically bad for heart health, but also have high content of amino acids and other 
micronutrients which when combined with the cholesterol give a different effect than 
the cholesterol alone (Miranda et al., 2015). 
Diets that focus on one nutrient such as protein or carbohydrates have negative 
consequences. A trend in low fat, high carbohydrate diets led to the reduction of total 
fat consumption without considering the type or quality of fat that was consumed and 
conversely led to an increased intake of refined carbohydrates and added sugar to the 
diet which in turn led to an increase in cardiometabolic diseases (Malik et al., 2010). 
Previously, it was thought that replacement of polyunsaturated fatty acids in the diet 
with high saturated fats led to increased cardiovascular disease; however, this 
generalisation does not take into account the physiological actions of individual fatty 
acids (Poudyal and Brown, 2015). 
Foods known for their health benefits include wholegrains, fruits and seeds. 
Wholegrains have protective effects against obesity, type 2 diabetes, cardiovascular 
disease, hypertension and metabolic syndrome (Sikand et al., 2015). The functional 
components of wholegrains are the non-digestible complex polysaccharides known as 
soluble and insoluble fibre such as inulin, β-glucan and resistant starch, as well as 
phenolics and tocopherols which increase satiety and decrease energy intake through 
the modulation of GLP-1, PYY and ghrelin (Huang et al., 2011, Beck et al., 2009a, 
Beck et al., 2010).  
Further research on the health benefits of whole foods is warranted as it is more 
translatable to the human diet, due to the synergy of bioactive and macronutrients and 
that people consume whole foods rather than nutrient supplements. Research into both 
the mechanisms of action of the nutrients as well as whole food components is 
important, because nutrients make up food and there is an interactive relationship 
between the nutrients in the food.  
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This study investigated oats as a wholegrain and coconut as a fruit/seed to see if 
different parts of the whole food gave similar or different health benefits. Oats and 
coconut have been consumed for thousands of years (Akeret, 2005) with anecdotal 
evidence for a wide variety of health benefits. Many studies have been undertaken in 
recent years, particularly on the bioactive components, such as β-glucans in oats 
(Martínez-Villaluenga and Peñas, 2017, Ho et al., 2016, Varma et al., 2016) and 
saturated fats in coconut (Babu et al., 2014). Previous studies have utilised different 
methods and models to examine the benefits of both oat products and coconut 
products. This study is using the same model, a high-carbohydrate, high-fat diet-
induced rat model of metabolic syndrome (Panchal et al., 2011b), to examine different 
products produced from the two types of plants to determine whether they attenuate 
metabolic syndrome and the impact on gastrointestinal structure and function. 
 
1.2 Oats and its health benefits 
Cereal grains constitute a major part of the daily diet for consumers worldwide, with 
wheat, rice and maize as the highest consumed crops (Bushuk, 2001). The 
domestication of grains containing fibre and carbohydrates such as oligosaccharides 
and their incorporation into the human diet began approximately 12,000 years ago in 
the Neolithic era (Ladizinsky, 1995). Although the genetic makeup of these grains 
such as oats may have been modified since then to increase yield and ease of harvest, 
many of the available “ancient grains” are heritage or heirloom varieties of the more 
common cereals that are mass produced today (Ladizinsky, 1995, Sweeney and 
McCouch, 2007, Pingali, 2012). 
The human diet has changed dramatically since Neolithic times with increased 
consumption of processed high carbohydrate, high fat foods leading to chronic diet-
induced conditions such as metabolic syndrome (Brown et al., 2009, Sweeney and 
McCouch, 2007, Pingali, 2012). ‘Ancient grains’, such as oats, can be classified as 
prebiotics, as they contain non-digestible carbohydrates not digested in the stomach 
but fermented by colonic microbes to increase selected bacteria and benefit the host 
(Roberfroid et al., 2010, Slavin et al., 2013). The definition of prebiotics has been 
recently updated by International Scientific Association for Probiotics and Prebiotics 
(ISAPP) to also include non-carbohydrate substances such as polyphenols and 
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polyunsaturated fatty acids that are converted to conjugated fatty acids assuming that 
adequate evidence of health benefits in the target host are seen (Gibson et al., 2017). 
These grains may also be functional foods, defined as foods that can prevent or reverse 
health problems as well as providing nutrition. Dietary interventions with these grains 
may be effective in modulating the gut environment, changing microbial populations 
and ameliorating obesity and metabolic syndrome (Dixit et al., 2011), possibly through 
the alteration of gut hormones that work on various segments of the gastrointestinal 
tract (Willis et al., 2010, Klosterbuer et al., 2012). 
 
1.2.1 Composition of grain 
Cereal grains are the fruit or seed of plants belonging to the Poaceae (formerly 
Gramineae) family of grasses. This family includes wheat, rice, barley, corn, rye, oats, 
millet, sorghum, teff and triticale, as well as the ‘pseudo-cereals’ of amaranth, quinoa 
and buckwheat which function as cereals (Rebello et al., 2014).  
The American Association of Cereal Chemists International (AACCI) classifies 
wholegrain as “consisting of intact, ground, cracked or flaked caryopsis, whose 
principal anatomical components – the starchy endosperm, germ and bran, are present 
in the same relative proportions as they exist in the intact caryopsis” (Rebello et al., 
2014). The AACCI classifies a product as wholegrain if it contains 8 g or more 
wholegrain per 30 g of product, while the FDA states that more than 51% of the total 
weight must be wholegrain (Rebello et al., 2014). Wholegrains are a major source of 
calories and offer a variety of nutrients and other food components such as 
phytochemicals (Liu, 2007). They are associated with the prevention of type 2 diabetes 
(Venn and Mann, 2004, Murtaugh et al., 2003), cancer (Jacobs et al., 1998) and other 
chronic diseases (Dixit et al., 2011, Johnston et al., 2010, Opie et al., 2016).  
 
1.2.2 Oats  
Oats (Avena sativa) belong to the Poaceae family of about 12,000 species, commonly 
known as grasses. Oats have been cultivated since the Bronze Age, approximately 
5000 years ago, which followed the Neolithic Age, with the oldest known cultivation 
found in caves in Switzerland (Ladizinsky, 1995, Akeret, 2005) and south-eastern Italy 
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(Mariotti Lippi et al., 2015). Wild oats were discovered in Neolithic villages near the 
Dead Sea in Jordan (Kuijt and Finlayson, 2009, Weiss et al., 2006) indicating the 
importance of both wild and cultivated oats in the diet of humans.  
Oats are an important crop in developing nations as it requires fewer nutrients (sodium, 
potassium and phosphorus) to cultivate than wheat or maize (Rasane et al., 2013). 
However, it needs more moisture to produce a unit of dry matter than any other cereal 
crop except rice (Rasane et al., 2013). Due to this, it is well suited to cool and moist 
climates. Oats are grown throughout North America and Europe, particularly Russia, 
Canada and USA (Forsberg and Reeves, 1995). 
Historically, oats were used for animal feed (Menon et al., 2016). This use declined 
with mechanisation of the harvesting process, as there was less need for feedstock. 
However, the interest in oats as a human health food has increased (Ahmad et al., 
2010). The five largest producers of oats are Russia, Canada, Poland, Finland (both 
included in the European Union figures) and Australia (US Department of Agriculture, 
2012) with consumption mirroring the production as seen in Table 1.1.  
The composition and therapeutic potential of oats have been studied extensively in 
particular in relation to hypocholesterolaemic (Braaten et al., 1994), anti-diabetic and 
cardiovascular effects (Tiwari et al., 2011). Oats and oat products such as bran are 
good sources of proteins, fats, vitamins and minerals, as well as dietary fibre, 
particularly β-glucans for its cardioprotective benefits (AbuMweis et al., 2010). Oats 
decrease blood cholesterol concentrations and prevent heart disease as β-glucans are a 
water-soluble fibre preventing the absorption of cholesterol in the stomach and 
intestines (Chen and Raymond, 2008).  
The consumption of wholegrain oats is advocated in dietary guidelines and nutritional 
policies in many countries including USA (2010), Australia (2013), Canada (2011), 
Mexico (2006) and across South America, Europe and Asia (Clemens and van 
Klinken, 2014a). The 2015 American Dietary Guidelines suggest consuming at least 
half of all grains as wholegrains with three serves of 16 g/day to reduce the risk of 
developing several chronic diseases including cardiovascular disease, diabetes and 
possibly some cancers (U.S. Department of Health and Human Services and U.S. 
Department of Agriculture, 2015) .  
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Table 1.1 World oats production and consumption 2011-2016  
adapted From USDA, 2016. 
 
 
1.3 Nutrients in oats 
Oats are a nutritious source of protein, carbohydrate, fibre, vitamins and minerals, with 
minor constituents such as β-glucans that reduce cholesterol and lower the risk of heart 
disease (Peterson, 2011). The outer layer of a mature, wholegrain oat is unpalatable, 
dry and brittle; this is the hull (Figure 1.1) composed of cellulose and hemicellulose 
(Ganßmann and Vorwerck, 1995, Welch, 1995). It acts as protection and a nutrient 
transportation system to the developing grain (Welch, 1995). Once the grain fully 
develops, the outer layer becomes hard and unfit for human consumption. Removing 
World oats production and consumption (thousand metric tons) 
Country 2011/12 2012/13 2013/14 2014/15 2015/16 
      
Argentina 345 496 445 525 485 
Australia 1262 1121 1255 1087 1300 
Belarus 448 422 352 470 400 
Brazil 354 361 380 300 300 
Canada 3158 2830 3906 2979 3430 
Chile 451 680 610 421 470 
China 600 600 580 600 600 
European Union 7927 7909 8380 7845 7640 
Kazakhstan 258 200 305 226 250 
Mexico 51 84 90 90 90 
Norway 231 232 214 236 236 
Russia 5332 4027 4932 5267 4550 
Turkey 218 210 210 210 210 
Ukraine 506 630 467 610 375 
Others 372 315 328 315 349 
United States 728 892 938 1019 1300 
World Total 22308 21119 23502 22310 22095 
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this layer leaves the oat groat, which can be consumed. It consists of three main 
elements – the bran, starchy endosperm and germ (Figure 1.1) (Welch, 1995).  
The outermost layer of the oat groat is composed of the bran. Unlike wheat bran, oat 
bran is harder to define. The AACCI defines it as “the food which is produced by 
grinding clean oat groats or rolled oats and separating the resulting oat flour by sieving, 
bolting, and/or other suitable means into fractions such that the oat bran fraction is not 
more than 50% of the original starting material and has a total β-glucan content of at 
least 5.5% (dry weight basis) and a total dietary fibre content of at least 16.0% (dry 
weight basis) and such that at least one-third of the total dietary fibre is soluble fibre” 
(Robert et al., 1985). This layer provides protection to the grain and is a rich source of 
fructans with small amounts of resistant starch (Bernstein et al., 2013), as well as being 
the largest source of vitamins and minerals (Peterson et al., 1975, Frølich and Nyman, 
1988), phytates (Fulcher et al., 1981) and phenolics (Gray et al., 2000) in the oat grain. 
The outer layers (Figure 1.1) (epidermis, hypodermis, cross and tube cells, seed coat 
and nucellar tissue) are composed of insoluble polysaccharides, cellulose, 
hemicellulose, including arabinoxylans and lignins (Bernstein et al., 2013). The 
aleurone, which forms the interface between bran and endosperm, contains cellulose, 
hemicellulose, β-glucans, proteins, B vitamins, vitamin E, minerals, phenolics, 
alkylresorcinols, phytosterols and ferulic acid (Bernstein et al., 2013).  
The starchy endosperm (Figure 1.1) is the largest component of the grain, making up 
approximately 70% of the dry weight (Gulvardy et al., 2014). It contains cellulose, 
hemicellulose, including arabinoxylans, xyloglucans and glucomannans, as well as 
resistant starch, proteins, B group vitamins and iron (Bernstein et al., 2013). The 
highest concentration of protein is in the periphery of the endosperm and decreases 
towards the centre of the kernel, while the starch is concentrated more towards the 
centre and decreases towards the aleuronic layer (Miller and Fulcher, 2011). This layer 
is also rich in lipids, accounting for up to 90% of the total lipid content of the oat groat 
(Youngs et al., 1977). Most of the lipids are in the subaleurone and endosperm cells in 
the vicinity of the germ layer (Heneen et al., 2009).   
The germ layer (Figure 1.1) from which the grains germinate contains cellulose, 
fructans, lignans, fatty acids, B vitamins, vitamin E and minerals (Bernstein et al., 
2013). The protein in the germ is surrounded by lipids (White et al., 2006), and, 
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although rich in proteins and lipids, it only accounts for a small proportion of the 
overall amount (Miller and Fulcher, 2011). 
 
Figure 1.1 Diagram of the structure of an oat grain 
Left: oat panicle with many florets. Right: cross-section of an oat grain.  
from: Encyclopedia Britannica 2015, retrieved 12 March 2016. 
http://www.britannica.com/topic/oats/images-videos 
 
While oats contain a wide variety of nutrients, the exact composition depends on many 
factors including the cultivar, growing conditions, processing and storage time. The 
range of nutrients found in 28 different cultivars included protein content ranging from 
14.5 - 20%, lipids 4 - 8%, starch 53 - 63% and β-glucans 3 - 6% (Guo et al., 2014). In 
other cultivars, the protein may be as low as 13% with dietary fibre at approximately 
10% (Butt et al., 2008). 
 
1.3.1 Proteins  
Oat groats contain the highest amount of protein of any commonly consumed cereal 
grain, ranging from 12.4 - 24.5% (Lásztity, 1998). Oats have a unique amino acid 
composition of the protein fraction of globulins, albumins, prolamin and glutelin (Wu 
et al., 1972, Draper, 1973). Proportions of the protein fractions differ between grain 
9 
 
species, with wheat containing higher concentrations of prolamins and globulins than 
oats. 
1.3.1.1 Amino acids 
Essential amino acids are not synthesised in the body. For humans, these include 
histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan 
and valine. These amino acids need to be supplied from dietary sources. Non-essential 
amino acids can be synthesised by the body and include alanine, arginine, aspartic acid, 
cysteine, glutamic acid, glycine, proline, serine and tyrosine.   
The high globulin fraction in oats ensures that the key essential amino acids are in 
higher concentrations compared to other grains (Gulvardy et al., 2014). Lysine, is a 
limiting factor in the amino acid balance of grains. However, it is approximately 4.2% 
in oats, greater than in other grains except rice (Peterson, 2011). When examining the 
whole protein fraction, while glutamine is lower than other grains, the combined 
glutamine-glutamic acid content (25% of total protein) is higher (Gulvardy et al., 
2014). Overall, the amino acid balance in oats (Table 1.2) makes it a superior 
wholegrain than wheat and corn for overall protein quality (Pomeranz et al., 1973, 
Klose and Arendt, 2012).  
 
1.3.1.2 Globulins 
Compared to other cereal grains, oats have a high proportion of globulin-type storage 
proteins found in the starchy endosperm (Shewry and Halford, 2002). They account 
for up to 50-80% of total oat proteins (Gulvardy et al., 2014), compared to the 
proportion in wheat, rye and barley of approximately 5% (Shewry and Halford, 2002). 
The globulins are co-located with prolamins within the endosperm. 
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Table 1.2 Amino acid composition of oats, wheat, corn and rice 
adapted from (Gulvardy et al., 2014, US Department of Agriculture, 2012) 
 
 
1.3.1.3 Prolamins 
Oats contain a lower proportion of prolamins relative to globulins with ~ 15% 
compared to ~ 80% of total oat protein (Rasane et al., 2013). The prolamins in oats are 
primarily avenins with low solubility (Shewry et al., 2013) due to their low molecular 
weight. Prolamins have a high percentage of proline and glutamine with low levels of 
lysine compared to other cereal grain protein fractions (Capouchova et al., 2004). 
Prolamins constitute 4 - 15% of the total protein found in oats (Gulvardy et al., 2014, 
Amino acid Oats Wheat flour Corn meal Brown rice 
Essential amino acids (g / 100 g) 
Histidine 0.405 0.357 0.248 0.202 
Isoleucine 0.694 0.443 0.291 0.336 
Leucine 1.284 0.898 0.996 0.657 
Lysine 0.701 0.359 0.228 0.303 
Methionine 0.312 0.228 0.170 0.179 
Phenylalanine 0.895 0.682 0.399 0.410 
Threonine 0.575 0.367 0.305 0.291 
Tryptophan 0.234 0.174 0.057 0.101 
Valine 0.937 0.564 0.411 0.466 
Non-essential amino acids (g / 100 g) 
Alanine 0.881 0.489 0.608 0.463 
Arginine 1.192 0.648 0.405 0.602 
Aspartic acid 1.448 0.722 0.565 0.743 
Cysteine 0.408 0.275 0.146 0.096 
Glutamic acid 3.712 4.328 1.525 1.618 
Glycine 0.841 0.569 0.333 0.391 
Proline 0.934 2.075 0.709 0.372 
Serine 0.750 0.620 0.386 0.411 
Tyrosine 0.573 0.275 0.330 0.298 
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Janatuinen  et al., 1995) compared with wheat (40 - 50%), rye  (30 - 50%) and barley 
(35 - 45%) (Janatuinen  et al., 1995).  
The low proline percentage in oats makes it less immunogenic than wheat, however it 
can still be toxic to coeliac disease patients if ingested in large quantities (Wieser, 
1996). Prolamins are the fraction of the grain that is harmful to those with coeliac 
disease (Gulvardy et al., 2014). Oats do not have T-cell stimulating epitopes (Hardy et 
al., 2015) and do not contain α-gliadin unlike wheat, barley and rye (Moulton, 1959), 
which makes it suitable for coeliac disease patients (Janatuinen  et al., 1995). However, 
in Australia and New Zealand, it is not recommended for coeliac disease patients to 
consume oats, as it is a mid-season crop that could be contaminated by gluten 
containing grains (Coeliac Australia, 2015).  Oats also is not recommended for coeliac 
disease patients as some are sensitive to avenin (Coeliac Australia, 2015). 
 
1.3.1.4 Avenin 
Avenins are the prolamin component of oat seeds, existing as both monomers and 
disulphide-linked aggregates. Avenins, like other cereal prolamins, contain proline and 
glutamine and have a low solubility (Comino et al., 2015). In vitro studies of jejunal 
mucosa have shown that the avenin portion of oats contains only two units per 
molecule of the amino acid sequences proline-serine-glutamine-glutamine or 
glutamine-glutamine-glutamine-proline (Shewry et al., 1992). These two amino acid 
sequences are the constituents that may be toxic to the mucosa in the small intestine of 
coeliac disease patients. The molecular weight is lower compared to one molecule of 
wheat prolamin (gliadin) which contains five units of these amino acid sequences. 
While oats contain these sequences, there is no antigenic relation to wheat gliadin or 
barley hordein (de Ritis et al., 1988), which may explain why oats are less toxic to 
coeliac disease patients compared to wheat and barley (La Vieille et al., 2016).  
Evidence of gluten reactive T-cell activation following ingestion of oats is limited. 
In vivo studies show 10% of coeliac disease patients have an activation of avenin 
specific T-cells with the ingestion of oats (Hardy et al., 2015). These T-cells are cross-
reactive with hordein proteins from barley. In an ex vivo challenge with barley, these 
T-cells that are capable of being activated by avenin peptides were activated, yet with 
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oats there was only a weak antigenic stimulation (Hardy et al., 2015) indicating that 
the avenin-reactive T-cells were activated by the consumption of barley not oats 
(Hardy et al., 2015). Further studies have indicated that oat consumption is safe for 
most coeliac disease patients including children (Högberg et al., 2004, Gatti et al., 
2013). 
 
1.3.1.5 Glutelin 
Glutelins make up between 5% and 66% of the total protein in oats (Robert et al., 
1985). Measurement of this fraction is difficult as they are hard to solubilise completely 
and are dependent on the extraction solvent and solvent concentration (Robert et al., 
1985). Other studies have found that they are less than 10% of the total fraction 
(Gulvardy et al., 2014). 
 
1.3.1.6 Albumin 
The most common protein within the oat grain is water-soluble albumin. It is 
approximately 1 - 12% of the total oat protein fraction (Lásztity, 1998). Processing of 
oats leads to degradation of oat proteins into smaller peptides and amino acids in the 
globulin, prolamin and glutelin fractions, although proteins increased in the albumin 
fraction (Klose et al., 2009, Klose and Arendt, 2012). Most metabolically active 
proteins are found in the albumin fraction, which may account for this increase. In 
general, albumin and globulin have a higher lysine content, and the higher content of 
these two proteins and a lower content of glutamic acid and prolamin than other cereal 
grains (Lásztity, 1998) may make oats as a suitable dietary component for coeliac 
disease patients. 
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1.3.2 Oats fibre and other carbohydrates 
1.3.2.1 Fibre 
Fibre is an integral part of the diet, as it is beneficial in the control of most signs of 
metabolic syndrome (Delzenne and Cani, 2005, Davy and Melby, 2003). In both 
humans and animal models, dietary fibre regulates body weight, food intake, glucose 
homoeostasis, insulin sensitivity and cardiovascular disease markers, including serum 
lipid concentrations, hypertension and inflammatory markers (Davy and Melby, 2003, 
Delzenne and Cani, 2005). Foods with higher concentrations of dietary fibre have a 
positive effect on obesity, cardiovascular disease and type 2 diabetes (McKeown et al., 
2004, Sahyoun et al., 2006). 
Dietary fibre in all foods, including oats, has many physiochemical characteristics and 
properties (Galisteo et al., 2008), including increasing viscosity in the upper 
gastrointestinal tract (Drozdowski et al., 2010, Shimoyama et al., 2007), fermentation 
in the colon (Bednar et al., 2001, Topping and Clifton, 2001) and prebiotic effects 
(Gibson et al., 2017). Not only does fibre alter gastrointestinal function by improving 
laxation and increasing stool bulk, fibre also has metabolic significance by enhancing 
serum lipid concentrations and postprandial glycaemia as well as promoting satiety (El 
Khoury et al., 2012).  
By combining different fibres, the chemistry of food is altered, and many have 
differing effects based on concentration and type of fibre present (Bernstein et al., 
2013). However, due to this complexity, it has been difficult to define which 
mechanisms exert the beneficial effects on metabolic syndrome. Soluble gel-forming 
fibres, such as β-glucans, regulate metabolic disturbances through mechanisms linked 
to this gel-forming capability (Galisteo et al., 2008) as well as their fermentability in 
the colon (Galisteo et al., 2008), while non-viscous insoluble fibre ameliorates these 
disturbances via other poorly understood mechanisms (Galisteo et al., 2008).  
Dietary fibre is characterised based on the solubility in a buffer and enzyme solution 
similar to those found in the human gastrointestinal tract (Cho et al., 1997). Insoluble 
fibre, such as cellulose, resistant starch and some hemicelluloses, increases faecal bulk 
and excretion of bile acids as well as having a laxative effect and decreasing intestinal 
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transit time (Cummings and Stephen, 2007). Soluble fibre, such as β-glucans, increases 
transit time by delaying gastric emptying and slowing glucose absorption (Cummings 
and Stephen, 2007). However, this is a generalised characterisation of fibre, as only 
soluble viscous fibre delays gastric emptying time and slow glucose absorption while 
non-viscous soluble fibre acts as a substrate for microbial fermentation in the colon 
(Wong et al., 2006). 
 
1.3.2.2 Soluble Fibre – Hemi-celluloses: arabinoxylans, β-glucans 
Hemicelluloses are polysaccharide fibres of the cell wall, of which the main ones are 
arabinoxylans and β-glucans, which are highly fermentable soluble fibres. These 
convey health benefits such as lowering cholesterol and stabilising post-prandial blood 
glucose concentrations (Bernstein et al., 2013). Pectins and arabinogalactans make up 
a small part of the cell wall, but no substantial contribution to health has been found 
for these components. Minor amounts of xyloglucans, glucomannans and 
galactomannans are also found (Bernstein et al., 2013). 
 
1.3.2.2.1 Arabinoxylans 
Arabinoxylans are found in a range of grains including oats, barley, sorghum, wheat, 
corn, millet and in the pseudo-cereals of quinoa and amaranth (Roubroeks et al., 2000, 
Damen et al., 2012, Bernstein et al., 2013). They are the major hemicellulose 
component of the cell wall of the starchy endosperm and bran (Ebringerova et al., 
2005). Arabinoxylans consist of a xylose backbone with arabinose side chains which 
attach randomly by 1α → 2 or 1α → 3 linkages (Roubroeks et al., 2000). The arabinose 
units bind water and assist in the production of viscous solutions and fermentation of 
short chain fatty acids (Damen et al., 2012). 
 
 15 
 
Figure 1.2 Structure of arabinoxylans 
  (US National Library of Medicine, 2016) 
 
Arabinoxylans (6 g/day or 12 g/day) decreased area under the curve for postprandial 
glucose concentrations by between 20% and 41%; however, this study only had 
12-participants (Lu et al., 2000). A small 6 - week study with 14 participants who 
included 15 g arabinoxylans in the diet showed decreases in plasma concentrations of 
glucose, insulin and triglycerides (Garcia et al., 2006). However, another 5 - week 
study with 15 g/day arabinoxylans in the diet showed no changes in blood lipids, body 
weight, fat mass or blood pressure (Johnston et al., 2010). A 3 - week study using 
arabinoxylan-oligosaccharide, a fibre produced through enzymatic manipulation of 
arabinoxylans, showed no effect on blood lipids (Cloetens et al., 2010, Damen et al., 
2012).  
Arabinoxylans may have health benefits when added to the diet. However, since most 
studies were of short duration with small sample sizes, the health claims for 
cardiovascular benefits have not been established, although it appears that 
arabinoxylans lower the glycaemic index when ≥ 7  g/day is consumed (Bernstein et 
al., 2013). 
 
1.3.2.2.2 β-Glucans 
β-glucans are a water-soluble, highly viscous fibre with high fermentability that is 
found mainly in oats and barley in similar concentrations (Brown et al., 1999). Oats 
contains more β-glucans than whole wheat, with 69% compared to 36%, and corn at 
23% (Gulvardy et al., 2014).  
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A major constituent of dietary fibre in both oats and barley is the β-1,3/1,4-glucan. The 
β-glucans consist of linear unbranched β – D - glucose with one 1β → 3 linkage for 
every three or four 1β → 4 linkages (Sundberg et al., 1996). β-glucans form long 
cylindrical molecules containing up to about 250,000 glucose units (Roubroeks et al., 
2000). 
                                                     
Figure 1.3 Structure of β-1,3/1,4-glucan 
(US National Library of Medicine, 2016) 
 
The mechanisms of the physiological effects of β-glucans may include increased 
viscosity, bile salt binding capacity or fermentability (Davidson and McDonald, 1998, 
Marlett et al., 1994) as the soluble fibre cannot be digested by humans but can be 
digested by various species of gut bacteria. β-glucans have a great potential in the 
treatment of diabetes (Chen and Raymond, 2008), certain cancers (Jacobs et al., 1998), 
high cholesterol (Braaten et al., 1994, Guo et al., 2014, Zhou et al., 2015) and to boost 
the immune system in immunocompromised patients (Volman et al., 2010). Many of 
these benefits appear to be due to β-glucans increasing satiety by modulating appetite 
regulating hormones, such as cholecystokinin (CCK), GLP-1 and PYY. Increases in 
postprandial CCK concentrations decreased insulin response and extended subjective 
satiety in overweight patients in a dose-related response from 2.16 g to 5.68 g/serve 
(Beck et al., 2009b). Plasma PYY increased after oat β-glucan ingestion, also in a dose-
related response between 2.2 g and 5.5 g/serve with a significant difference after 4 
hours between controls and the highest dose of β-glucan (Beck et al., 2009a). Another 
dose-related study showed that 2 g/serve lowered blood glucose concentrations, 4 
g/serve was needed for gastrointestinal effects including the release of appetite 
hormones, while 10 g/serve in a drink that had its viscosity lowered by β-glucanases 
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increased CCK and GLP-1 compared to a high viscosity version of the same drink 
(Beck et al., 2010). 
Many of the benefits gained from β-glucans depend on their molecular weight. β-
glucans induced changes in gut microbiota populations and abundance in a molecular 
weight-dependent manner (Wilczak et al., 2015, Wang and Ellis, 2014). Low 
molecular weight β-glucans at 3 g/day and 5 g/day failed to alter gut microbiota, while 
3 g/day of high molecular weight β-glucans increased Bacteroidetes and decreased 
Firmicutes. This change in microbial abundance correlated with improvements in 
cardiovascular risk factors, such as BMI, waist circumference, systolic blood pressure 
and plasma triglycerides (Wang et al., 2016). 
The processing of oats has an impact on the cholesterol-lowering ability of the β 
glucans, as it changed the structure and solubility (AbuMweis et al., 2010). The lipid-
lowering effects of β-glucans depended on the food matrix (Kerckhoffs et al., 2003).  
β-glucans have a wide range of physiological benefits depending on dose, form, 
molecular weight and carrier food, therefore continued studies are needed to clarify 
these interactions.  
In 2013, the European Union accepted two health claims for β-glucans: firstly, that 
they help control blood cholesterol concentrations and secondly, that they attenuate 
postprandial peaks in blood glucose concentrations following EFSA scientific opinion 
(EFSA Panel on Dietetic Products, 2011). In addition to this, the EU acknowledges 
that insoluble fibre improves the wellbeing of the stomach and gut, but has not accepted 
this as a health claim. The recommended daily intake of β-glucans in both the USA 
and Europe is 3 g/day which is 30  – 150 g oats/day as oats contain between 2 - 10% 
β-glucans depending on the component of the oat consumed (El Khoury et al., 2012). 
 
1.3.2.3 Insoluble Fibre - Cellulose and Resistant starch 
1.3.2.3.1 Cellulose 
Cellulose has little effect on concentrations of either blood lipids or glucose (Bernstein 
et al., 2013). However, cellulose adds to the faecal bulk and improves digestion within 
the colon. 
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1.3.2.3.2 Resistant starch 
Resistant starch is soluble and non-viscous fibre that has variable fermentability and 
as yet there are no established cardiovascular benefits (Johnston et al., 2010). Resistant 
starches found in the endosperm are composed of amylose, a linear glucose polymer, 
and amylopectin, a branched-chain glucose polymer.   
  
 
 
 
   
              
a) amylose                  b) amylopectin 
Figure 1.4 Structure of a) amylose and b) amylopectin  
(US National Library of Medicine, 2016) 
 
Resistant starch behaves as a dietary fibre as it remains undigested until reaching the 
colon. Resistant starch has four subtypes based on its structure and source, labelled 
RS1 - 4. RS1 is physically inaccessible to digestive enzymes and found in whole grains 
or partially milled grains (Haralampu, 2000). RS2 has the nature of a starch granule 
and comes in raw potatoes, bananas and legumes. Its nature is due to the tightly packed 
amylose and amylopectin chains within the granule (Haralampu, 2000).  RS3 has 
retrograded amylose and amylopectin in cooked and cooled foods, such as potatoes 
and bread (Haralampu, 2000). Retrogradation occurs when amylose and amylopectin 
are heated and then cooled, reforming a more crystalline structure with more hydrogen 
bonding than before heating, leading to greater gelatinisation of the starches and 
greater viscosity (Wang et al., 2015). RS4 comes about through chemical modification 
(Peterson, 2011). Each subtype has its own physical and chemical characteristics, and 
these influence the rate and site of fermentation in the gut.  
Resistant starch contents are lower in cereal flour than in wholegrains, possibly due to 
the encapsulation of the starch within the grain structure (Haralampu, 2000). Starch 
granule size plays a role in increasing digestibility as enzymatic reactions in smaller 
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granules are facilitated by the larger specific surface area (Tester et al., 2004). Oat 
starch has a granule size of between 3 - 10 µm (Delcour, 2010) compared to other 
cereals such as quinoa (1 - 2 µm), buckwheat (3-9 µm), teff (2 - 6 µm), sorghum (~ 20 
µm) and wheat (2 - 10 µm or 20 - 35 µm depending on variety) (Wolter et al., 2013). 
                        
Figure 1.5 Scanning electron microscope image of oat starch 
(Wolter et al., 2013) 
 
There is limited long-term data on the effect of resistant starch on glucose metabolism 
(American Diabetes Association, 2008). However, short-term studies indicate that RS2 
can improve insulin sensitivity, but not change body weight, visceral or liver fat 
deposits, or inflammation (Robertson et al., 2003, Maki et al., 2012). By consuming 
both resistant starch and β-glucans concurrently, post-prandial plasma glucose and 
insulin concentrations improve (Behall et al., 2006).  
Both the Dietitians Association of Australia and the National Institute of Medicine in 
the USA have given a guideline of daily fibre intake of 14 g/1000 kcal, which average 
at 25 g fibre/day for women and 38 g fibre/day for men (Food and Nutrition Board, 
2002, Dietitians Association of Australia, 2016). 
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1.3.2.3.3 Starch digestibility 
The rate of starch digestion plays a significant role in the physiological responses 
achieved through its consumption. The combination of starch granule size, the extent 
of gelatinisation, composition and structure (Tester et al., 2004), physical 
encapsulation of the starch within in the grain and the protein and lipid content within 
the matrix of the grain (Singh et al., 2010) control the rate of digestion. A higher 
gelatinisation temperature in oats, as well as sorghum and teff compared to wheat, 
leads to a lower predicted glycaemic index for these grains (Wolter et al., 2013). 
Digestion rates of oat grains by α-amylase are slower than other grains such as quinoa, 
buckwheat and teff due to its larger granule size (3-10 µm) which is comparable to 
wheat (which is bimodal with 2-10 µm – B - type, and 20-35 µm – A - type) (Delcour, 
2010).  
The composition of the starch found in the grain is also important as starches that are 
high in amylose have a highly compact structure decreasing the availability of surface 
area to enzymatic attack. Starches with increased amylopectin, a larger molecule with 
a larger surface area, are the preferential molecular target for α-amylase (Singh et al., 
2010). The higher amylose content in oats (20.5% dry weight) leads to a lower 
predicted glycaemic index (Wolter et al., 2013). The formation of amylose-lipid 
complexes impedes susceptibility to enzymes, and the higher lipid content of oats 
(7.5% dry weight) together with its high amylose may lead to an amylose-lipid 
complex hindering the enzymatic breakdown of starch (Wolter et al., 2013). Dietary 
fibre may also impede α-amylase actions by increasing the viscosity of the 
gastrointestinal contents (Sasaki and Kohyama, 2012). The presence of β-glucans in 
oats may lead to the reduced digestibility of starch by increasing viscosity resulting in 
decreased carbohydrate absorption in the gut (Rao and Tattiyakul, 1999).  
 
1.3.3 Lipids 
1.3.3.1 Fatty acids 
Oats have a relatively high fatty acid content compared to other cereal grains 
(Morrison, 1978, Youngs, 1986). Thirteen fatty acids are in the lipid fraction of the oat 
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endosperm (Table 1.3). Palmitic, oleic and linoleic make up 95% of the total, with 
myristic, stearic and α-linolenic being the other major contributors. Palmitoleic, 
arachidic, gadoleic, behenic, erucic, lignoceric and nervonic fatty acids are also present 
in minimal concentrations (Zhou et al., 1998). Australian oat varieties have shown 
medium chain fatty acid concentrations of 38 - 43% oleic, 36 - 40% linoleic and 
17 - 19% palmitic acids (Zhou et al., 1998), indicating that oats have mostly 
unsaturated fatty acids which may play a major role in realising the health benefits.  
 
Table 1.3 Fatty acid concentration of Australian oat varieties 
adapted from (Zhou et al., 1998) 
 
 
These medium chain fatty acids are rapidly absorbed, transported to and metabolised 
by the liver, which makes them similar to carbohydrates rather than other fats as there 
is less tendency for excess to be stored as body fat (Chwen et al., 2013). Medium chain 
Fatty acid           Common name % in Australian 
oat varieties 
Unsaturated 
16:1 Palmitoleic > 1 
18:1 Oleic 38 – 43 
18:2 Linoleic 36 - 40 
18:3 Linolenic 1 - 2 
20:1 Gadoleic >1 
22:1 Erucic >1 
24:1 Nervonic >1 
Saturated 
14:0 Myristic > 2 
16:0 Palmitic 17 – 19 
18:0 Stearic 1 – 2  
20:0 Arachidic >1 
22:0 Behenic >1 
24:0 Lignoceric >1 
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fatty acids stimulate intestinal mucosal growth and increased villi height which directly 
affect nutrient absorption by increasing the absorptive and surface area of the 
duodenum, jejunum and ileum (Chwen et al., 2013, Czernichow et al., 1996).  
 
1.3.3.2 Phytosterols 
Phytosterols (plant sterols) are chemically similar to cholesterol and compete with it 
for absorption from the gastrointestinal tract. Usual consumption of phytosterols does 
not affect this absorption; however, when consumed in higher amounts, phytosterols 
inhibits cholesterol production (Maki et al., 2003). The main sterols found in oats are 
sitosterol, sitostanol, campesterol and campestanol (Maki et al., 2003, Laakso, 2014). 
 
 
 
 
 
 
 
 
a)  sitosterol              b) sitostanol 
 
 
 
 
 
 
 
 
c) campesterol            d) campestanol 
Figure 1.6 Structures of oat phytosterols  a) sitosterol b) sitostanol 
c) campesterol  and d) campestanol   
(US National Library of Medicine, 2016) 
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1.3.4 Phytochemicals 
1.3.4.1 Phenolics 
Oats are a valuable source of phenolic compounds, generally derived from 
hydroxybenzoic acid and hydroxycinnamic acids, that may contribute to the nutritional 
and functional benefits (Rasane et al., 2013). The major phenolic acids in oats are 
ferulic, p-coumaric, caffeic, vanillic and hydroxybenzoic acids (Figure 1.7) and their 
derivatives (Mattila et al., 2005, Kova cova and Malinova, 2007). 
 
   
  
 
 
  
 
 
 
 
 
 
 
 
e) 4-hydroxybenzoic 
 
Figure 1.7 Major phenolic acids found in oats a) ferulic b) p-coumaric c)-caffeic 
d) vanillic  and e) 4-hydroxybenzoic acids 
(US National Library of Medicine, 2016, Sigma Aldrich, 2016) 
 
 
 
 
a) ferulic  b) p-coumaric  c) caffeic  
d) vanillic  
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1.3.4.2 Avenanthramides 
The avenanthramides are a unique group of antioxidants, found only in oats (Dimberg 
et al., 2001). There are over 20 different types of avenanthramides; however, the most 
abundant are 2c, 2p and 2f (Figure 1.8). The number 2 indicates that it is a 5 
hydroxyanthranilic acid derivative and the letter is the type of hydroxycinnamic acid 
attached, either caffeic, p-coumaric or ferulic acids (Dimberg et al., 2001). 
Avenanthramides are produced in greater concentrations in oat leaves that are suffering 
from salinity stress and crown rust (Oraby et al., 2017, Antonini et al., 2016).         
 Avenanthramides have antioxidant potential up to 30 times greater than vanillin and 
caffeic acid (Dimberg et al., 1993). They may be anti-inflammatory and 
anti-atherogenic, as they inhibit monocyte adhesion to endothelial cells, inhibit release 
of pro-inflammatory compounds from macrophages (Liu et al., 2004) and control 
blood pressure through increased production of nitric oxide and dilatation of blood 
vessels (Nie et al., 2006). Avenanthramides are more bioavailable in plasma, liver, 
heart and skeletal tissue in humans and hamsters than in rats (Koenig et al., 2011).  
Wild green oat extract (WGOE) contains high concentrations of avenanthramides. 
WGOE improved cognition a dose of 1600 mg in older adults of below average 
cognition (Berry et al., 2011). However, a dose of 1500 mg in older adults with normal 
cognition gave no change in any cognitive measure (Wong et al., 2012). These studies 
indicate that avenanthramides which suppress inflammatory cytokines by inhibiting 
NF-κB activation (Guo et al., 2008) and enhance nitric oxide (NO) production in 
smooth muscles (Nie et al., 2006) causing vasodilation may improve the function of 
systemic and cerebral arteries and have a potential role in the maintenance of 
cardiovascular health. 
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Figure 1.8 Structure of the most common avenanthramides in oats, a) 2c b) 2p 
and c) 2f 
(US National Library of Medicine, 2016) 
 
 
1.3.4.3 Vitamin E 
Oats are high in tocopherols, particularly α-tocopherol (Figure 1.9) which is found in 
its highest concentration in the germ, while the tocotrienols, mainly α-tocotrienol 
(Figure 1.9) with small amounts of β-tocotrienol, are mainly concentrated in the 
endosperm (Rasane et al., 2013). Of the total tocols in oats, 86 - 91% are α-tocotrienol 
and α-tocopherol (Rasane et al., 2013). The tocol composition of oat and barley is 
similar, with α-tocotrienol predominant. However, barley averages twice the total tocol 
content of oat (58 mg/kg compared to 26 mg/kg) (Peterson, 2001). In wheat, 
β-tocotrienol is predominant, with γ-tocopherol highest in corn (Barnes, 1983). 
δ-tocotrienol and γ-tocotrienol have hypocholesterolaemic effects. However, both of 
these are in low concentrations in barley and absent or with only trace amounts in oats 
(Peterson, 2001). The processing of oats leads to faster degradation of these 
compounds, with unprocessed groat tocols stable for over seven months at room 
temperature, but for only 1 - 2 months after processing (Peterson, 2001). For the tocols 
to be beneficial to health, relatively large amounts of oats need to be consumed 
unprocessed or as soon after processing as possible. 
 
 
a) avenanthramide 2c  b) avenanthramide 2p 
c) avenanthramide 2f 
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Figure 1.9 Structure of the most abundant tocols in oats  a) α-tocotrienol and 
b) α-tocopherol  
(US National Library of Medicine, 2016) 
 
 
 
 
 
1.4 Potential for metabolic syndrome and gastrointestinal health 
Cereal wholegrains, such as oats, containing a combination of fibre, protein, vitamins 
and minerals are digested more slowly than refined grains and have protective effects 
in the body potentially due to the stimulation of growth of appropriate gut bacteria. 
Wholegrains also generally maintain lower blood glucose concentrations and improve 
insulin response in the body (Honda et al., 1999). Subjects who consume higher 
amounts of dietary fibre have lower blood pressure and serum cholesterol 
concentrations, with reduced glycaemia and improved insulin sensitivity (Zhou et al., 
2015). These improved markers of health indicate lower risks of developing stroke, 
hypertension, type 2 diabetes, obesity and gastrointestinal diseases (Honda et al., 
1999). 
 
a) α-tocotrienol b) α-tocopherol 
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1.4.1 Metabolic syndrome 
Metabolic syndrome is associated with an increased risk of type 2 diabetes and 
cardiovascular disease. Co-morbidities such as hypertension, insulin resistance, 
dyslipidaemia, fatty liver and obesity make up metabolic syndrome. According to the 
International Diabetes Foundation, metabolic syndrome is defined as a combination of 
central obesity (waist circumference)  and two of high blood pressure, raised 
triglyceride concentrations, low HDL-C, high fasting glucose or diagnosed type 2 
diabetes or history of treatment for the above abnormalities (Parikh and Mohan, 2012).  
Other national health foundations, such as American Heart Association and the 
National Cholesterol Education program also had similar definitions although differing 
slightly. In 2009, these groups came together with a consensus definition as shown in  
Table 1.4.  
Additional symptoms may be considered when diagnosing metabolic syndrome, 
including abnormal uric acid metabolism, pro-thrombotic factors such as plasminogen 
activator inhibitor-1 and fibrinogen, inflammatory markers such as C-reactive protein, 
white blood cell count and endothelial dysfunction such as mononuclear cell adhesion 
and endothelial-dependent vasodilatation (Einhorn et al., 2003, Parikh and Mohan, 
2012). 
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Table 1.4 Consensus definition of metabolic syndrome 
NCEP ATP III: National Cholesterol Education Program Adult Treatment Panel III, 
AHA: American Heart Association; NHLBI: National Heart, Lung and Blood Institute; 
IDF: International Diabetes Foundation 
CRITERIA NCEP ATP III 
(2001) 
AHA/NHLBI 
(2004) 
IDF 
(2005) 
Consensus 
Panel (2009) 
Criteria Any 3 of 5 
criteria 
Any 3 of 5 
criteria 
Central 
obesity plus 
2 of the 
other 4 
criteria 
 
Any 3 of the 
5 criteria 
Central obesity 
(abdominal 
circumference) 
Men: > 102 cm 
Women: >88 
cm 
Men: >102 
cm 
Women: >88 
cm 
Population 
and country 
specific 
definitions 
Population 
and country 
specific 
definitions 
Hypertension ≥ 130/85 
mmHg 
≥ 130/85 
mmHg 
≥ 130/85 
mmHg 
 
≥ 130/85 
mmHg 
Dyslipidaemia 
(triglycerides) 
≥150 mg/dL 
(1.7 mmol/L) 
≥ 150 mg/dL 
(1.7mmol/L) 
≥150 mg/dL 
(1.7 
mmol/L) 
≥ 150 mg/dL 
(1.7mmol/L) 
Dyslipidaemia  
(HDL-C) 
Men: <40 
mg/dL (1.0 
mmol/L) 
Women: <50 
mg/dL 
(1.3 mmol/L) 
Men: <40 
mg/dL  
(1.0 mmol/L) 
Women: <50 
mg/dL 
(1.3 mmol/L) 
Men: <40 
mg/dL 
(1.0 
mmol/L) 
Women: 
<50 mg/dL 
(1.3 
mmol/L) 
Men: <40 
mg/dL 
(1.0 mmol/L) 
Women: <50 
mg/dL 
(1.3 mmol/L) 
 
Hyperglycaemia ≥110 mg/dL ≥ 100 mg/dL ≥100 mg/dL ≥ 100 mg/dL 
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1.4.2 Effect of oats on metabolic syndrome   
1.4.2.1 Anti-hypercholesterolaemic and anti-lipidaemic effects 
Dyslipidaemia is characterised by low plasma concentrations of HDL cholesterol and 
high concentrations of triglycerides, which indicate an increased risk of developing 
cardiovascular disease (Galisteo et al., 2008). Many studies indicate the 
hypocholesterolaemic effects of dietary fibre, particularly soluble fibre on blood lipids 
and cholesterol concentrations (Braaten et al., 1994, Maki et al., 2003). Oat proteins, 
lipids and phytosterols content may also play a role in reducing plasma cholesterol 
concentrations (Guo et al., 2014, Maki et al., 2003, Biel and Jacyno, 2014). 
Oats are known for their hypocholesterolaemic effects, with β-glucans as the most 
effective bioactive component (Braaten et al., 1994). A meta-analysis in 2011 found 
that β-glucans produced cardiovascular health benefits with between 2 - 10  g/day, the 
equivalent of 30 - 100 g of wholegrain oats/day decreasing total cholesterol and 
LDL-cholesterol concentrations (Tiwari and Cummins, 2011). β-glucans in both oats 
and barley decreased total cholesterol and LDL-C, however, only the β-glucans in oats 
increased HDL-cholesterol (Tiwari and Cummins, 2011, Ripsin et al., 1992). Barley 
β-glucans decreased LDL-cholesterol, and as the structure is very similar to that of 
oats, it could be suggested that the same may occur in a diet consisting of oats (De 
Angelis et al., 2015). The recommended daily intake (RDI) of 3 g/day of β-glucans 
revealed a modest decrease in total plasma cholesterol concentrations of 0.30 mmol/L, 
yet there was no additional change when the dosage was increased to above 3 g/day 
(Tiwari and Cummins, 2011).  
Although the fibre in oats has a hypocholesterolaemic effect, this is likely only to be 
slight (Brown et al., 1999). However, when wholegrain oats are the source of fibre, the 
overall effect is greater (Galisteo et al., 2008, Connolly et al., 2012), indicating the 
benefit is coming from more than just the fibre content. The satiation effects of both 
soluble and insoluble fibre may be the key to the cholesterol-lowering ability with an 
increase in bile acid excretion (van Bennekum et al., 2005, Fernandez, 2001). The 
viscosity of the fibre in the intestinal lumen has an impact on hepatic cholesterol 
metabolism and the synthesis of lipoproteins (Galisteo et al., 2008). This viscosity may 
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be the mechanism behind oats cholesterol lowering abilities as β-glucans increase the 
viscosity of digesta within the gastrointestinal tract.  Incretin hormones, such as GLP-
1, could have a hypolipidaemic effect (Kok et al., 1998). The incretin hormones control 
glucose homoeostasis and insulin secretion through the regulation of fatty acid 
synthase in the liver, which is enhanced by insulin (Kim and Egan, 2008) . However, 
this mechanism still requires further clarification regarding responses to oats.  
 
1.4.2.2 Anti-glycaemic effects 
The glycaemic index is the incremental area under the curve (AUC) of blood glucose 
concentrations occurring upon ingestion of a carbohydrate-containing food relative to 
glucose as the reference food (GI glucose = 100) (Wolter et al., 2013). Food are 
classified as low (> 55, such as legumes, nuts, dairy, pasta), intermediate (55 - 70, such 
as muesli, different types of bread) or high GI (> 70, such as wholemeal barley bread 
and white wheat bread) (Wolter et al., 2013, Atkinson et al., 2008). High GI foods 
cause a rapid release of glucose, while a low GI food is one that has a high 
concentration of slowly digestible starch that enables a slower and lower increase of 
glucose concentrations. 
The glycaemic response varies based on the food matrix, such as starch susceptibility, 
protein and lipid content as well as the physical structure of the food (Atkinson et al., 
2008). While there is plenty of information regarding the glycaemic response of gluten-
containing foods, studies on gluten-free foods are minimal, with those studies 
conducted on composite recipes rather than specific foods (Di Giacomo et al., 2013). 
In vitro assays can evaluate starch digestibility and calculate a predicted glycaemic 
index for food. However,  in vivo results are altered by metabolic factors, such as 
gastric emptying rate, gut hormone profiles, absorption of glucose through the 
intestinal mucosa, accessibility of α-amylase to the starch, all of which will modify 
glycaemia. As the food structure may alter digestion rates through mechanical reasons, 
such as the slowing of gut transit time, wholegrains tend to have a lower GI than milled 
products (Granfeldt et al., 2000, Atkinson et al., 2008). 
Oats have a lower GI of 71 compared to other grains including wheat - 100, 
sorghum - 72, quinoa - 95, teff - 74, buckwheat - 80 (Wolter et al., 2013), white rice - 92 
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and brown rice - 87 (University of Sydney, 2016). Although the GI of oats is classified 
as high, it can still lower insulin secretion in vivo due to its low carbohydrate content 
(Wolter et al., 2013). An improved glycaemic response through the consumption of 
oats affects the availability of energy stores by modifying physiological adaptations to 
energy restriction.  
The mechanism in which oats may improve glycaemic control depends on the rate of 
starch digestion, through the combination of granule size, gelatinisation, composition 
and structure of the grain, as well as the lipid and protein matrix (Singh et al., 2010). 
In vitro studies indicate that starch digestibility plays a relevant role in the effect that 
oats have on glycaemia.  However, metabolic factors in vivo, such as rate of gastric 
emptying, gut hormone profiles, absorption of glucose through the intestinal mucosa 
and availability of starch to enzymatic attack also play a significant role (Berti et al., 
2004, Fardet et al., 2006).  
 
1.4.2.3 Anti-hypertensive effects 
Extensive clinical and animal trials with dietary oat supplementation in hypertension 
have taken place. However, results are inconclusive with a small number of studies 
indicating that the consumption of oats reduced systolic blood pressure by 4 - 6%, but 
with small sample sizes (Saltzman et al., 2001, Keenan et al., 2002). These studies 
were conducted with hypocaloric diets and on subjects with mild or borderline 
hypertension, which may have been confounding factors. Many of these studies were 
evaluating the effect of the wholegrain or bran, which provide several factors that may 
lead to reductions in blood pressure, such as fibre, magnesium and potassium, and 
these synergistic interactions can result in a greater reduction in blood pressure.  
 Other studies found that oat consumption, specifically β-glucans, had no effect on 
systolic blood pressure (Thies et al., 2014, Swain  et al., 1990, Maki et al., 2007, Davy 
et al., 2002, Kestin et al., 1990). These effects could have been due to limitations in 
the restrictions on the subjects to those with high BMI, relatively high attrition rates 
and compliance issues, as palatability of the study food was less than with wholegrain 
or bran.   
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1.4.2.4 Adiposity and anti-obesity effects 
Several studies suggest an inverse relationship between dietary fibre intake and body 
weight (Koh-Banerjee et al., 2004, Slavin, 2005), body mass index (van de Vijver et 
al., 2007) and body fat mass(Nelson and Tucker, 1996) in men (Nelson and Tucker, 
1996, Koh-Banerjee et al., 2004). Studies in women (Liu et al., 2003) also demonstrate 
this relationship. However, many studies on oat bran and β-glucans have failed to show 
any effect (Anderson et al., 1990, Kirby et al., 1981, Jenkins et al., 2000, Judd and 
Truswell, 1981, Robitaille et al., 2005, Saltzman et al., 2001, McKeown et al., 2004). 
These studies were mainly investigating the impact on hypercholesterolaemia and 
hypertension rather than changes in body weight parameters.  
 
1.4.2.5 Anti-inflammatory and antioxidant effects 
Inflammatory markers such as C-reactive protein (CRP), IL-6 and intercellular 
adhesion molecule 1 (ICAM-1) are associated with cardio-metabolic disease risk, but 
only CRP is considered an independent marker of cardiovascular disease risk (Pearson 
et al., 2003). Observational studies have suggested that a high fibre diet may reduce 
CRP concentrations (Ma et al., 2006, Ajani et al., 2004) while oat bran and wheat bran 
reduced oxidative stress induced by a high-fat diet in pigs (Rezar et al., 2003). 
It is speculated that some of the 20 avenanthramide compounds in oats are anti-
inflammatory and anti-atherogenic by inhibiting monocyte adhesion to the endothelial 
cells of the aorta and down-regulation of inflammatory cytokines and chemokines (Liu 
et al., 2004). There have been a limited number of studies examining the bioavailability 
of avenanthramides. However, most examine 2c, 2f and 2p avenanthramides only 
which can be detected at low concentrations in the circulating blood and taken up by 
hepatic, cardiac and skeletal tissues of rats (Yang et al., 2014).  
Since oat grains are rich in lipids, they contain a number of compounds that protect the 
lipids from oxidation, with both tocopherols and avenanthramides having antioxidant 
effects (van den Broeck et al., 2016). It may be that this synergistic relationship is 
leading to the effect rather than any individual component. 
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Anti-inflammatory activity was found in a study utilising β-glucan-enriched pasta 
(75% durum wheat and 25% wholegrain barley flour) which modified gut microbiota 
composition leading to improved health outcomes (De Angelis et al., 2015). Faecal 
and blood samples were collected before consumption and after eight weeks on the 
β-glucan pasta diet. Faecal samples showed an increase in beneficial Lactobacilli and 
a decrease in the harmful Enterobacteriaceae species. An increased production of short 
chain fatty acids including 2-methylpropionic, acetic, butyric and propionic acids as 
bacterial metabolites may lead to anti-inflammatory activity (De Angelis et al., 2015). 
1.4.3 Gastrointestinal Health 
The impact of cereal grains, particularly wholegrains, on intestinal microbiota and the 
contribution this makes to cardio-metabolic disease has recently become a more 
focused area of study (Carvalho-Wells et al., 2010, Costabile et al., 2008). Many grains 
contain components classified as prebiotics, including oats that contain β-glucans. 
Although they have not been definitively proven to be prebiotic, β-glucans are 
classified as having prebiotic potential (Arena et al., 2014). β-glucans may possess 
immunomodulatory characteristics, stimulating gut immune responses in several 
animal species (Bonaldo et al., 2007, Eicher et al., 2006, Li et al., 2006). However, 
most of these studies have studied the β-glucans found in the cell walls of yeast 
(Saccharomyces cerevisiae), not from grains (oats or barley). Therefore, results may 
be different due to the change in molecular weight and structure when comparing the 
two types. 
1.4.3.1 Prebiotics 
Prebiotics are a substrate that is selectively utilised by host microorganisms to confer 
a health benefit (Gibson et al., 2017). Until recently, these substrates were 
carbohydrates (Roberfroid et al., 2010, Gibson et al., 2015), however the updated 
consensus statement from the International Scientific Association for Probiotics and 
Prebiotics (ISAPP) now includes non-carbohydrate substances, such as polyphenols 
and polyunsaturated fatty acids converted to conjugated fatty acids assuming adequate 
evidence of health benefits  in the target host (Gibson et al., 2017). For a prebiotic to 
34 
be effective, it must be able to resist gastric acidity, enzymatic hydrolysis and 
absorption in the upper gastrointestinal tract. It also must be fermentable by one or 
more intestinal microflora and selectively stimulate the growth of these bacteria 
(Roberfroid et al., 2010, Slavin, 2013). Humans have consumed prebiotics for many 
thousands of years as a normal part of the diet (Leach and Sobolik, 2010, Pontzer et 
al., 2012). However, it is only recently that studies have investigated the mechanisms 
of their potential health benefits (Costabile et al., 2015, Rastall and Gibson, 2015, 
Gibson et al., 2017, Richards et al., 2016, Kumar et al., 2016). Prebiotics may attenuate 
obesity, obesity-related inflammation and obesity-related diseases (Bednar et al., 2001, 
Neyrinck et al., 2008, Roberfroid et al., 2010) through fermentation in the colon which 
alters the gut microbiome (Ley, 2010, Rowland et al., 2017). Further information on 
prebiotics in obesity is contained in the journal article in section 1.4.3.1.1 Prebiotics 
in Obesity. 
As prebiotics improve gut barrier function, pathogenic bacteria are restricted from 
entering the bloodstream to initiate inflammation (Wells et al., 2017, Catalioto et al., 
2011) . Further, the beneficial bacteria can produce compounds that enhance host 
metabolism and endocrine function (Moreira et al., 2012). The gut microbiome 
produces by-products such as hydrogen, lactate, methane, carbon dioxide and short 
chain fatty acids, including acetate, propionate and butyrate. The mechanisms of action 
of prebiotics and short chain fatty acids on the benefits to gut health, reduced 
inflammation and obesity have been reviewed (Slavin, 2013). 
Propionic and butyric acids may have a positive metabolic effect by modulating 
pro- and anti-inflammatory markers present in the gut (Galisteo et al., 2008). The 
consumption of oats increased caecal amounts of short-chain fatty acids, particularly 
propionic and butyric acid (Berger et al., 2014); however, the amounts differed 
depending on the type of oat product (Berger et al., 2014).  
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store energy during times of excess, to be used in 
times of famine. This attractive hypothesis has gen-
erated intense discussion and interesting arguments 
including that genetic variability in metabolic genes 
within populations is a means of distributing risk 
across offspring in the absence of strong selective 
pressures.1 However, the thrifty gene hypothesis has 
been deemed untenable for many reasons, including 
that hunter-gatherers do not become obese between 
famines, with body mass index values remaining be-
tween 17 and 21.2 Further, the presence of both slim 
and obese humans in modern societies suggests that 
gene mutations are essentially neutral, suggesting 
genetic drift rather than selection.3
The prevalence of obesity has increased markedly 
in the last two centuries, but there is sufficient evi-
dence for obesity dating back tens of thousands of 
years.4 From prehistoric times until the eighteenth 
century, overweight and obesity were probably rare-
ly seen, and this remains a characteristic of mod-
ern hunter-gatherer societies. Prehistoric statuettes 
such as the so-called Venus figurines found across 
southern and central Europe show exaggerated fe-
male abdomen, breasts, hips and thighs. The old-
est of these Palaeolithic statuettes, found in 2008 at 
Hohle Fels in southern Germany, is between 35,000 
and 40,000 years old 5 while the well-known Venus 
of Willendorf in Austria is about 25,000 years old.6 
Since the first statuettes were found in the 1860’s, 
arguments have focused on whether they are depic-
tions of actual obesity or rather symbols of fertility 
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Obesity was probably rare in ancient times, with the current 
increase starting in the Industrial Revolution of the eight-
eenth century, and becoming much more widespread from 
about 1950, so concurrent with the increased consumption of 
carbohydrates from cereals in the Green Revolution. Howev-
er, dietary components such as oligosaccharides from plants 
including cereals may improve health following fermentation 
to short-chain carboxylic acids in the intestine by bacteria 
which constitute of the microbiome. Such non-digestible 
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been part of the human diet since at least Palaeolithic times, 
and include components of the cereals domesticated in the 
Neolithic Revolution. If consumption of these cereals has now 
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simple sugars, thus changing the bacteria in the microbiome. 
Processing of food has played an important role in this change 
of diet composition. Since obesity is a low-grade inflamma-
tion, changing the microbiome by increased consumption of 
simple carbohydrates and saturated fats may lead to obes-
ity via increased systemic inflammation. Conversely, there 
is now reasonable evidence that increased dietary prebiotic 
intake decreases inflammation, improves glucose metabo-
lism and decreases obesity. Would widespread increases in 
prebiotics in the modern diet, so mimicking Palaeolithic or 
Neolithic nutrition, decrease the incidence and morbidity of 
obesity in our communities?
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excessive food intake. Both famine and obesity are 
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and abundance. The historical evidence for obesity 
continues with figurines from the Neolithic period,7 
defined as the beginning of farming between 10,200 
and 8,800 BC and ending between 4500 and 2000 
BC. In ancient civilisations, only the wealthy could 
afford to be obese; one documented example is the 
Ptolemy rulers of Egypt who succeeded Alexander 
the Great, reigning until 30 BC.8 The concept that 
obesity is evidence of conspicuous consumption is 
an ancient one, but it became clearly developed in 
the Age of Enlightenment (eighteenth century) as a 
negative social perception of obesity together with 
an association with suspect morals and excess, and 
as an outward representation of the soul.9
Prevention of obesity also has a long history, be-
ginning with the writings of Hippocrates (c. 460 
BC-c. 370 BC) 5 and continued with the writings of 
Soranus of Ephesus (2nd century AD) and Caelius 
Aurelianus (5th century AD).10-12 Treatments includ-
ed purging and vomiting, fasting and exercise.4, 10-12 
Many physicians of antiquity recognised that diet 
was an important factor in both the cause and the at-
tenuation of the disease. Dietary treatments included 
foods such as cheese, vegetables, mustard seeds and 
herbs. Alexander Trallianus wrote in the 6th century 
AD of a diet including indigestible foods, vegeta-
bles, barley, rice and legumes as well as fish, seafood 
and fruit to treat obesity, so an early version of func-
tional foods.12 The ideas of the ancients appear to be 
a foundation for modern conservative management 
of obesity.
This review will discuss the relationships between 
prebiotics and obesity, without attempting to cover 
the enormous literature on either prebiotics or obes-
ity. A prebiotic is defined as a selectively fermented 
ingredient that allows specific changes, both in the 
composition and/or activity in the gastrointestinal 
microflora that confers benefits upon host well-be-
ing and health.13 The WHO defines overweight and 
obesity as abnormal or excessive fat accumulation 
that presents a risk to health for a number of chronic 
diseases including diabetes, cardiovascular diseases 
and cancer.14
The Neolithic Revolution – successful 
in providing healthy diets?
The domestication of plants including cereals in 
the Fertile Crescent during the Neolithic period,15, 16 
termed the Neolithic Revolution, allowed a seden-
tary life-style with the formation of permanently 
settled farming towns, later developing into cities. 
Domestication of cereals is part of a continuum 
from gathering to cultivation of wild plants, their 
domestication and then agriculture that probably 
occurred over thousands of years in widely spread 
areas.17 There have been fascinating discoveries and 
vigorous discussions on the domestication of cere-
als; some of the more recent reviews discuss the do-
mestication of rice, wheat and maize.16, 18-22
Maize was domesticated in modern Mexico, while 
another ancient crop from the Andean countries of 
modern Bolivia and Peru has gained recent atten-
tion. Quinoa (Chenopodium quinoa willd.), techni-
cally known as a pseudocereal, has been cultivated 
for 5000-7000 years with transmission throughout 
South America via livestock migrations and trade 
from Venezuela in the north to the southern extremi-
ties of Argentina and Chile.23 Quinoa was consid-
ered by the Incas as the mother of grains, with the 
Emperor using a golden spade to dig the soil to plant 
the first seed of the new crop each spring. After the 
Spanish conquest in the 1500’s, quinoa cultivation 
retreated to isolated pockets above 3500m where 
introduced European crops such as wheat, rye and 
oats could not be grown. Quinoa has all the proper-
ties of an ancient cereal with high protein content 
(12-17%), dietary fibre content (2-10%), lipids (5-
9%) and carbohydrates (60-70%), with 11% as amy-
lose.23 Quinoa contains essential amino acids, with 
similar values to casein, the protein found in milk. 
Quinoa flour is high in xylose and maltose, and low 
in glucose and fructose, along with ribose and ga-
lactose, giving it a low glycaemic index value. The 
total lipid content of quinoa is 14% with linoleic 
(39%) and oleic (28%) acids being the most preva-
lent.23 The rediscovery of quinoa and other ancient 
grains by consumers in developed countries may be 
no more than a consumer fad, but these functional 
foods may change the way we think about the com-
ponents of our foods, especially prebiotics.
The human diet has changed dramatically since 
the introduction of agriculture in the Neolithic 
Revolution, unlike the human genome. Many fac-
tors including geography, agricultural advances and 
technology, the advent of food processing and food 
technologies, wars, climatic extremes and modern 
marketing have changed the food we eat. For most 
of human history, people only ate what was avail-
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expenditure as agricultural production increased.25 
Although the Green Revolution is hailed as one of 
the most positive changes in modern agriculture, did 
the increased yield and profit come at the expense 
of nutritional quality and variety in the modern-day 
diet?
During the Green Revolution, emphasis was 
placed on increased production, with high-yielding 
strains with low economic input becoming predomi-
nant, specifically of rice, maize and wheat. The use 
of powerful breeding tools, increased nutrient inputs 
and shared knowledge resulted in provision of large 
quantities of food. The doubling in cereal produc-
tion came largely from increased carbohydrate con-
tent, with grain weights typically being inversely 
proportional to the protein percent.15, 16, 26 Increases 
in carbohydrate content require much less nitrogen 
input than improved protein content. Further, the se-
lective increases in the major cereals may have led 
to decreased availability and hence consumption of 
other staple foods such as legumes, grains and cere-
al-based crops. Production of legumes in the Punjab 
region of India, a major food production area, has 
halved during the Green Revolution, with the dif-
ference being filled by rice and wheat cultivation.27 
This change decreased the nutritional diversity, 
purely due to availability.
The microbiome
The processes of absorption of nutrients from 
food are complex, with important roles of enzymes 
and hormones released into the gastrointestinal tract. 
Further, the essential role of the bacteria, especially 
in the colon, is now being realised. These bacteria, 
termed the microbiome or microbiota, are diverse 
with around 500 to 1000 bacterial species present 
accounting for 2 to 4 million genes (about 100-fold 
more genes than the human genome) and about 100 
trillion bacteria (about 10-fold more cells than the 
human cells).28 These bacteria obtain their nutrients 
from the food we eat, and they also change the com-
ponents of the food before absorption by the human 
host. The different bacteria of the microbiome have 
very specific environmental needs, which are most-
ly met by the conditions in the distal colon. They are 
often unable to survive outside this environment, so 
culture of these species ex vivo is relatively unsuc-
cessful with estimates suggesting only 30-40% can 
able in their locality. There were exceptions, but 
only for the very wealthy, such as the importation 
of spices from India to Europe. From the 15th cen-
tury, when Western Europeans started exploring the 
world, exposure to new foods occurred with new 
species being introduced to new cultures. Agricul-
tural advances saw the rise of certain crops and re-
duced production and consumption of others. In our 
more recent history, food processing has changed 
the way many humans hunt and gather their food, 
and with this has come a dramatic change in the in-
take of both micro- and macro-nutrients. Further, 
advances in agricultural productivity have changed 
the source and quality of the food.
The modern Green Revolution - 
unsuccessful in providing healthy diets?
Since the Industrial Revolution, there have been 
several periods of major changes in agricultural 
production and productivity, including famines 
such as the potato famine in Ireland from 1845-
1852. In the following generation, Northern Eu-
rope went through a Green Revolution from 1870 
to 1914 with marked increases in productivity.24 
The much more publicised Green Revolution from 
about 1960 to 2000 was hailed as the world’s an-
swer to imminent famine due to a rapidly increas-
ing population. Production increased dramatically, 
with increases of 208% in wheat production, 109% 
for rice production and 157% for maize in devel-
oping countries between 1960 and 2000.25 Further, 
these increased yields came with shorter growing 
periods. Without this Green Revolution, it has been 
estimated that food prices would have been 35-65% 
higher, with the risk of political instability, and ca-
loric availability would have decreased by 11-13%; 
these changes have benefited all consumers, es-
pecially the poor.25 Gains have been uneven, with 
China and India showing large improvements with 
much smaller improvements in sub-Saharan Africa. 
Even in countries with successful Green Revolution 
changes in productivity, poverty and food insecurity 
still exist as does micronutrient malnutrition. Fur-
ther, environmental impacts have been mixed, with 
increased production allowing marginal land to re-
turn to forest cover, but with increased soil degra-
dation and chemical run-off from productive land. 
Another critical issue has been the reduced research 
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any food containing dietary fibre is likely to con-
tain some form of prebiotics, although in varying 
amounts. The definition of a prebiotic concludes by 
stating that these bacteria must improve the health 
of the host. There is a long history of prebiotic con-
sumption by humans, but scientific evaluation of the 
health benefits is relatively recent.
Many ancient foods contain prebiotics as well as 
nutrients, so the daily prebiotic intake was signifi-
cant. One of many examples is the yacon, a tradi-
tional root used by many Andean tribes in Ecuador, 
Peru, Bolivia and Argentina. The dietary fibre con-
tent of the root, usually eaten raw, is approximately 
10.4% of dry matter, with an insoluble fraction of 
approximately 8.7% and soluble fraction of 1.7% of 
dry matter.41 The fibre consists of cellulose, galac-
tose, arabinose and galactose, with lower amounts 
of xylose, mannose and rhamnose.41 The fructose 
oligosaccharide content of yacon varies between 24 
and 35% with some studies indicating higher con-
tent of 54-62%.41, 42
Prebiotics were present in the components of an-
cient diets and were consumed routinely. In the an-
cient Indian diet, unlike the modern European diet, 
prebiotics were a major component through con-
sumption of grains, fruits and vegetables.43 Also, the 
Indian diet contained spices and herbs in home-made 
food which were quite different from the processed 
food in European diet.43 Palaeodietary studies, for 
example in the Chihuahuan Desert of Mexico, have 
shown that prehistoric people consumed a wide va-
riety of plants, including inulin-rich sotol, agave and 
onion.44 Conservative estimates indicate that the av-
erage male hunter-forager consumed 135g prebiot-
ics per day, while females consumed 108g/day.44 
When the whole diet was considered as the energy 
source, it was estimated that a larger proportion of 
the energy was derived from fermentation of prebi-
otics in the large intestine on a daily basis. However, 
the total dietary intake of prebiotics has reduced in 
the modern era, for example, to less than 20g/day in 
the USA.44 Although there are current social trends 
to target refined carbohydrates as the cause of the 
obesity epidemic, it is likely more caused by what 
these originally plant-based, yet highly processed 
products lack, as opposed to what they contain. The 
increase in simpler starches with a high digestibil-
ity has certainly come at the cost of non-digestible 
starches and other dietary fibres, which are not use-
ful economically or in a processing context.
be cultured.29 The advent of molecular techniques 
has allowed the potential extent of the relationship 
between the microbiome and the human host to be 
investigated.
There is debate about the inheritability of the 
microbiome with some suggesting it is high,30, 31 
whilst others suggest it is low,32 leading to ambigu-
ity as to whether there may be directed co-evolution. 
Among different primate species, there are typical 
microbiomes, with the host phylogeny being the 
driving determinant, showing significant evidence 
for co-evolution.30 There appears to be geographi-
cal differences among human populations,33 likely 
to be the result of local traditions and exposure to 
external elements.32 The local diet is one of the el-
ements that undoubtedly influence both the long-
term changes and the immediate composition of the 
microbiome. The proportion of fermentable compo-
nents in the diet influences the species of bacteria 
present, and the species of bacteria influences the 
host, allowing complex interactions.34 The microbi-
ome is very susceptible to short-term changes in the 
diet,35, 36 suggesting that the relationship between 
the diet and the microbiome could be both the cause 
and the treatment of obesity. The microbiomes of 
ancient and modern humans are distinct, and geo-
graphical variation has probably decreased in the 
post-Columbian period.37 These changes continue 
and so may stunt the evolution of the microbiome, 
due to reduced diversity and possible gene transfers 
between species.34
Prebiotics
Fermentation of dietary carbohydrates provides 
the energy for the growth and activity of the micro-
biome; this is the first part of the definition of these 
carbohydrates as prebiotics.13 All known and sus-
pected prebiotics include resistant starches, and 
non-starch polysaccharides with different sugar 
monomers and chemical linkages.38 Prebiotics must 
be able to resist gastric acidity, resist human enzy-
matic hydrolysis, resist absorption in the upper gas-
trointestinal tract, be fermentable by one or more in-
testinal microflora, and selectively stimulate growth 
or activity of intestinal bacteria.39 Prebiotics can be 
found naturally in many foods including leeks, as-
paragus, chicory, Jerusalem artichokes, onions, gar-
lic, wheat, rye, barley, oats and soybean.40 Typically, 
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Processing and prebiotics
The shift toward increased processing has de-
creased the fibre intake in many countries. It can 
be clearly seen that the increased processed food 
consumption mimics the trends in obesity and diet-
related diseases. Many link the decreased fibre con-
sumption with a decreased intake of grain and cereal 
crops. Japan decreased its average fibre consump-
tion per capita by almost 10 grams over the period 
of 1911-1980.51, 52 This change can be directly attrib-
uted to a decrease in whole grain intake.52 Alterations 
in the American diet were marked with fibre intake 
declining by 28% from 1909 to 1975. The cause is a 
reduced intake in whole plant-based foods, with the 
greatest decline coming from the grain intake.53 In 
Brazil, the consumption of ultra-processed foods in-
creased over the period of 1987-2003, which led to 
much lower dietary fibre intake over this period.54
Grain crops contain both fermentable and non-
fermentable fibres that may confer health benefits. 
These fermentable fibres are of particular interest as 
they typically act like prebiotics to change the com-
position of the gut microbiome. Of particular interest 
are resistant starches and non-starch polysaccharides. 
Grains, cereals and legumes have different amounts 
of non-starch polysaccharides and resistant starches 
depending on their species, variety and growing con-
ditions. Of particular significance to the prebiotic 
concept are soluble dietary fibres, many of which are 
fermentable, and non-starch polysaccharides, all of 
which are fermentable. The primary grains that in-
creased in production throughout the Green Revo-
lution were rice, maize and wheat with total dietary 
fibre of 19.6%, 5.7% and 17%, respectively and total 
soluble dietary fibres of approximately 3.6%, 1.4% 
and 2.3%, respectively. Other cereals such as millet 
contain 5.4% total dietary fibre and 3.8% soluble fi-
bres and oats contain 37.7% total dietary fibre and 
3.8% soluble fibres.55 Barley, depending on vari-
ety, can contain from 4.5-26.9% soluble non-starch 
polysaccharides.56 By replacing 100g of white rice 
with 100g quinoa, carbohydrate content decreases by 
17.5 g and protein content increases by 7.3 g.57 Gram 
for gram, ancient grains such as quinoa, amaranth, 
barley and millet offer fewer carbohydrates and more 
protein as well as containing beneficial fibres.
Processing reduces the content of soluble dietary 
fibres.55 Common food additives such as corn starch 
and potato starch do not include fibre, processed 
The advent of processed foods
Changes in lifestyle due to modernisation created 
the need for processed and fast foods. The delivery 
of large volumes of food to a widespread population 
resulted in industries realising the potential economic 
gains. Industries aimed to produce low cost, highly-
consistent foods with palatable tastes and textures. 
Raw grains and non-refined materials are mostly un-
suitable for these processed foods, hence the indus-
tries aimed to include non-fibre carbohydrates, mostly 
including simple sugars. Highly-refined white bread, 
wheat, rice and maize products became a norm of the 
modern westernised diet. Furthermore, the addition 
of these derivatives to non-wheat-based products in-
creased the amounts of rapidly digestible carbohy-
drates with no addition of fibrous components. The 
estimated intake of refined grain was approximately 
89% of the cereal intake in the USA in 2005.45
The increased consumption of processed foods 
has been a product of both convenience and cost. 
Although some credit to this may be derived from 
the Green Revolution, it would appear that the ma-
jor driver is the consumer markets pushing toward 
convenient, cheap and consistent foods. Globalisa-
tion may be responsible for the nutritional changes 
resulting in increased processed food consumption 
and increased obesity.46 The increased consumption 
of processed foods has come together with increased 
foreign investment in food processing in developing 
countries.47 The advances in industrialisation and 
commercialisation of processed foods since the late 
1800s has outpaced increases in dietary knowledge 
which may explain the current situation.48 Consum-
ers have then perpetuated the decline in whole food 
consumption with their increased desire for proc-
essed foods.
The marked differences between the whole-food 
and processed food diets are likely to have contrib-
uted heavily to the rising health epidemics of obes-
ity and metabolic syndrome. Epidemiological stud-
ies have correlated decreased whole grain intake 
and increased refined grain intake with weight gain 
in short-term studies.49 This evidence suggests that 
long-term dietary changes contribute to increased 
body weights and related diseases. The most obvious 
differences are the increased addition of sweeteners, 
the decreased amounts of dietary fibres, the addition 
of preservatives, and the increases in hydrogenated 
fats.50
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presence of components in the diet such as saturated 
fatty acids. Hence, this metabolic dysfunction can 
be described as a dysfunctional gut microbiome. In 
contrast, the incidence of obesity and obesity-related 
diseases in communities that follow a more tradition-
al whole-food diet is lower.66 Pimo Indians eating 
traditional diets showed lower body mass index and 
cholesterol concentrations than people of similar her-
itage eating a westernised diet. The traditional Pimo 
diet contains over 50 g/day of potentially prebiotic 
dietary fibre, primarily from corn and beans.67 Tra-
ditional diets in urban Brazil have a protective ef-
fect against obesity, with possible reasons including 
the high-fibre intake in traditional diets.68 A similar 
trend is evident in tribes of the Solomon Islands. In 
communities where a westernised diet has begun to 
infiltrate, the plasma cholesterol concentrations are 
higher and the percentage of males with high blood 
pressure is increased.69 Female teachers in Tehran 
consuming westernised diets high in refined carbo-
hydrates, processed meats and low in dietary fibre 
have higher body mass index and increased risk of 
developing metabolic syndrome.70 These are a few 
examples, with most studies indicating similar trends 
following consumption of highly-refined, acellular 
diets.66
The ever-increasing obesity epidemic also increas-
es the financial costs of health care.50 It has been es-
timated that, in the year 2000, the burden of obesity 
from both direct health care and indirect costs was as 
high as 4.06% of gross national product of China. In 
the USA and the United Kingdom, estimated costs 
are likely to increase by $48-66 billion and £1.9-2 
billion per year over the next 15 years, respectively.71 
Other countries with rising obesity will have similar 
increases in health costs.
Chronic inflammation in obesity
Metabolic endotoxaemia, a chronic low-grade in-
flammatory condition, has been identified as an early 
predictor of obesity and diabetes.72 Multiple studies 
associate obesity with this chronic low-grade inflam-
matory status. The inflammatory state is characterised 
by the presence of elevated plasma concentrations of 
cytokines and by the presence of macrophages and 
monocytes within the adipose tissue. As the adipose 
tissue is an endocrine tissue, imbalances and disrup-
tions in adipose tissue status can have marked effects 
white rice contains 0.3% soluble dietary fibre, and 
processed oats contain less than a third of the total 
dietary fibres of their unprocessed equivalent.55 The 
soluble non-starch polysaccharide content of com-
monly consumed processed foods while obesity was 
rapidly increasing were much lower than the raw 
whole grains. Kellogg’s Cornflakes™ contain 0.48% 
non-starch polysaccharides, puffed rice 0.41%, brown 
rice 0.89%, white rice 0.92%, Kellogg Krispies™ 
0.32%, and white spaghetti 1.82%.58 With process-
ing comes a reduced intake of the dietary fibre which 
have potential prebiotic affects and as a result, our 
overall health is likely to have been impacted.
Obesity-related disease
The changes in nutrient composition and intake 
due to processing of food are partly to blame for the 
current prevalence of obesity. Many countries now 
report more than 50% of their population as over-
weight or obese with marked increases since the 
1980s.59 The prevalence of obesity today varies from 
3-4% in Japan and Korea, to 30% or more in the USA 
and Mexico.59 The incidence has appeared to plateau 
in the USA over the past decade.60 In Australia, 60% 
adults and 25% children, or more than 12 million 
people, are classified as being overweight or obese.61 
Due to these increases, obesity-associated illnesses 
have also increased, along with an increased financial 
burden.62, 63
Obesity has a major impact on the energy metabo-
lism and regulatory mechanisms that lead to meta-
bolic diseases including type 2 diabetes, cardiovascu-
lar disease, dyslipidaemia, hormone-linked cancers 
and gastrointestinal diseases including inflammatory 
bowel disease and colon cancer.64 Type 2 diabetes 
is closely associated with obesity and insulin resist-
ance, and is affected by the inflammatory status of 
adipose and other tissues. The associations are clear 
with increasing incidence of diabetes, hypertension, 
asthma and arthritis as body mass index increases.65
Obesity is a very slowly developing metabolic 
disorder. While there is evidence showing the rela-
tionship between obesity and the above-mentioned 
diseases, the clear development of obesity is not 
identified until the person looks obese. During the 
asymptomatic development of obesity, metabolic 
dysfunction develops. The process is unclear but it is 
speculated that the gut microbiome changes with the 
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carboxylic acids. Plasma short-chain carboxylic ac-
ids initiated activation of specific receptors classified 
as GPR43 leading to reduced lipolysis and reduced 
plasma free fatty acids.89 Reduction of plasma free 
fatty acids by this mechanism should reduce the in-
flammatory response by reducing the exposure of 
membrane TLR to plasma free fatty acids. GPR43-
knockout mice showed exacerbated inflammation 
mediated by immune cells and increased release of 
reactive oxygen species.90 Thus, GPR43 plays a role 
in metabolic inflammation.90
Several studies have investigated the effects of 
short-chain carboxylic acids produced by colonic 
fermentation on the inflammatory state. The pres-
ence of short-chain carboxylic acids reduced the 
presence of TLR4 mRNA leading to reduced active 
protein levels and subsequent inflammatory respons-
es.91 Treatment of neutrophils with butyrate, pro-
pionate and acetate at concentrations of 3 mM can 
counteract the release of TNF-a induced by lipopoly-
saccharide.92 Similar effects have been noted in cul-
tured colon epithelial cell lines where short-chain 
carboxylic acids inhibit NF-kB activity.92 Similar 
anti-inflammatory responses have been noted in adi-
pose tissue 93 and cultured macrophages where pro-
inflammatory cytokine release can be decreased.93, 94 
These results have not been consistent with evidence 
suggesting that the presence of short-chain carboxy-
lic acids can enhance the TLR2-induced expression 
of TNF-a and IL-8.95
Whole grains with their combination of fibre, pro-
tein, vitamins and minerals appear to have protective 
effects in the body as they are digested more slowly 
than refined grains and have the potential to stimu-
late the growth of appropriate gut bacteria. They also 
generally maintain lower blood glucose concentra-
tions and improved insulin responses in the body. 
Subjects with high dietary fibre intake have lower 
blood pressure and serum cholesterol concentrations, 
reduced glycaemia, improved insulin sensitivity with 
lower risk of developing stroke, hypertension, type 2 
diabetes, obesity and gastrointestinal diseases.52
Prebiotic effects on obesity
Obesity is a complex metabolic disorder with 
impairments in lipid and carbohydrate metabolism. 
Different prebiotics have been tested for their effects 
in obesity as the microbiome fermentation products 
on metabolic processes. The increased plasma cy-
tokines in obesity are in response to increased plasma 
microbial components and lipotoxicity. The presence 
of lipotoxic substances, including the saturated fatty 
acids, palmitic, stearic and lauric acid,73-76 and mi-
crobial components 77, 78 have the ability to activate 
toll-like receptors (TLR) which then initiate immune 
responses.
Obesity has been associated with distinct gut 
microbiomes and increased gut permeability leading 
to a low-grade endotoxaemic state.79 This state leads 
to the initiation of several inflammatory pathways in 
adipose tissue. TLR4 responds to increased plasma 
lipopolysaccharides and lipids, and the induction of 
the NF-kB gene transcription.80, 81 The result is an 
increased expression and secretion of cytokines lead-
ing to recruitment and infiltration of macrophages 
to adipose tissue. The macrophages then further the 
inflammatory response by increased cytokine expres-
sion mediated by NF-kB.82, 83 TLR2 induces a similar 
response to the presence of lipopolysaccharide, with 
the induction of the NF-kB mediated transcription of 
cytokines;81 however, it interacts with a wider variety 
of ligands than TLR4.
Prebiotic interventions
There is increasing evidence that prebiotics have 
the potential to attenuate obesity, obesity-related 
inflammation and obesity-related diseases.84-87 The 
mechanism of action of prebiotics involves their 
fermentation in the colon, which changes the gut 
microbiome.88 The prebiotics appear to improve gut 
barrier function, potentially reduce pathogenic bacte-
rial populations and produce compounds which can 
improve host metabolism and endocrine function.79 
Bacteria produce by-products when fermenting preb-
iotics including hydrogen, lactate, methane, carbon 
dioxide and short-chain carboxylic acids including 
acetate, propionate and butyrate. Much research into 
the mechanism of action of prebiotics on inflamma-
tion and obesity has revolved around the benefits to 
gut health of these short-chain carboxylic acids.38
Prebiotic effects on inflammation
Supplementation with prebiotics increases the 
plasma and colonic concentrations of short-chain 
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oligosaccharides in streptozotocin-induced diabetic 
rats showed that the improved body weight, reduced 
mortality and increased population of Bifidobacteria 
and Lactobacilli in the caecum may be due to a de-
creased pH with increased concentrations of short-
chain carboxylic acids.104
Butyrate is rapidly absorbed from the lumen of the 
cecum to influence glucose and cholesterol concen-
trations and lipid metabolism. Supplementation with 
5% butyrate to high-fat diet-fed mice inhibited the 
development of obesity and insulin resistance due 
to reduced adipose tissue,104 which suggests it may 
be an effective compound in the treatment of obes-
ity and insulin resistance. Butyrate also has an im-
portant function in maintaining metabolism and the 
proliferation and differentiation of epithelial cells 
types.104 Similarly, propionate reduced cholesterol 
in rats possibly through inhibition of HMG CoA re-
ductase, redistribution of cholesterol from plasma to 
liver and enhanced synthesis and secretion of bile 
acids.105
The interrelationships between satiety hormones 
and the gut microbiota are complex; however, these 
hormones reduce energy consumption and metabolic 
processes and may be important in the development 
and attenuation of obesity. Satiety hormones change 
with administration of prebiotics. Prebiotics appear 
to have a stimulatory effect on peptide YY secre-
tion85, 101, 106 and tend to increase glucagon-like pep-
tide-1.107, 108 This change is associated with better 
regulation of post-prandial glucose concentrations, 
improved insulin tolerance and improved satiety.
Conclusions
There is a widespread concept that our genome 
and our modern diet are mis-matched, with only the 
genome remaining unchanged since the Neolithic 
Revolution. Discussion of the optimal human diet to 
decrease modern diseases such as obesity leads to 
passionate discussions, with many of the proposals 
being incompatible. As one example, should we con-
sume high protein, high saturated fat and almost no 
carbohydrates as in the Atkins diet? Or is the Ornish 
diet more appropriate, with 80% carbohydrates and 
minimal animal protein and fat? Would widespread 
substitution of the modern diet with Palaeolithic or 
pre-Palaeolithic nutrition decrease the incidence and 
morbidity of obesity in our communities? If so, this 
of prebiotics can affect host metabolism.96 Many 
prebiotics alter blood lipid profiles by binding cho-
lesterol and bile acids in the upper gut, increasing 
sterol excretion and causing a bulking effect in the 
intestine improving satiety.38, 97 Animal studies have 
shown that dietary interventions by prebiotics, es-
pecially fructans, inulin and oligofructose, decrease 
serum triglycerides.97 A Japanese study found that 
when Japanese millet was fed to diabetic mice, plas-
ma concentrations of adiponectin and high density 
lipoprotein cholesterol increased while glucose and 
triglyceride concentrations decreased.98 In human 
studies, decreases in serum triglycerides by inulin 
and oligofructose are independent of gender, type of 
prebiotic, background diet, overweight, dyslipidae-
mia or diabetes.99 Despite lowering triglyceride and 
cholesterol concentrations, prebiotic dietary supple-
mentation in both animal and human trials showed 
inconsistent modulation of lipid concentrations.99 
Of the studies reviewed, 8 out of 21 showed no 
change in blood lipid concentrations while the rest 
indicated lower lipid biomarkers (triglyceride, total 
cholesterol) for cardiovascular disease risk.99 More 
studies of prebiotics targeting selected symptoms or 
disease such as metabolic syndrome and obesity are 
required.
Several studies have linked diets supplemented 
with indigestible oligosaccharides (fructo-oligosac-
charides, galacto-oligosaccharides and arabinoxy-
lan) to reduced dietary intake in mice 86, 87 and 
rats84, 85. Most studies in mouse and rat models re-
sulted in decreased body weight gain where high-
fat diets were administered with supplementation 
against a high-fat diet alone; however, the decrease 
in caloric intake was not sufficient to account for 
the total weight loss.84, 86, 87 Human studies of fruc-
to-oligosaccharides supplementation have shown 
promise in obesity attenuation with long-term sup-
plementation leading to reduction in body weight, 
body mass index and waist circumference in obese 
women.100, 101 A study with fructo-oligosaccharies 
has indicated gender differences in responses with 
reduced calorie intake in women and increased in-
take in men.102 It may be possible to have responsive 
and non-responsive hosts to galacto-oligosaccha-
rides despite having similar gut microbiomes before 
the treatment.103 This trend is likely to be similar 
for other prebiotics; however the mechanisms and 
interactions require further investigation. Supple-
mentation with xylo-oligosaccharides and fructo-
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would argue that our diet should be optimised to the 
time when the modern human genome stabilised. As 
we have had the Green Revolution to increase the 
production of cereals, do we need a Nutrition Revo-
lution to increase wellness? This could include incor-
poration of the Palaeolithic diets into current nutri-
tional recommendations but this requires a thorough 
examination of these diets.108, 109 Is it possible to be-
come a 21st century hunter-gatherer110 and still have 
the same quality of life as currently enjoyed in devel-
oped countries? To answer these questions, we need 
a better understanding of the complex relationships 
between components of the diet, especially prebiot-
ics, and the bacteria of the gastrointestinal tract, the 
microbiome. Ultimately, this increased understand-
ing will use past nutritional experience to provide the 
foundation for a healthy future, including decreasing 
chronic disorders such as obesity.
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1.4.3.2 Gut morphology 
The morphology of the intestinal tract varies from duodenum through to the distal 
colon as digestive function changes. The small intestine (duodenum, jejunum and 
ileum) contains villi, which enables a greater surface area to be available for absorption 
of nutrients. The large intestine or colon has no villi, as the majority of nutrient 
absorption is complete before entry into this part of the digestive system. A healthy 
gastrointestinal tract is covered in long healthy villi, shallow crypts and a continuous 
epithelial lining (Baurhoo et al., 2009). Shallow crypts within the small intestine show 
the capability of needing fewer nutrients for regeneration and allow the intestinal cells 
to produce more digestive enzymes, gastrointestinal hormones giving improved 
nutrient absorption (Baurhoo et al., 2009).  
An increase in villi height and villi height to crypt depth ratio due to β-glucan 
consumption correlated with epithelial cell turnover (Baurhoo et al., 2009, Monro et 
al., 2012), rather than increased cell size. Intestinal morphology is altered based on 
dietary intake, with studies on broiler chickens and piglets indicating that the addition 
of prebiotics, particularly mannan oligosaccharides and fructo-oligosaccharides, 
improved the structure of the intestine allowing for improved nutrient absorption 
(Baurhoo et al., 2009, Awad et al., 2008). The colonic mucosal thickness and ileal 
goblet cell production increased with the addition of oligosaccharides to diet (Breves 
et al., 2001). The addition of β-glucans improved the intestinal barrier formed by 
epithelial cells and tight junction proteins (such as claudin-1) (Baurhoo et al., 2009).  
Along with adheren junctions, gap junctions and desmosomes, they are important in 
the absorption of nutrients and assist in the maintenance of the intestinal barrier 
function protecting the gut from pathogens (Shao et al., 2013). Poultry fed brewer’s 
yeast containing β-1,3/1,6-glucan increased production of mucin-producing goblet 
cells in the small intestine (de los Santos et al., 2007, Cox et al., 2010), indicating that 
the addition of oats, which contains β-1,3/1,4-glucan, to the diet may also restore villus 
loss and gastrointestinal damage by improving the mucosal layer.  
 
1.4.3.3 Gut fermentation 
The association between diet and the gut microbiome has an important role to play in 
human health (Costabile et al., 2008). The fermentation of fibre in the large intestine 
decreases pH and increases bacterial biomass that leads to an increased faecal output 
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and gas production (CO2, methane and hydrogen) as well as short-chain fatty acids 
(SCFA) (Blottiere et al., 2003, Connolly et al., 2010, Costabile et al., 2008, Topping 
and Clifton, 2001, Wong et al., 2006). SCFA are the main product of carbohydrate 
catabolism. Each SCFA has distinct physiological effects, including shaping the gut 
environment, influencing colonic physiology, as energy sources for host cells and 
intestinal microbiota and participation in different host-signalling mechanisms (Ríos-
Covián et al., 2016). Dietary supplementation of SCFAs decreased triglycerides and 
cholesterol (Lu et al., 2016) in high-fat fed mice. 
Short-chain fatty acids are two to six carbons long with acetate (C2:0), propionate 
(C3:0) and butyrate (C4:0) (Figure 1.10) as the main by-products of gut fermentation 
(Blottiere et al., 2003, Bornet et al., 2002). SCFA are usually present in a 60:20:20 
ratio (acetate: propionate: butyrate) in both the colon and faecal matter  (Cummings, 
1981).  
 
                                                              
a) acetate    b) propionate    c) butyrate 
 
Figure 1.10 Structure of the most abundant SCFA produced by oats a) acetate 
b) propionate c) butyrate 
(US National Library of Medicine, 2016) 
 
Acetate (C2:0) is the most abundant colonic SCFA and makes up more than half of 
total faecal SCFA (Louis et al., 2007). The liver uses acetate as a precursor for 
cholesterol and long-chain fatty acid synthesis (Wong et al., 2006). It is utilised in the 
production of acetyl coenzyme A (Figure 1.11) and is metabolised through acetyl-CoA 
and butyryl-CoA to butyrate (Louis et al., 2010). Acetate has a direct role in appetite 
regulation as it avoids hepatic clearance and reaches the brain through peripheral 
circulation (Frost et al., 2014). Acetate can have an anorectic effect by inducing 
neuropeptide expression and reducing hypothalamic AMPK catalysis (Frost et al., 
2014). There is a negative association between serum acetate and visceral adipose 
tissue and insulin concentrations (Layden et al., 2012). 
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Propionate (C3:0) plays a role in the liver as a major energy source for gluconeogenesis 
promoting fatty acid β-oxidation and reducing food intake (Chen et al., 1984). Serum 
and liver cholesterol concentrations were lower when an increase in propionate was 
available to upregulate PPARα (Anderson et al., 1984, Higashimura et al., 2015). As a 
key regulatory factor in lipid metabolism, increases in PPARα indicates improvements 
in fatty acid β-oxidation (Higashimura et al., 2015). Potential roles have also been 
found in the activation of GPR41 and GPR43 (Kimura et al., 2011), releasing satiety 
hormones (Lin et al., 2012) and other metabolic and anti-inflammatory effects (Al-
Lahham et al., 2010).  Acetate and propionate competitively inhibit each other in the 
hepatocytes and portal vein into the liver tissue to be utilised for gluconeogenesis. 
Therefore, any change in this proportion will change the energy available within the 
liver.  
Butyrate (C4:0) (Figure 1.10) is used as an energy source by colonocytes and oxidises 
to carbon dioxide and ketone bodies (Roediger, 1990). It has a major role in colonocyte 
proliferation and differentiation and is also associated with decreased colon cancer and 
other intestinal disorders (Sakata, 2007). It also plays a role in the modulation of 
epithelial cell cycle and mucosal immune responses (Topping and Clifton, 2001, Bajka 
et al., 2010, Sakata, 2007). Butyrate is utilised by the colonocytes for intracellular 
metabolism (Lu et al., 2016), stimulates Na+ and fluid absorption with reduced 
contractility which may lead to lower colonic motility increasing uptake of water and 
minerals (Sakata, 2007, Dass et al., 2007). Colonic absorption of SCFA by surface and 
crypt epithelial cells is through Na+-dependent symporters related to Na+-glucose 
symporters in the small intestine (sodium monocarboxylate transporter - SMCT). 
SMCT’s lower intracellular concentrations of Na+  are used as an energy source for the 
colonocytes (Lu et al., 2016). Butyrate may regulate the expression of specific genes 
in colonic epithelial cells and may suppress the development of malignancies as the 
expression of SMCT1 is reduced in colon cancers (Lu et al., 2016). 
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Figure 1.11 Representation of microbial metabolic pathways contributing to 
SCFA production in the gut 
adapted from (Ríos-Covián et al., 2016) 
 
Diet has an impact on SCFA production with changes in gut microbiota altering the 
SCFA produced (Costabile et al., 2008) and therefore leading to various health 
outcomes. Reductions in faecal butyrate are associated with colorectal 
adenocarcinomas in human studies (Chen et al., 2013). Increases in total faecal SCFA 
concentrations have been correlated with increased obesity (Fernandes et al., 2014, 
Rahat-Rozenbloom et al., 2014), while SCFA decreased following anti-obesity 
treatment (Patil et al., 2012, Salazar et al., 2015). Prebiotic substrates also induced 
changes in SCFA production of healthy individuals (Lecerf et al., 2012) and patients 
with irritable bowel syndrome (Majid et al., 2011). 
Many human feeding studies have shown no observable effects with over 90% of 
SCFA absorbed in the colon and utilised by the host (Connolly et al., 2012), and due 
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to the inaccessibility of the human colon for direct investigation, it is hard to quantify 
SCFA production rates (Verbeke et al., 2015). Studies using in vitro methods to 
produce SCFA from non-digestible components of whole grain cereals determine the 
quantity and ratio of the various SCFA produced. These studies vary from simple batch 
fermentation (Salazar et al., 2009, Arboleya et al., 2013) to complex multistage 
continuous culture systems such as SHIME (Van den Abbeele et al., 2013a, Van den 
Abbeele et al., 2010, Van den Abbeele et al., 2013b), SIMGI (Barroso et al., 2015) 
EnteroMix Lacroix (Mäkeläinen et al., 2007) which are computer-generated 
simulations. However, some of these models showed bias towards butyrate and 
propionate-producing gut microbiota (Van den Abbeele et al., 2010), issues alleviated 
by simulation of intestinal mucosal surfaces (Van den Abbeele et al., 2013a).   
Proportions of SCFA vary based on the type of carbohydrate fermented (Timm et al., 
2010, Fässler et al., 2006, Van den Abbeele et al., 2013b, Rodriguez-Colinas et al., 
2013). Oat bran and β-glucan fractions increased propionate (Connolly et al., 2010, 
Kedia et al., 2009, Van den Abbeele et al., 2013b) proportions while oligofructose 
increased acetate (Pan et al., 2009). Different fermentation patterns exist due to the 
speed of fermentation, microbial populations and cross-feeding interactions (Hernot et 
al., 2009, Zhou et al., 2015, Puertollano et al., 2014). 
Dietary supplementation of acetate, propionate or butyrate in in vivo studies are 
common. However, this does not give an accurate measure of what is occurring with 
the consumption of food products as fermentation rates are not taken into consideration 
(Hara et al., 1999). Comparisons of in vivo and in vitro fermentation have indicated 
that a suppressed rate of synthesis occurs with higher levels of SCFA in the liver 
absorbed from the intestine (Hara et al., 1999). Faecal propionate and butyrate 
concentrations increased in mice fed these SCFA compared to the high fat control diet, 
with no changes in mice fed acetate suggesting that dietary acetate is more efficiently 
absorbed by the intestine (Lu et al., 2016). The prebiotic effect of these more complex 
carbohydrates could be enhanced compared to pure culture fermentation (van Zanten 
et al., 2012) due to the intricacies of the biological system. 
Consideration of diurnal changes must also be made when collecting samples for 
SCFA analysis, as these impact the concentrations of acetate, propionate and butyrate 
in plasma and faecal samples (Hara et al., 1999). For example, portal concentrations 
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were increased 5 hours after feeding compared to 15 hours after feeding when they had 
returned to pre-feeding concentrations (Hara et al., 1999). Considerable individual 
variability in gut motility and transit time from caecum to rectum may lead to 
unexpected results when determining SCFA concentrations. In the small intestine, 
rates are relatively constant; however, in the colon, contents may take from hours to 
days without there being any dysfunction (Patten et al., 2015). Ex vivo studies of rats 
fed resistant starch have shown that ileal contractility does not change, yet colonic 
contractility is modified (Patten et al., 2015).  
Studies have shown differences in faecal SCFA patterns in rats that were on the 
different oat-based diets compared to a rice diet (Mårtensson et al., 2002). These 
indicate that different diets affect the SCFA in the colon and faecal excretion of these 
SCFA (Mårtensson et al., 2002). SCFA production by wholegrain oats is projected to 
have a role not only in the colon but also on serum lipids and cholesterol (Mårtensson 
et al., 2002, Ji-Lin et al., 2014),  as well as blood glucose and insulin concentrations 
(Connolly et al., 2012, Giacco et al., 2016). With processing, the bran of the oat grain 
is removed. Compounds such as fibre, phytochemicals, vitamins and minerals are also 
removed, altering the physiological responses (Connolly et al., 2012). Therefore, it is 
necessary to compare the differences that each component of an oat grain has on risk 
factors of metabolic syndrome in conjunction with the gastrointestinal changes that 
take place due to SCFA production (Figure 1.12).  
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1.5 Dietary implications 
While a rat model may be useful to examine the interaction of wholegrain oat, oat bran 
and β-glucans with the intestinal morphology and function, anatomical differences are 
important to note when translating to human studies. For example, the caecum of the 
rat, in which most fermentation takes place, needs to be compared with the proximal 
colon of a human, while the rat colon functions mainly in dehydrating and retaining 
unfermented residue which correlates to the human distal colon (Monro et al., 2012). 
Physiological responses to various oat products vary based on structure, composition 
and production techniques (Zhou et al., 2016, Wang and Ellis, 2014, Shewry et al., 
2013). Short-term feeding studies in metabolically controlled confines can produce a 
meaningful difference in response between experimental and control diets, while they 
control confounding factors such as nutrient composition, food type and preparatory 
methods. These studies have little translatability to everyday situations in humans and 
Figure 1.12 Effects of SCFA on colonic morphology and function 
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for long-term weight change, insulin regulation and blood pressure control where 
individuals have access to food ad libitum. Nevertheless, they still may inform and 
influence energy metabolism and body weight regulation. Wholegrain oats and 
associated oat products have the ability to improve stored metabolic fuel, alter gut 
motility, gastric emptying and affect the production of gut hormones to leading to 
satiation. The knowledge of these beneficial effects is being disseminated to encourage 
the consumption of these functional foods which leads to improvements across the 
range of metabolic syndrome symptoms. 
1.5 Coconut literature review 
1.5.1 Coconut and its health benefits 
The coconut (Cocos nucifera) has, for many civilisations, particularly in tropical and 
subtropical regions, been seen as the “tree of life” (DebMandal and Mandal, 2011). 
Coconut products have been used as a traditional food source, particularly across Asia 
and the Pacific Islands for hundreds of years (DebMandal and Mandal, 2011), yet until 
recently, the health benefits have been anecdotal rather than scientifically proven, with 
many previous studies focusing only on coconut oil (Arunima and Rajamohan, 2012; 
Liau et al., 2011; Zakaria et al., 2011) and not on the other components of coconut. 
Traditionally, all parts of the coconut, including the shell, fibre, pulp and water have 
been used to treat diseases such as diabetes, asthma, gastrointestinal and skin disorders, 
as well as for their antipyretic and diuretic responses (Lima et al., 2015). The coconut 
husk is a source of fibre that gives antimalarial, antibacterial and antidepressant 
responses (Akinpelu et al., 2015; Lima et al., 2016). 
The health benefits of coconut have been known for centuries (Zakaria et al. 2011). 
However, for many years, coconut oil was seen as harmful due to the high percentage 
content of saturated fatty acids. Many tests performed in the 1980s were undertaken 
using hydrogenated coconut oil which is different in content to virgin coconut oil 
(VCO) with none of the benefits (Clarke, 1988; Vaca, 1986). Not all saturated fatty 
acids are bad -(Poudyal & Brown 2015) and some have health benefits, including 
boosting metabolism, augmenting the immune system (Zakaria et al, 2011) and being 
a powerful antioxidant (Nevin, 2006). 
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The benefits of coconut as part of the diet can be seen in South Pacific Islanders who 
consume coconut in its natural state, and as a major dietary staple. Many have low 
incidence of coronary heart disease, degenerative diseases and low serum cholesterol 
concentrations compared to islanders who have adopted a Western-style diet and 
decreased intake of coconut while increasing concentrations of total cholesterol 
(Lindeberg et al., 1999; DiBello et al., 2009). Coconut or coconut products as part of 
the regular diet along with seafood in Samoan islanders protected against risk factors 
for cardiovascular disease (DiBello et al., 2009). These changes included higher HDL-
cholesterol concentrations and lower abdominal circumference (DiBello et al., 2009). 
Similar observations were seen in the Kitava population from the Tobriand Islands in 
Papua New Guinea when compared with a Swedish population. The Kitava population 
is free from overweight, hypertension, cardiovascular disease and malnutrition 
(Lindeberg et al., 1999). The regular diet of Kitava people includes tubers, coconuts 
and seafood (Lindeberg et al., 1999). 
1.5.2 Composition of coconut 
Coconut oil contains mainly medium-chain fatty acids (MCFA) instead of long-chain 
fatty acids (LCFA) (Marina et al., 2008). These MCFA are easily digested, absorbed 
and oxidised, and are transported directly to the liver for energy conversion through 
the tri-carboxylic acid cycle allowing hepatic cells to produce more energy and 
therefore utilise fat stores (St-Onge et al., 2002). This rapid absorption from the 
intestine into the liver takes place without pancreatic lipase catabolism (Liau et al., 
2011; Arunima and Rajamohan, 2012). VCO has a bland flavour and pleasant odour 
with a high resistance to rancidity. A narrow melting temperature range makes it easily 
digestible and gives good absorptive capacity (Marina et al., 2009).  
VCO is composed of approximately 90% saturated fatty acids (SFAs), particularly 
lauric (~50%) and myristic (~20%) acids (Katragadda et al., 2010). As MCFA, both 
lauric and myristic acids are rapidly oxidised by both the mitochondrial and 
peroxisomal pathways without being taken up into fat depots. In humans, VCO 
reduced body fat, especially abdominal fat, since abdominal circumference was 
decreased (Liau et al., 2011). Previous studies have reported on the various impacts of 
SFA on human health (Orsavova et al., 2015), and it has been concluded that lauric 
and myristic acids raise plasma total cholesterol concentrations, with lauric acid 
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increasing LDL cholesterol and myristic acid increasing both LDL and HDL 
cholesterol concentrations. However, it is important to note that it is the ratio of total 
cholesterol to HDL that is a more specific marker of coronary heart disease than the 
LDL value (Lawrence, 2013; Mensink et al., 2003). Lauric acid lowered the ratio of 
total cholesterol to HDL, while myristic acid showed no change (Lawrence, 2013).  
Lauric acid is converted to monolaurin in the body (Lieberman 2006). Monolaurin is 
not formed by the body unless there is a source of lauric acid in the diet, therefore 
indicating that coconut products should be included in the diet. Monolaurin acts as an 
antiviral, antibacterial and antiprotozoal monoglyceride destroying lipid-coated 
viruses, bacteria and protozoa (DebMandal and Mandal, 2011). Monolaurin only 
affected potentially pathogenic microorganisms while having no adverse effect on 
desirable gut bacteria (DebMandal and Mandal, 2011). Recent studies showed that 
lauric acid when compared to palmitic and stearic acids prevented induction of 
obesity and osteoarthritis in high carbohydrate, high fat diet fed rats (Sekar et al., 
2017).  
Capric acid, a minor component of CO (~6%), converts to monocaprin and acts as an 
antimicrobial agent (DebMandal and Mandal, 2011). The major triacylglycerides 
(TAG) found in VCO are LaLaLa (22-25%), CCLa (14-16%), CLaLa (19-21%), 
LaLaM (13-15%) and LaMM (7-9%) (La – lauric acid; C – capric acid and M – 
myristic acid) with the proportions of each individual fatty acid varying with the source 
and product production history (Marina, 2009). The quality of VCO and amount of 
beneficial MCFA and TAG in the oil varies depending on geographical location and 
ecological conditions (Nevin and Rajamohan, 2008).  
1.5.3 Coconut oil extraction methods 
Commercial grade coconut oil can be extracted by several methods. Coconut oil made 
from copra needs to be purified and refined to be suitable for consumption due to its 
susceptibility to aflatoxin contamination. (Marina, 2009). However, VCO is produced 
through a wet process direct from the coconut kernel under controlled temperatures, 
without any refining, bleaching or deodorising, allowing it to retain the beneficial 
components such as polyphenols and phenolic acids. 
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Compared to copra-based oil, VCO decreased total cholesterol, TAG, phospholipids, 
LDL-cholesterol, VLDL-cholesterol and increases HDL-cholesterol concentrations in 
serum (Nevin and Rajamohan, 2008). VCO also improved activity of antioxidant 
enzymes and decreased lipid peroxidation (Nevin and Rajamohan, 2008).  
VCO that has been heated can lead to increases in blood pressure and inflammatory 
markers such as ICAM, VCAM, CRP and TXB, whereas non-heated VCO does not 
possess these detrimental effects (Hamsi, 2014). Further, non-heated VCO conserved 
all the functional components of the coconuts, including tocopherols, sterols and 
squalene) as well as not losing the structural integrity of fatty acids (Zakaria et al., 
2011), preserving the natural antioxidant properties of the VCO. 
1.5.4 Therapeutic benefits of coconut 
1.5.4.1 Hepatoprotective responses 
Oxidative stress induced by generated free radicals plays a lead role in development 
of hepatic toxicity (Otuechere et al, 2014). In 2,4-dichlorophenoxyacetic acid (2,4-D) 
induced liver damage in rats, increased serum transaminases and alkaline phosphatase 
enzyme activity, and hepatic lipid peroxidation liver free fatty acids occur along with 
increased inflammation and necrosis. With the addition of VCO to the diet, serum total 
protein, albumin and hepatic superoxide dismutase and glutathione peroxidase 
activities were reduced (Hanaa et al 2013). Another study found that VCO-treated 
animals improved hepatic antioxidant enzymes, serum transaminase activity and liver 
free fatty acids, and decreased inflammation and necrosis (Zakaria et al 2011).  
VCO decreased total cholesterol, triglyceride and phospholipid concentrations in 
plasma, while also reducing LDL and VLDL cholesterol concentrations and increasing 
HDL cholesterol (Nevin et al 2004). It also lowered LDL:HDL ratio as VCO is not 
deposited in adipose tissue (Dayrit 2003). MCFA such as lauric and myristic acids are 
directly absorbed from intestine and sent straight to liver to be rapidly metabolised for 
energy production and therefore, do not participate in biosynthesis and transport of 
cholesterol (Enig 2004). 
One study investigated the effect of coconut flakes compared with oat bran and corn 
flakes on human serum cholesterol concentrations. Results indicated that reduction in 
serum total and LDL cholesterol concentrations for both coconut flakes and oat bran 
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compared to the cornflakes and triglycerides were reduced in all test foods (Trinidad 
2004). This study indicates that coconut flour is a good source of both soluble and 
insoluble dietary fibre and that they both may have a role in reducing lipid biomarkers.  
1.5.4.2 Anti-inflammatory, analgesic and anti-pyretic responses 
The addition of VCO had moderate anti-inflammatory effects in rats with ethyl phenyl 
propiolate-induced ear oedema or carrageenan and arachidonic acid-induced paw 
oedema. (Intahphuak et al. 2010) VCO had an inhibitory effect on chronic 
inflammation (Intahphuak et al. 2010) with a reduction of transudative weight, 
granuloma formation and serum alkaline phosphatase activity (Intahphuak et al. 2010). 
VCO induced moderate analgesic and antipyretic effects in acetic-acid induced 
writhing (model for analgesic activity) and yeast-induced hyperthermia (anti-pyretic 
activity) (Intahphuak et al 2010). 
1.5.4.3 Anti-hypertensive responses 
There has been limited human research on which to assess the responses of coconut 
oil or coconut products in relation to cardiovascular health as most of the evidence 
relates to lipid profiles. However, the high amounts of potassium found in tender 
coconut water (the liquid endosperm) lowered blood pressure (Loki, 2003). 
The consumption of coconut products that contain fibre, such as coconut flesh and 
coconut flour, within a diet that includes sufficient PUFA (omega-3) and an absence 
of excessive calories from refined carbohydrates does not pose a risk for heart disease 
(Trinidad 2004). 
1.5.4.4 Anti-glycaemic responses 
The potency of the insulinotropic effect of MCFA depends on chain length. Both 
capric and lauric acids have the most potent effects on insulin secretion (Garfinkel 
1992). In a study comparing coconut oil and sunflower oil, the coconut oil enhanced 
insulin action and improved binding affinity of the insulin receptors (Ginsberg 1982). 
Coconut kernel protein, mainly arginine, has potent anti-glycaemic activity through 
reversal of glycogen deposition, activities of carbohydrate metabolising enzymes and 
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the pancreatic damage due to its effect on pancreatic β-cell regeneration by means of 
arginine (Salil 2010). 
1.5.4.5 Anti-obesity responses 
Daily intake of medium and long chain triacyclglycerols (MLCT) reduced body weight 
and body fat accumulation (Assuncao 2009). Biochemical and anthropometric profiles 
of women with abdominal obesity (waist circumference >88cm) given VCO decreased 
abdominal fat compared to soybean oil (Assuncao 2009). 
1.5.4.6 Immunomodulatory responses 
MCFA in virgin coconut oil have shown antimicrobial properties in killing harmful 
viruses, bacteria, fungi and parasites (Shilling 2013). MCFA break down into free fatty 
acids and monoglycerides (Ogbolu 2007). Lauric, capric and caprylic acids in coconut 
oil are converted to their monoglyceride form as monolaurin, monocaprin and 
monocaprylin which prevent microbes from inhibiting the immune system. These fatty 
acids act on microbes in different ways. Some kill organisms that cause fungal 
infections but may not be useful on other microbes. Together these fatty acids form a 
high-powered defence system against disease with monolaurin giving the best 
antiviral, antifungal and antibacterial effects (Shilling 2013). 
VCO has been successful and effective against lipid-coated viruses such as 
Epstein-Barr, influenza, hepatitis C and cytomegalovirus (CMV) as it interferes and 
disrupts the virus membrane, assembly and maturation (DebMandal and Mandal 
2011). 
1.5.4.7 Antioxidant responses 
VCO is rich in polyphenols which contribute to increased antioxidant enzymes which 
reduce inflammation and lipid peroxidation (Yeap et al., 2015). One study compared 
VCO to copra, olive and sunflower oils on endogenous antioxidant status and 
paraoxonase-1 activity in ameliorating oxidative stress in rats. Virgin coconut oil 
improved antioxidant capacity compared to other oils by increasing catalase, 
superoxide dismutase, glutathione peroxidase and glutathione reductase activities in 
tissues (Arunima and Rajamohan, 2013). 
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1.5.4.8 Other therapeutic benefits 
There are many other benefits of coconut products, particularly coconut oil, that have 
been found over many years of use including wound healing, Alzheimer’s disease, 
dermatitis and stress. For example, topical applications on skin components and 
antioxidant status during dermal wound healing of young rats have shown within 24 
hours of application complete epithelisation and improvements of the parameters of 
wound granulation tissue (Nevin 2010). The solubility pattern of collagen, 
glycohydrolase activity and granulation tissue histopathology have also been studied. 
Animals treated with VCO had much faster healing with decreased time to complete 
epithelisation, increased pepsin soluble collagen and glycohydrolase activity leading 
to higher collagen crosslinking and turnover. This may have been due to the 
cumulative effect of various minor biologically active components present in coconut 
oil (Nevin, 2010).  
Other benefits have shown following the consumption of medium chain triacylglycerol 
(MCT) found in coconut may offer enhanced lipid oxidation and greater energy 
expenditure and a greater elevation of post-prandial oxygen consumption in healthy 
men compared to long-chain triacyclglycerols (Seaton 1986). 
1.5.5 Conclusion  
With the renewed emphasis on incorporating heart healthy fats into our diet, VCO and 
other coconut products show their versatility as a cooking medium and for their 
pharmacotherapeutic properties. However, there has been limited human research and 
further research is needed to provide conclusive evidence on clinical applications.  
While the health benefits of VCO have been well documented, there has been little 
done to discover the benefits of other components of coconut, such as the dried flesh 
which remains after the removal of the oil. Coconut Nourish does more than simply 
deliver coconut oil to the system, with proteins and carbohydrates as well as SFA, it 
may be a food source that is useful for combating the signs of metabolic syndrome. 
The study completed as part of this thesis has examined the impact that commercially 
available coconut products (Banaban extra virgin coconut oil (VCO) and Banaban 
Coconut Crunch supplied by Nature Pacific, Burleigh Heads, Qld) have on the signs 
of metabolic syndrome. 
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1.6 Objectives 
The main objective of this research is to investigate the effects of whole foods as 
functional foods on a validated rat model of metabolic syndrome.  
The aims are: 
1. To determine the effects of various oat products (wholegrain oat groats, oat 
bran and β-glucan powder supplement) on cardiometabolic health and 
gastrointestinal structure and function. 
2. To determine the effects of adding 20% wholegrain oat groats in the diet on 
cardiometabolic health and gastrointestinal structure and function.  
3. To determine the effects of virgin coconut oil and coconut Nourish on 
cardiometabolic health. 
The hypotheses of this research are that: 
1. Oats will induce metabolic changes and alter gastrointestinal structure and 
function in the host and these will be greater with more processing.  
2. Wholegrain oat groats will induce metabolic changes and alter gastrointestinal 
structure and function when added to a high carbohydrate, high fat diet and 
therefore will be a viable alternative to replace other grains in the diet. 
3. Virgin coconut oil and coconut Nourish will induce cardiometabolic changes 
when substituted into a high carbohydrate high fat diet.  
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 - Materials and Methods 
 
2.1 Ethics 
All animal handling and experimental protocols were approved by the Animal Ethics 
Committee of the University of Southern Queensland under the guidelines of the 
NHMRC (National Health and Medical Research Council of Australia) before 
experiments started. All rats were treated and housed as per the NHMRC 2014 
guidelines for ethical treatment of animals (National Health and Medical Research 
Council, 2013a). 
University of Southern Queensland Animal Ethics project numbers are as follows: 
 
 
 
 
 
 
AEC Project ID 13REA008 
 
AEC Project Title Effects of purified saturated fatty acids in 
normotensive male Wistar rats 
Commencement Date 09/07/2013 
Expiry Date 31/12/2014 
Experiments undertaken March 2014 – May 2014 
AEC Project ID 13REA005   
AEC Project Title  Diet-induced obesity in young male Wistar rats – 
Stage III 
Commencement Date 10 /09/2013 
Expiry Date 30/09/2016 
Experiments undertaken March 2014 - March 2015 
AEC Project ID 15REA003  
AEC Project Title  Cereal prebiotics for the treatment of diet-induced 
obesity in rats 
Commencement Date 20/07/2015 
Expiry Date 20/07/2018 
Experiments undertaken July 2015 – December 2015 
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The following handling and diagnostic Standard Work Procedures were utilised:  
USQ AEC SWP HP001 Rat blood collection - small volume (tail prick) • USQ AEC 
SWP HP002 Rat abdominal circumference measurement • USQ AEC SWP HP003 
Rat injectable anaesthesia with tiletamine-zolazepam (Zoletil) • USQ AEC SWP 
HP005 Rodent recognition and management of pain • USQ AEC SWP HP006 Rodent 
(rat or mouse) administration of a substance (oral gavage) • USQ AEC SWP HP007 
Rodent (rat or mouse) non-invasive identification methods • USQ AEC SWP HP009 
Rodent handling and restraint • USQ AEC SWP HP013 Rat blood collection  • USQ 
AEC SWP HP017 Rodent (rat or mouse) humane killing or euthanasia by pentobarbital 
sodium (Lethabarb®) • USQ AEC SWP HP020 Rodent (rat or mouse) transportation 
• USQ AEC SWP DP001 Rat oral glucose tolerance test • USQ AEC SWP DP002 Rat 
insulin tolerance test • USQ AEC SWP DP003 Rat systolic blood pressure 
measurement • USQ AEC SWP DP004 Rat in vivo heart function measurement 
(echocardiograph) • USQ AEC SWP DP005 Rat body composition measurement 
using dual-energy Xray absorptiometry (DEXA) • USQ AEC SWP DP006 Rat ex vivo 
heart function measurement (Langendorff) • USQ AEC SWP EX001 Request for 
veterinary care to be provided for approved AEC project animals • USQ AEC SWP 
AF005 Carcass disposal • USQ AEC SWP AF013 Rodent Environmental Enrichment 
 
2.2 Rat diets and experimental protocol 
2.2.1 – 5% oats 
Male Wistar rats were purchased from Animal Resource Centre (Canning Vale, WA) 
and housed individually in a temperature-controlled (21 ± 2ºC), 12 - hour light/dark 
cycle environment with ad libitum access to food and water at the University of 
Southern Queensland Animal House. 
Rats aged 8 - 9 weeks and weighing 330 – 340 g were randomly divided into four 
separate groups and were fed with either of the following diets for 16 weeks: corn 
starch rich diet (C) (n = 12); high carbohydrate, high fat diet (H) (n = 12). C diet 
consisted of corn starch (570 g/kg), powdered rat food (155 g/kg), salt mixture (25 
g/kg) and water (250 mL/kg). The H diet consisted of fructose (175 g/kg), condensed 
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milk (395 g/kg), powdered rat food (155 g/kg), beef tallow (200 g/kg), salt mixture (25 
g/kg) and water (50 mL/kg). In addition, rats on H diet were given drinking water 
containing 25% fructose. This common set of C and H rats were used for comparison 
against all intervention groups.  
To test interventions in these diets, the C and H diets were supplemented with either 
5% wholegrain oat groats (CO and HO rats) (n = 10/group), 5% oat bran (CB and HB 
rats) (n = 12/group) or 5% beta-glucan powder (CG and HG rats) (n = 8/group) with 
this 50 g/kg addition replacing 50 ml/kg of water. Interventions were started after 
8-weeks of the diet and continued for the remaining 8 weeks.  
Oat groats (Batch #160110598) (Figure 2.1) were sourced from Kialla Purefoods 
(Greenmount, Qld) and is commercially available. Oat bran (Lot #137162) (Figure 
2.1) was sourced from Trumps (Brisbane, Qld) and is commercially available. 
β-glucan powder (Batch #235177) (Figure 2.1) is a commercially available supplement 
purchased from Blooms Health (Alexandria, NSW), known as Cholesterol Balance 
Beta-glucan powder (Figure 2.1) Macronutrient and micronutrient contents of the three 
interventions were similar apart from protein and β-glucan concentrations (Table 2.1). 
 
Figure 2.1 Oat products used as interventions showing differences due to 
processing. Wholegrain oat groats (left), oat bran (middle), β-glucan powder 
(right)  
 
Energy intake was calculated from daily measurements of food and water intake using 
the following values in kJ/g: fructose 15.40, C 15.94, condensed milk 13.8, beef tallow 
37.70 and powdered rat feed 13.80 using food intake, and 3.85 kJ/ml for rats with H 
diets for the fructose-supplemented water (Panchal et al., 2011b). Energy contents of 
the diets were 11.2 kJ/g food for the C diet and 21.7 kJ/g food and fructose water for 
the H diet. Energy content for the CO diet was 12.0 kJ/g food, and 22.5 kJ/g food and 
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fructose water for the HO diet including fructose water. Energy content for the CB diet 
was 12.0 kJ/g food, and 22.5 kJ/g food and fructose water for the HB diet. Energy 
content for the CG diet was 11.9 kJ/g food, and 22.3 kJ/g food and fructose water for 
the HG diet.  
 
2.2.2 -  20% modified diet  
The C and H diets were then modified so that interventions up to 20% w/w of the diet 
could be included. The modified corn starch-rich diet (mC) consisted of corn starch 
(570 g/kg), salt mixture (25 g/kg), canola oil (5 ml/kg), skim milk powder (25 g/kg), 
vitamin mix (5 g/kg) and water (250 mL/kg). The modified high carbohydrate, high 
fat diet (mH) consisted of fructose (175 g/kg), condensed milk (395 g/kg), canola oil 
(5 ml/kg), skim milk powder (25 g/kg), vitamin mix (5g/kg), beef tallow (200 g/kg), 
salt mixture (25 g/kg) and water (50 mL/kg). Both diets were tested using 8 male 
Wistar rats weighing 330 - 340 g.  
To test an intervention in these modified diets, the mC and mH diets were 
supplemented with 20% wholegrain oat groats (mCO and mHO rats) with this 
200-g/kg addition replacing 200 ml/kg of water. Interventions were started after 8 
weeks of the diet and continued for the remaining 8 weeks with 8 rats in each 
intervention. The same batch of oat groats were used as in the CO and HO groups 
described above.  
Energy contents of the diets were 9.9 kJ/g food for the mC diet, 18.5 kJ/g for the mH 
diet (including fructose water), 13.1 kJ/g food for the mCO diet and 21.7 kJ/g for the 
mHO diet (including fructose water). 
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Table 2.1 Macronutrient and micronutrient composition of oat products 
Component/100 g Wholegrain 
oat groats 
Oat bran β-glucan 
powder 
Energy (kJ) 1597 1600 1377 
Protein (g) 13 13 22 
Fat (total) (g) 9 8 4 
- Saturated fat (g) 3 5 1 
Carbohydrates (g) 55 65 62 
β-glucan soluble fibre (g) 4 6 12 
 
Full nutrient analysis of β-glucan powder was carried out by Agrifood Technology 
after results of β-glucan testing returned with results different from the nutritional 
panel. β-glucan testing of oat groat and oat bran was within the expected range 
therefore the nutritional panel results were used. Oat groat testing was performed by 
Symbio Laboratories.  
 
2.3 Physiological measurements 
Body weight, food and water intakes were measured daily for all rats. Feed conversion 
efficiency (%) was calculated as  
𝑚𝑒𝑎𝑛 𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 𝑔𝑎𝑖𝑛 (𝑔)
𝑑𝑎𝑖𝑙𝑦 𝑒𝑛𝑒𝑟𝑔𝑦 𝑖𝑛𝑡𝑎𝑘𝑒 (𝑘𝐽)
 𝑥 100 
Abdominal circumference and body length (nose to anus) were measured at 0, 8 and 
16 weeks using a standard measuring tape under light anaesthesia with Zoletil 
(tiletamine 10 mg/kg, zolazepam 10 mg/kg, intraperitoneal; Virbac, Peakhurst, NSW, 
Australia). Body Mass Index (BMI) was calculated as body weight (g) / body length2 
(cm2).   
Visceral adiposity index (%) was calculated from wet weights of abdominal fat 
contents at euthanasia and expressed as adiposity percentage using the following 
formula: 
 66 
𝑟𝑒𝑡𝑟𝑜𝑝𝑒𝑟𝑖𝑡𝑜𝑛𝑒𝑎𝑙 𝑓𝑎𝑡 (𝑔) + 𝑜𝑚𝑒𝑛𝑡𝑎𝑙 𝑓𝑎𝑡 (𝑔) + 𝑒𝑝𝑖𝑑𝑖𝑦𝑚𝑎𝑙 𝑓𝑎𝑡 (𝑔)
𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑔)
 ×  100 
 
 
2.4 Oral glucose tolerance tests 
Oral glucose tolerance tests were performed at 0, 8 and 16 weeks. Rats were deprived 
of food for ~ 14 hours (12 hours fasting + 2 hours testing). Fructose-supplemented 
drinking water in the H, HO, HB, HG, mH and mHO groups was replaced with normal 
water for the food-deprivation period. Following this, basal blood glucose 
concentrations were measured in blood samples taken from rat tail vein using 
Medisense Precision Q.I.D. glucometer (Abbott Laboratories, Bedford, MA, USA). 
Glucose (2 g/kg body weight glucose as 40% aqueous solution) was given to the rats 
via oral gavage. Tail vein blood samples were taken at 30, 60, 90 and 120 minutes 
following glucose administration. 
 
2.5 Body composition by dual X-ray absorptiometry 
Dual-energy X-ray absorptiometric (DXA) measurements were performed on rats after 
16 weeks of feeding using a Norland XR36 DXA instrument (Norland, Fort Atkinson, 
WI, USA). The scans were analysed using manufacturer's recommended software for 
use in laboratory animals (Small Subject Analysis Software, version 2.5.3/1.3.1; 
Norland Corp) (Iftikhar et al., 1994). The precision error of lean mass for replicate 
measurements with repositioning was 3.2%.  
 
2.6 Systolic blood pressure 
Systolic blood pressure was measured at 0, 8 and 16 weeks. Rats were lightly sedated 
using an intraperitoneal injection of Zoletil (toletamine 10 mg/kg, zolazepam 
10-mg/kg; Virbac, Peakhurst, NSW, Australia) and measurements taken using a 
MLT1010 Piezo-Electric Pulse Transducer and inflatable tail-cuff connected to a 
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MLT844 Physiological Pressure Transducer. Data were acquired using PowerLab data 
acquisition unit (ADInstruments, Sydney, Australia). 
2.7 Echocardiography 
Echocardiographic examination (Hewlett Packard Sonos 5500, 12MHz transducer) 
was undertaken at 16 weeks at The Prince Charles Hospital, Chermside, Brisbane in 
accordance with the guidelines of the American Society of Echocardiography using 
the leading-edge method (American Society of Echocardiography, 2016). Rats were 
anaesthetised using an intraperitoneal injection of Zoletil (toletamine 10 mg/kg and 
zolazepam 10 mg/kg; Virbac, Peakhurst, NSW, Australia) and Xylazil (xylazine 6 
mg/kg; Troy Laboratories, Smithfield, NSW, Australia). Echocardiography was only 
undertaken on mC, mH, mCO and mHO rats (n = 8/group). 
 
2.8 Termination 
Rats were euthanised by intraperitoneal injection of Lethabarb (pentobarbitone 
sodium; 100 mg/kg; Virbac, Peakhurst, NSW, Australia). Heparin (200 IU; Sigma-
Aldrich Australia, Sydney, NSW, Australia) was administered through the right 
femoral vein followed by withdrawal of ~5 mL blood from the abdominal aorta. Blood 
was collected into heparinised tubes and centrifuged at 5000  g for 15 minutes within 
30 minutes of collection. Plasma was collected and stored at − 20°C until further 
analysis. 
Heparinised blood collection is utilised to inhibit thrombin formation and coagulation 
of blood and to allow the plasma to be centrifuged and collected for analysis. Plasma 
analysis was undertaken to determine total cholesterol, triglycerides, NEFA, liver 
enzymes (ALT, AST) and inflammatory marker concentrations.  
2.9 Left ventricular diastolic stiffness 
After euthanasia, left ventricular function of rats from all groups was assessed using 
isolated Langendorff heart preparation. Hearts isolated from euthanised rats were 
perfused with modified Krebs-Henseleit bicarbonate buffer containing NaCl 
119.1-mM, KCl 4.75 mM, MgSO4 1.19 mM, KH2PO4 1.19 mM, NaHCO3 25.0 mM, 
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glucose 11.0 mM and CaCl2 2.16 mM. Carbogen gas (95% O2 – 5% CO2) (BOC) was 
used to oxygenate the buffer at 35oC. Isovolumetric ventricular function was measured 
by inserting a latex balloon catheter into the left ventricle connected to a Capto SP844 
MLT844 physiological pressure transducer and Chart software on a MacLab system 
(ADInstruments, Sydney, NSW, Australia). The heart was electrically stimulated at 
250 beats per minute during the measurement of the diastolic pressure-volume 
relationship of the left ventricle. Pressures were obtained from 0 up to 30 mmHg for 
calculation of diastolic stiffness constant (κ, dimensionless) (Panchal et al., 2011b). 
 
2.10 Organ weights  
Following perfusion experiments, the right ventricle and left ventricle (with septum) 
were separated and weighed. Liver, kidney, retroperitoneal fat, epididymal fat and 
omental fat were removed and weighed. Organ weights were normalised relative to 
tibial length (mg/mm) at the time of removal. 
 
2.11 Intestinal lengths 
Small and large intestines were laid out on the bench for measurement following 
removal of omental fat and immediately prior to sections being collected for ileum and 
colon contractility studies. Small intestine lengths were taken from junction of stomach 
and duodenum (pyloric sphincter) to ileo-caecal junction. Large intestine lengths were 
taken from caeco-colonic junction to rectum. 
 
2.12 Organ bath studies 
2.12.1 Thoracic aortic ring reactivity 
A section of thoracic aorta was collected immediately after euthanasia and removal of 
heart and placed in oxygenated (carbogen 95% O2- 5% CO2) Tyrode’s buffer 
containing NaCl 136.9 mM, KCl 5.4 mM, MgCl2 1.05 mM, NaH2PO4 0.42 mM, 
NaHCO3 22.6 mM, CaCl2 1.8 mM, D-glucose 5.5 mM, ascorbic acid 0.28 mM and 
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Na2 - EDTA 0.1 mM). Thoracic aortic rings (~ 4 mm length) were suspended in an 
organ bath chamber with resting tension of ~10 mN, buffer was equilibrated at 37oC 
in each chamber. Forces of contraction were measured using a Chart MacLab System 
(ADInstruments, Castle Hill, Australia). For measurement of sodium nitroprusside and 
acetylcholine responses, thoracic aortic rings were pre-contracted with noradrenaline 
and allowed to stabilise. Cumulative concentration-response (contraction) curves were 
measured for noradrenaline (Sigma-Aldrich Australia, Sydney, NSW, Australia), and 
cumulative concentration-response (relaxation) curves were measured for 
acetylcholine and sodium nitroprusside (Sigma-Aldrich Australia, Sydney, NSW, 
Australia) in the presence of a submaximal (~ 70%) contraction to noradrenaline at 
half log units from 1x10‾9 mol/L to 3x10‾5 mol/L or until no further increases in 
contraction were observed. 
2.12.2 Ileum and colon reactivity 
Approximately 1 cm sections of both ileum and proximal colon were collected and 
washed gently in Tyrode’s buffer. Sections were strung at a tension of ~ 10 mN in 
organ baths containing 25 ml Tyrode’s buffer equilibrated to 37oC oxygenated with 
carbogen gas (95% O2 - 5% CO2 (BOC)).  Each tissue was washed twice in equilibrated 
Tyrode’s buffer prior to and between the addition of each drug concentration and 
allowed to equilibrate to ~ 10 mN. Force of contraction was measured by a Chart 
MacLab System (ADInstruments, Castle Hill, Australia). Maximal contractility (mN 
tension) was measured at half-log increases using acetylcholine from 1x10‾9 mol/L to 
3x10‾5 mol/L as a concentration-response curve or until no further increases in 
contraction were observed. 
 
2.13 Histological analysis 
Two rats per group were used exclusively for histological analysis. The following 
tissues were collected: duodenum, jejunum, ileum, proximal colon, mid colon, distal 
colon, liver, heart. All intestinal samples collected were ~ 1 cm in length. Sections 
were immediately washed in cold Tyrode’s buffer and placed in 10% buffered 
formalin.   
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Duodenal sections were collected 1 cm from junction with stomach. Jejunal sections 
were taken at the midpoint between duodenum and ileum (based on prior small 
intestinal measurements). Tissues were processed using a Shandon Pathcentre 
Automatic tissue processor. Using a pre-set protocol as follows: Dehydration with 
increasing series of ethanol for 1 hour each 70%, 90%, 95%, 100% x 3, followed by 
rehydration with xylene 3 times. Samples were then soaked in four sets of wax for 
1-hour each.  
Following processing, tissues were embedded in paraffin using a Microm International 
EC350 Tissue Embedding Centre. Tissue specimens were prepared on two slides per 
specimen and two random, non-overlapping fields per slide were taken to avoid biased 
analysis. Organs from rats used in perfusion studies were also collected. Thin sections 
(5 μm) of tissues were cut and stained with haematoxylin and eosin stain (Figure 2.2) 
for determination of inflammatory cell infiltration (heart and liver), fat vacuole 
deposition (liver) and gastrointestinal morphology. Picrosirius red staining (Figure 
2.3) was used to define collagen distribution in the left ventricle of the heart. Periodic 
Acid-Schiff’s stain (Figure 2.4) was used to determine glycoprotein distribution within 
the gastrointestinal tract. 
 
 
Figure 2.2 - Haematoxylin & Eosin tissue staining protocol 
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Figure 2.3 - Picrosirius Red tissue staining protocol 
 
 
Figure 2.4 - Periodic Acid - Schiff tissue staining protocol 
  
Xylene - 2 minutes Xylene - 2 minutes Xylene - 2 minutes 
100% ethanol - 2 
minutes
100% ethanol - 2 
minutes 
90% ethanol - 2 
minutes
70% ethanol - 2 
minutes
Running Water - 2 
minutes 
Distilled Water - 30 
seconds
Phosphomolybdic 
acid - 5 minutes
Running Water - 2 
minutes
Picosirius Red 0.1% 
- 60 minutes
HCl  0.1N - 2 
minutes 
95% ethanol - 2 
minutes
100% ethanol - 2 
minutes
100% ethanol - 2 
minutes
100% ethanol - 2 
minutes
Xylene - 2 minutesXylene - 2 minutesXylene - 2 minutes 
Xylene - 2 
minutes 
Xylene - 2 
minutes 
Xylene - 2 
minutes 
100% ethanol -
2 minutes
100% ethanol -
2 minutes 
90% ethanol - 2 
minutes
70% ethanol - 2 
minutes
Running Water 
- 2 minutes 
Distilled Water 
- 30 seconds
Periodic Acid 
0.5% - 5 
minutes
Distilled Water 
- 30 seconds
Schiff Reagent -
15 minutes
Lukewarm 
Water - 5 
minutes
Distilled Water 
- 30 seconds
Haematoxylin -
1 minute 
Tap Water - 5 
minutes
Distilled Water 
- 30 seconds
95% ethanol - 2 
minutes
100% ethanol -
2 minutes
100% ethanol -
2 minutes
100% ethanol -
2 minutes
Xylene - 2 
minutes
Xylene - 2 
minutes
Xylene - 2 
minutes 
 72 
2.13.1 Tissue imaging  
EVOS FL Cell imaging system (Life Technologies, Carlsbad, CA) using a Sony 
ICX285AQ camera at 10 x and 20 x magnification was used to determine the structural 
integrity of the gastrointestinal tract and the extent of collagen and fat deposition in 
selected tissue sections. 
Nikon Eclipse E600 with a UPLFL 4 x / 0.13 objective using a Olympus DP26 camera 
was used to measure intestinal structures.  
The CellSens Standard 1.9 imaging program system was used for structural analysis. 
Villi height, crypt depth and mucosal thickness of each section were measured. Each 
parameter was measured 6 - 8 times using random selection of complete villi / crypt / 
mucosal structure within the field of view, and an average taken for each section with 
4 - 6 sections measured per control and intervention groups. Villi height was 
determined using villi that were standing vertically, from tip to the top of the crypt. 
Crypt depth was top of crypt to base. Total mucosal thickness was measured in the 
small intestine from tip of the villi to start of the muscularis layer while in the large 
intestine it was measured from lumen to muscularis layer.  
 
2.14 Plasma analysis 
Frozen plasma collected in section 2.8 was thawed. Plasma liver enzyme activities – 
ALT and AST (alanine transaminase and aspartate transaminase), triglycerides, total 
cholesterol and NEFA (non-esterified fatty acids) were determined using 
commercially available kits and controls (Olympus) using an Olympus analyser 
(AU400, Tokyo, Japan). These measurements were undertaken by staff at The 
University of Queensland Veterinary Laboratory Services, Gatton Campus.   
Plasma C-reactive protein (CRP) was determined using a Rat C-reactive Protein 
ELISA kit (BD Biosciences) as per manufacturer’s instructions. Briefly, wash buffer 
was prepared (PBS in 1 L distilled water). CRP standards were serial diluted from 10-x 
stock. Plasma samples collected following euthanasia was diluted 1:10000. 100 µL 
plasma was pipetted into each well of a 96 - well plate in duplicate, then incubated at 
room temperature for 30 minutes. The plate was washed 4 - 5 times with wash buffer 
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and 100 µL (1:100 dilution from working concentration) Horseradish Peroxidase 
(HRP) was added to each well, covered and incubated for 30 minutes at room 
temperature. The plate was again washed 4 - 5 times and tapped dry. 100 µL 
3,3′,5,5′ - Tetramethylbenzidine (TMB) substrate was added and incubated for 
5-- 6- minutes at room temperature. 100 µL stop solution was then added and 
absorbance (450 nm) read using a Fluostar Omega plate reader. 
 
2.15 Fatty acid analysis 
2.15.1 Fatty acid extraction 
Fatty acids were extracted from 6 - 8 faecal samples per experimental group using 
diethyl ether (Bacto Laboratories). ~ 0.5 g faeces were placed in a tube with 5 ml 
MilliQ water, vortexed to break up the samples and acidified with 12 - 15 drops of 
analytical grade 32% hydrochloric acid (Labserv) and shaken for 30 seconds. 2 ml 
diethyl ether was added to each sample and centrifuged for 5 minutes at 4000 rpm. 
Supernatant was removed and stored, and process repeated. Supernatant was combined 
for each sample and transferred to a 2 ml gas chromatography vial for immediate 
analysis.  This method of extraction recovers >99% of fatty acids that are in samples.   
 
2.15.2 Chromatographic conditions 
Fatty acids were identified using gas-chromatography-flame ionisation detector. A 
Shimadzu GC -  2010 gas chromatograph with an AOC - 20i autoinjector sampled 
from an AOC - 20s autosampler using a Restek RTX - 5MS capillary column (30 m x 
0.25 mm x0.25 µm) (serial number 800436).  
An initial oven temperature of 130°C was held for 3 minutes, the temperature was 
increased to 200°C at a rate of 15°C/min-1. Upon reaching 200°C, the oven was held at 
this temperature for 3 minutes. The method required a total run time of 10.67 minutes. 
A volume of 1.0 µL was injected for each sample with an injection temperature of 
200°C utilising a 10:1 split ratio using ultra-pure helium carrier gas at a linear velocity 
of 13.3 cm/s-1 at a pressure of 49.9 kPa. The column flow rate was 0.36 mL/min-1. A 
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purge flow of 3.0 mL/min-1 was used, with a total flow rate of 7.0 mL/min-1. The flame 
ionisation detector used temperature of 200°C with a sample rate of 40 msec.  
Oven conditions for this method were developed using a multi-standard of acetic acid 
(C2:0) (Rowe Scientific), propionic acid (C3:0) (Sigma-Aldrich) and butyric acid 
(C4:0) (Sigma-Aldrich) was made up in 4 different concentrations of 0.1 M, 0.01 M, 
0.001 M and 0.0001 M to produce a calibration curve. All calibration curves were 
linear across the ranges tested. Each multi-standard concentration was run to determine 
retention time of the standard acids (Figure 2.4 and Table 2.2). A standard curve for 
each acid was done for their quantitation in the samples (Figure 2.6). Accuracy was 
determined by using a spiked placebo sample and a spiked faecal control sample at a 
known concentration.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 Sample chromatogram of standard acids at 0.1M to determine 
retention time of acetic acid, propionic acid and butyric acid. 
 
Table 2.2 Retention times of acetic, propionic and butyric acids. 
 
 
Compound Retention time (minutes) 
Acetic acid 6.636 
Propionic acid 7.299 
Butyric acid 8.067 
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Figure 2.6 Calibration Curves for Acetate, Propionate and Butyrate for faecal 
SCFA analysis 
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Figure 2.7 Example of validation chromatograms with C and H faecal samples 
with the addition of 0.01M standard to determine accuracy of retention times 
and sample selection. 
 
 
2.16 Statistical analysis 
Data are presented as mean ± standard errors of the means (S.E.M). Differences 
between the groups were determined by 1 - way and 2 - way analysis of variance 
(ANOVA). Statistically significant variables were treated with Newman-Keuls post 
hoc test to compare all the groups of animals. P < 0.05 was considered statistically 
significant. GraphPad Prism version 7.00 for Windows (San Diego, CA, USA) was 
used to perform all statistical analyses. 
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 - Oat products attenuate metabolic syndrome in 
high carbohydrate, high fat-fed rats. 
 
3.1 Introduction 
Metabolic syndrome and obesity are major worldwide health issues that affect between 
20 and 40 percent of the adult population (Moreira et al., 2014, O'Neill and O'Driscoll, 
2015). Diets high in fats and carbohydrates, particularly fructose, are one of the major 
contributing factors towards metabolic syndrome (ter Horst et al., 2016, Moreira et al., 
2014). In recent years, diet has become an integral therapeutic component to return the 
biomarkers of metabolic syndrome to normal. Functional foods that confer a health 
benefit in addition to nutrition are becoming part of the treatment. Diets that include 
cereal grains, such as oats, may protect the body against cardiovascular disease and 
diabetes (Connolly et al., 2012, Zhou et al., 2015, Dixit et al., 2011). As reviewed in 
Chapter 1, β-glucans decreased blood cholesterol concentrations and improved 
postprandial glycaemic response by binding cholesterol and bile acids assisting in their 
elimination from the body (Queenan et al., 2007, Drozdowski et al., 2010). The fibre 
and micronutrients contained in the cereal grain may have protective effects depending 
on their solubility (Jonnalagadda et al., 2011). However, the beneficial effects of these 
grains may vary in response to soluble fibre concentrations.  
In recent years, oats have become more fashionable as a food source around the world 
due to its status as a functional food. Unlike wheat and most other cereal grains, oats 
do not contain gluten but avenin, which may make oats suitable for coeliac disease 
patients (Moulton, 1959, Janatuinen  et al., 1995). However, in Australia and New 
Zealand, it is recommended that coeliac disease patients do not consume oats 
(Gastroenterological Society of Australia, 2012) as some people also have a sensitivity 
to avenin (Hardy et al., 2015). 
Oats are generally consumed as a wholegrain (van den Broeck et al., 2016), however 
many previous studies have focussed on oat β-glucans. The 2015 American Dietary 
Guidelines note that 3 g/day β-glucans and 16 g/day of wholegrains reduce the risk of 
developing chronic diseases, including diabetes, cardiovascular disease and possibly 
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some cancers (U.S. Department of Health and Human Services and U.S. Department 
of Agriculture, 2015). Although the gastrointestinal tract is integral to the absorption 
of nutrients and the environment of the microbiome, there is a paucity of information 
regarding the impact of oat products on gastrointestinal morphology, especially in 
relation to high carbohydrate, high fat diets and metabolic syndrome. 
One possible mechanism of action is through the production of shortchain fatty acids 
(SCFA). As β-glucans may have prebiotic effects (Arena et al., 2014), these 
wholegrain oat groats, oat bran and  β-glucans should increase concentrations of SCFA 
in the colon. The physiological functions of SCFA are discussed in Chapter 1.  
Previous limited work has concentrated on the gut microbiota composition, showing 
that wholegrain oat, oat bran and oat β-glucan altered the microbiota (Wolever et al., 
2010, Mantzouridou et al., 2013, Kedia et al., 2009). Whether these microbiome 
changes modify the colonic and plasma concentrations of SCFA and subsequent 
physiological effects are currently unknown.  
The objectives of this study were to determine the effects of wholegrain oat groats, oat 
bran and partially purified β-glucans on the physiological and metabolic parameters 
associated with metabolic syndrome. Further, this study assessed whether these 
changes were associated with changes to the morphology of the gastrointestinal tract 
and the faecal SCFA in male Wistar rats fed a high carbohydrate, high fat diet. It is 
hypothesised that, with increased processing of oats in the diet, the parameters 
associated with metabolic syndrome will be improved to a greater degree. The second 
hypothesis is that the various oat products will give similar responses in both C and H 
diets. The third hypothesis is that it is not just the β-glucans in the oat that are 
beneficial, so that all nutrients work synergistically to improve metabolic syndrome 
parameters. 
3.2 Methods 
This study was  approved by the USQ Animal Ethics Committee (AEC #13REA005 
valid until 30 September 2016) using approved methods, diets, cardiovascular, 
metabolic, hepatic and gastrointestinal studies as outlined in Chapter 2. 
8 groups of rats were used for this study, defined as cornstarch (C) or high 
carbohydrate, high fat (H) controls (n = 12/group), cornstarch + wholegrain oat groats 
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(CO) or high carbohydrate, high fat + wholegrain oat groats (HO) (n = 10/group), 
cornstarch + oat bran (CB) or high carbohydrate, high fat + oat bran (HB) (n = 
12/group) and cornstarch + β-glucan powder (CG) or high carbohydrate high fat + β-
glucan powder (HG) (n = 8/group). The concentration of β-glucans increased from 4% 
in the wholegrain oat groat to 6% in oat bran and 12% in the partially purified β-glucan 
powder.  
The following tests on control and intervention groups were performed as in the 
methods detailed in Chapter 2 of this thesis: body weight, food, water and energy 
intake, oral glucose tolerance test, body composition (DXA), systolic blood pressure, 
diastolic stiffness, aortic contractility, ileum and colon contractility, blood lipid 
analysis, liver enzyme analysis, gastrointestinal structural analysis, short chain fatty 
acid analysis  and plasma and tissue inflammatory marker analysis. 
To define the responses to each intervention, this study has been separated into three 
parts: wholegrain oat groats, oat bran and β-glucan powder. Differences between C 
and H will be discussed in the wholegrain oat groats section as they are common to all 
groups.  
 
3.3 Results 
3.3.1 Body Composition and dietary intake 
Body weights of H, HO (H + wholegrain oat groats), HB (H + oat bran) and HG (H + 
β-glucan powder) were higher than C, CO (C + wholegrain oat groats), CB (C + oat 
bran) and CG (C + β-glucan powder) after 16 weeks while CO and CG were heavier 
than C after 16 weeks. There was no change in final body weight in CB, HB and HG 
compared to respective controls (Figures 3.1a, 3.1b and 3.1c).  
The overall percentage weight gain from week 8 - 16 was not significantly different 
between any of the diets (Tables 3.1, 3.2 and 3.3). The abdominal circumference of H 
was increased compared to C; CO was greater than C and HO, HB and HG were 
decreased compared to H; CB and CG were not significantly different to C (Tables 
3.1, 3.2 and 3.3).  
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The retroperitoneal, omental, epididymal and total abdominal fat pads of H were 
increased compared to C (Tables 3.1, 3.2, 3.3). No significant differences in any of the 
fat pads were shown between controls and interventions (Tables 3.1, 3.2 and 3.3). 
 Lean mass increased in CO, CB and CG compared to C and HG compared with but 
there was no significant difference between C, H and HO or HB (Tables 3.1, 3.2 and 
3.3). Fat mass was increased in H compared to C with no significant difference 
between HO, HB and H or CO, CB, CG, HG and C; there was a decrease in fat mass 
in HG compared to H (Tables 3.1, 3,2 and 3.3).  
Food intakes (g/day) were decreased in H compared to C and were unchanged in the 
HO, HB, HG, CO and CG compared to respective controls; CB had a decreased food 
intake compared to C (Tables 3.1, 3.2 and 3.3). Water intake was the same in H, C all 
intervention groups except CO had an increased intake compared to C (Tables 3.1, 3.2 
and 3.3).  
Energy intakes for weeks 8-16 were greater in H, HO, HB and HG compared to C, 
CO, CB and CG. There was no significant difference between interventions and 
controls except CO had a decreased intake compared to C (Tables 3.1, 3.2 and 3.3).  
Feed efficiency was improved with the addition of wholegrain oat groats, oat bran or 
β-glucan powder to the diet regardless of control (Tables 3.1, 3.2 and 3.3).  
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Figure 3.1 Weekly body weight of male Wistar rats fed a diet of cornstarch or high carbohydrate, high fat (common to all 
groups) supplemented with a) wholegrain oat groats, b) oat bran or c) β-glucan powder after 8 weeks 
Values are mean ± S.E.M. n = 8 - 10 per group. Means without a common superscript letter differ  
C = cornstarch; CO = C + wholegrain oat groats; CB = C + oat bran;  CG = C + β-glucan powder; H = high carbohydrate, high fat;  HO = H 
+ wholegrain oat groats; HB =  H  + oat bran;  HG = H + β-glucan powder.
b) a) 
c) 
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Table 3.1 Body composition and food, water, energy intakes of male Wistar rats following a dietary intervention of wholegrain 
oat groats 
Values are mean ± S.E.M. and n = 8 - 10 per group. Means without a common superscript letter differ, * indicates P < 0.05   
C = cornstarch; CO = C + wholegrain oat groats; H = high carbohydrate, high fat;  HO = H + wholegrain oat groats. 
 
 
 
      P-value   
variable C CO H HO diet intervention interaction 
Initial body weight (g) 340±3a 340±3a 336±1a 335±3a 0.0984 0.8516 0.8516 
8-week body weight (g) 348±6a 353±6a 452±7b 442±7b <0.0001* 0.7068 0.2628 
Final body weight (g) 392±8a 420±8b 541±11c 543±11c <0.0001* 0.1274 0.1847 
Body weight gain 8-16 week (%) 11.1±1.1a 11.8±2.3a 11.5±1.2a 12.2±1.1a 0.07775 0.6566 0.9819 
Abdominal circumference (cm) 18±0.2a 19±0.1a 23±0.4b 22±0.4c <0.0001* >0.9999 0.0020* 
Retroperitoneal fat (mg/mm) 199±21a 209±17a 449±43b 445±17b <0.0001* 0.9197 0.8141 
Omental fat (mg/mm) 106±10a 148±11a 246±22b 231±8b <0.0001* 0.2508 0.8168 
Epididymal fat (mg/mm) 87±9a 127±8a 252±22b 266±9b <0.0001* 0.0705 0.3758 
Total fat pads (mg/mm) 392±33a 484±27a 948±80b 942±26b <0.0001* 0.4226 0.3615 
Lean mass (g) 255±10a 294±10b 263±11ab 260±8ab 0.2033 0.0824 0.0448* 
Fat mass (g) 121±12a 112±7a 254±18b 237±7b <0.0001* 0.3078 0.7515 
Food intake (g/day) 41±1a 38±1a 25±1b 24±1b <0.0001* 0.0551 0.3288 
Water intake (g/day) 27±2a 33±2b 29±1ab 26±1a 0.1323 0.3620 0.0086 
Energy intake 8-16 weeks (kJ/day) 447±18a 409±9c 534±8b 511±14b <0.0001* <0.0001* <0.0001* 
Feed efficiency (g/kJ) 0.08±0.01a 0.17±0.01c 0.13±0.01b 0.18±0.01c 0.0052 <0.0001* 0.0555 
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Table 3.2 Body composition and food, water, energy intakes of male Wistar rats following a dietary intervention of oat bran  
Values are mean ± S.E.M. and n = 8 - 10 per group. Means without a common superscript letter differ, * indicates P < 0.05 
C = cornstarch; CB = C + oat bran;   H = high carbohydrate, high fat;  HB =  H  + oat bran;   
 
 
      P-value  
variable C CB H HB diet intervention interaction 
Initial body weight (g) 340±3a 334±0a 336±1a 340±2a 0.6304 0.6304 0.0203* 
8-week body weight (g) 348±6a 339±3a 452±7b 442±6b <0.0001* 0.1211 0.9339 
Final body weight (g) 392±8a 404±5a 541±11b 537±8b <0.0001* 0.6439 0.3572 
Body weight gain 8-16 week (%) 11.1±1.1a 11.9±1.2a 11.5±1.2a 12.0±1.1a 0.8395 0.5898 0.8461 
Abdominal circumference (cm) 18±0.2a 18±0.1a 23±0.4b 22±0.3c <0.0001* 0.0683 0.0683 
Retroperitoneal fat (mg/mm) 199±21a 218±13a 449±43b 530±28b <0.0001* 0.1069 0.3128 
Omental fat (mg/mm) 106±10a 100±13a 246±22b 246±18b <0.0001* 0.8612 0.8612 
Epididymal fat (mg/mm) 87±9a 84±7a 252±22b 249±32b <0.0001* 0.8884 >0.9999 
Total fat pads (mg/mm) 392±33a 403±30a 948±80b 1026±75b <0.0001* 0.4832 0.5971 
Lean mass (g) 255±10a 296±11b 263±11ab 266±8ab 0.2842 0.0375* 0.0697 
Fat mass (g) 121±12a 94±10a 254±18b 246±5b <0.0001* 0.0638 0.7759 
Food intake (g/day) 41±1a 36±1b 25±1c 23±1c <0.0001* 0.0011* 0.1415 
Water intake (g/day) 27±2a 27±2a 29±1ab 26±1a <0.0001* 0.3480 0.3480 
Energy intake 8-16 weeks (kJ/day) 447±18a 429±10a 531±9b 497±7b <0.0001* 0.0913 0.6393 
Feed efficiency (g/kJ) 0.08±0.01a 0.15±0.01b 0.13±0.01b 0.17±0.01c 0.0015* <0.0001* 0.1503 
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Table 3.3 Body composition and food, water, energy intakes of male Wistar rats following a dietary intervention of β-glucan 
powder 
Values are mean ± S.E.M. and n = 8 - 10 per group. Means without a common superscript letter differ, * indicates P < 0.05  
C = cornstarch; CG = C + β-glucan powder; H = high carbohydrate, high fat;  HG = H + β-glucan powder. 
*** C & H are the same for all 3 intervention groups. ***
      P-value  
variable           C CG H HG diet intervention interaction 
Initial body weight (g) 340±3a 334±1a 336±1a 334±1a 0.3399 0.0611 0.3399 
8-week body weight (g) 348±6a 352±7a 452±7b 428±9b <0.0001* 0.1775 0.0622 
Final body weight (g) 392±8a 443±7b 541±11c 511±17c <0.0001* 0.3508 0.0009* 
Body weight gain 8-16 week (%) 11.1±1.1a 12.8±3.4a 11.5±1.2a 11.6±3.9a 0.8763 0.7030 0.7220 
Abdominal circumference (cm) 18±0.2a 19±0.1a 23±0.4c 21±0.5b <0.0001* 0.0735 <0.0001* 
Retroperitoneal fat (mg/mm) 199±21a 250±21a 449±43b 384±51b <0.0001* 0.8299 0.1245 
Omental fat (mg/mm) 106±10a 141±12a 246±22b 206±25b <0.0001* 0.9027 0.0526 
Epididymal fat (mg/mm) 87±9a 111±12a 252±22b 173±32b <0.0001* 0.1753 0.0151* 
Total fat pads (mg/mm) 392±33a 502±39a 948±80b 762±103b <0.0001* 0.5877 0.0400* 
Lean mass (g) 255±10a 324±7b 263±11a 340±10b 0.2293 <0.0001* 0.7041 
Fat mass (g) 121±12a 88±10a 254±18b 138±23a <0.0001* 0.0001* 0.0182* 
Food intake (g/day) 41±1a 40±2a 25±1b 25±1b <0.0001* 0.7141 0.6412 
Water intake (g/day) 27±2a 25±1a 29±1a 31±1a 0.0356* 0.8035 0.2625 
Energy intake (kJ/day) 447±18a 421±12a 534±8b 507±17b <0.0001* 0.0813 0.9732 
Feed efficiency (g/kJ) 0.08±0.01a 0.20±0.01d 0.13±0.01b 0.16±0.01c 0.6346 <0.0001* <0.0001* 
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3.3.2 Cardiovascular parameters 
Systolic blood pressure was higher in H than the C; HO, HB and HG were decreased 
compared to H; HO was normalised to C while CO, was decreased compared to C; CB 
and CG were similar to C (Tables 3.4, 3.5 and 3.6).  
Left and right ventricular wet weights were not significantly different across any of 
the intervention or control groups. Left ventricular diastolic stiffness was increased in 
the H compared to C; All intervention groups were the same as both controls (Tables 
3.4, 3.5 and 3.6). 
 Inflammatory cell infiltration increased in H compared to C, infiltration normalised 
in HO, HB and HG hearts (Figure 3.4). Collagen deposition was greater in H rats 
compared to C, with decreased deposition in HO, HB and HG (Figure 3.5)  
.  
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Table 3.4 Cardiovascular parameters of male Wistar rats following a dietary intervention of wholegrain oat groats 
      P-value  
Variable C CO H HO Diet intervention interaction 
Systolic Blood Pressure (mmHg) 131±2a 128±1b 152±1c 135±2a <0.0001* <0.0001* 0.0001* 
Left ventricular + septum wet weight (mg/mm) 18±2a 23±1a 20±2a 23±1a 0.5846 0.0337* 0.5846 
Right ventricular wet weight (mg/mm) 4±1a 6±0.6a 5±0.7a 6±0.3a 0.5372 0.0696 0.4372 
Left ventricular diastolic stiffness constant κ 25±1.6a 28±0.4ab 31±1.5b 30±2.0ab 0.0204* 0.5359 0.2223 
 
Table 3.5 Cardiovascular parameters of male Wistar rats following a dietary intervention of oat bran 
 
Table 3.6 Cardiovascular parameters  of male Wistar rats following a dietary intervention of β-glucan powder  
Values are mean ± S.E.M. and n = 8 - 10 per group. Means without a common superscript letter differ, * indicates P < 0.05 
C = cornstarch; CO = C + wholegrain oat groats; CB = C + oat bran; CG = C + β-glucan powder; H = high carbohydrate high fat;  
HO = H + wholegrain oat groats; HB = H + oat bran; HG = H + β-glucan powder *** C & H are the same for all 3 intervention groups*** 
     P-value 
variable C CB H HB diet intervention interaction 
Systolic Blood Pressure (mmHg) 131±2a 133±1a 152±1b 140±1c <0.0001* 0.0006* <0.0001* 
Left ventricular + septum wet weight (mg/mm) 18±2a 23±1a 20±2a 24±1a 0.37331 0.0100* 0.7656 
Right ventricular weight (mg/mm) 4±1a 6±0.6a 5±0.7a 6±0.4a 0.4033 0.0152* 0.4033 
Left ventricular diastolic stiffness constant κ 25±1.6a 28±1.2ab 31±1.5b 28±0.7ab 0.0338* >0.9999 0.0338* 
      P-value  
Variable C CG H HG diet intervention interaction 
Systolic Blood Pressure (mmHg) 131±2a 130±2a 152±1c 139±3b <0.0001* 0.0007* 0.0009* 
Left ventricular + septum wet weight (mg/mm) 18±2a 24±1a 20±2a 25±1a 0.4199 0.0050* 0.7872 
Right ventricular wet weight (mg/mm) 4±1a 5±0.3a 5±0.7a 5±0.6a 0.5365 0.5365 0.5365 
Left ventricular diastolic stiffness constant κ 25±1.6a 26±2.9ab 31±1.5b 30±1.8b 0.0286* >0.9999 0.6461 
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Figure 3.2 Inflammatory cells (IC) in the left ventricle of the heart of male Wistar rats induced by high carbohydrate, high fat diet 
and following a dietary intervention of wholegrain oat groats, oat bran or β-glucan powder for 8 weeks  
Haematoxylin & eosin staining, 20 x magnification. 
 C = cornstarch; CO = C + wholegrain oat groats; CB = C + oat bran; CG = C + β-glucan powder;  
H = high carbohydrate high fat; HO = H + wholegrain oat groats; HB = H + oat bran; HG = H + β-glucan powder  
 
 
IC 
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Figure 3.3 Collagen deposition (CD) in left ventricle of the heart of male Wistar rats induced by high carbohydrate, high fat diet 
and following a dietary intervention of wholegrain oat groats, oat bran or β-glucan powder for 8 weeks  
Picrosirius red staining, 20 x magnification. 
C = cornstarch; CO = C + wholegrain oat groats; CB = C + oat bran; CG = C + β-glucan powder; H = high carbohydrate high fat;  
HO = H + wholegrain oat groats; HB = H + oat bran; HG = H + β-glucan powder  
. 
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3.3.3 Liver Parameters 
Liver wet weight of H was increased compared to C, HO, HB and HG showed no 
change compared to H; CO and CG showed no change to C; however, CB was 
increased compared to C (Tables 3.7, 3.8 and 3.9).  
Plasma ALT was higher in H than C; HO and CO, CB remained unchanged compared 
to their relevant controls; HB decreased compared to H and was not significantly 
different to C; HG was increased compared to H and CG was not significantly different 
to either H or C (Tables 3.7, 3.8 and 3.9). 
Plasma AST was similar in H and C and remained unchanged in HO, CO and CG; CB 
and HB were decreased compared to relevant controls; HG increased compared to both 
H and C. (Tables 3.7, 3.8 and 3.9) 
 Fat vacuoles in the liver were obvious in H but were not visible in C, CO, CB, CG or 
HO and HG; HB had fewer and smaller fat vacuoles than H (Figure 3.10).  
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Table 3.7 Liver weight and plasma ALT, AST of male Wistar rats following a dietary intervention of wholegrain oat groats  
 
Table 3.8 Liver weight and plasma ALT, AST of male Wistar rats following a dietary intervention of oat bran 
 
Table 3.9 Liver weight and plasma ALT, AST of male Wistar rats following the a dietary intervention of β-glucan powder 
Values are mean ± S.E.M. and n = 8 - 10 per group. Means without a common superscript letter differ, * indicates P < 0.05  
C = cornstarch; CO = C + wholegrain oat groats; CB = C + oat bran; CG = C + β-glucan powder; H = high carbohydrate high fat; HO = 
H + wholegrain oat groats; HB = H + oat bran; HG = H + β-glucan powder. *** C & H are the same for all 3 intervention groups***. 
     P-value 
variable C CO H HO diet intervention interaction 
Liver wet weight (mg/mm) 229±11a 238±8a 320±11b 323±6b <0.0001* 0.5566 0.7684 
Plasma ALT (U/L) 25±4a 33±4a 36±3a 30±2a 0.2838 0.7865 0.0665 
Plasma AST (U/L) 75±9a 78±7a 67±3a 68±8a 0.2332 0.7883 0.8932 
     P-value 
variable C CB H HB diet intervention interaction 
Liver wet weight (mg/mm) 229±11a 271±11c 320±11b 325±9b <0.0001* 0.0309* 0.0861 
Plasma ALT (U/L) 25±4a 22±2a 39±3b 27±2a 0.0128* 0.0434* 0.2496 
Plasma AST (U/L) 75±9a 58±2b 69±3a 56±2b 0.5095 0.0182* 0.7343 
     P-value 
variable C CG H HG diet intervention interaction 
Liver wet weight (mg/mm) 229±11a 246±9a 320±11b 301±18b <0.0001* 0.9370 0.1608 
Plasma ALT (U/L) 25±4a 32±4ab 36±3b 43±5c 0.0001* <0.0001* <0.0001* 
Plasma AST (U/L) 75±9a 108±19ab 69±3a 134±30b 0.5006 0.0029* 0.2934 
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Figure 3.6 Fat deposition (FV) and inflammatiory cells (IC) in male Wistar rat livers induced by high carbohydrate, high fat diet 
and following a dietary intervention of wholegrain oat groats, oat bran or β-glucan powder 
Haematoxylin & eosin staining, 20 x magnification  
C = cornstarch; CO = C + wholegrain oat groats; CB = C + oat bran; CG = C + β-glucan powder; H = high carbohydrate high fat;  
HO = H + wholegrain oat groats; HB = H + oat bran; HG = H + β-glucan powder 
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3.4 Plasma biochemistry and inflammatory markers 
Plasma total cholesterol concentrations were not significantly different between any 
of the groups (Tables 3.10, 3.11 and 3.12). Plasma triglyceride concentrations were 
higher in H than C with no change in the HO, HB CO and CB compared to respective 
controls; HG concentrations decreased compared to H and CG was similar to both C 
and HG (Tables 3.10, 3.11 and 3.12).  
Plasma NEFA concentrations were increased in H compared to C, CO and CB were 
unchanged compared to C; HO and HB were unchanged compared to H; HG was 
decreased compared to H and CG increased compared to C and similar to H and HG 
(Tables 3.10, 3.11 and 3.12).  
Plasma C-reactive protein concentrations were not significantly different between any 
of the groups (Tables 3.10, 3.11 and 3.12).  
Fasting blood glucose concentrations were increased in H while concentrations in HO, 
HB and HG were normalised to C after 8 weeks of intervention CO, CB and CG 
remained unchanged from C (Table 3.10, 3.11 and 3.12). Similarly, the glucose area 
under the curve (AUC) was elevated in H; CO, CB and HB were at not significantly 
different compared to C values while CG, HO and HG had an increased glucose AUC 
than C but was decreased compared to H (Tables 3.10, 3.11 and 3.12).  
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Table 3.10 Plasma biochemistry and C-reactive protein of male Wistar rats following a dietary intervention of wholegrain oats 
groats  
 
 
 
 
 
 
      P-value  
variable C CO H HO diet intervention interaction 
Plasma total cholesterol 
(mmol/L) 
1.5±0.1a 1.5±0.2a 1.6±0.1a 1.5±0.1a 0.6296 0.6296 0.6296 
Plasma triglycerides 
(mmol/L) 
0.3±0.0a 0.5±0.0a 1.5±0.3b 2.2±0.5b <0.0001* 0.0757 0.3136 
Plasma NEFA (mmol/L) 1.2±0.2a 1.4±0.2a 4.1±0.6b 5.8±0.6c <0.0001* 0.0264 0.0745 
Plasma C-reactive protein 
(ng/ml) 
356±14a 359±27a 305±21a 283±19a 0.0049* 0.6511 0.5523 
Fasting blood glucose 
(mmol/L) 
4.0±0.1a 4.0±0.1a 5.1±0.2b 4.5±0.2a <0.0001* 0.0607 0.0607 
Glucose AUC 
(mmol/L/min) 
651±13a 619±19a 831±28b 730±24c <0.0001* 0.0035* 0.1223 
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Table 3.11 Plasma biochemistry and C-reactive protein of male Wistar rats following a dietary intervention of oat bran 
      P-value  
variable C CB H HB diet intervention interaction 
Plasma total cholesterol 
(mmol/L) 
1.5±0.1a 1.5±0.1a 1.6±0.1a 1.5±0.1a 0.6359 0.6359 0.6359 
Plasma triglycerides 
(mmol/L) 
0.3±0.0a 0.6±0.3a 2.0±0.3b 2.0±0.3b <0.0001* 0.5588 0.5588 
Plasma NEFA (mmol/L) 1.2±0.2a 2.2±0.5a 5.1±0.5b 4.4±0.4b <0.0001* 0.7228 0.0536 
Plasma C-reactive protein 
(ng/ml) 
356±14a 345±47a 305±21a 293±27a 0.0960 0.7034 0.9868 
Fasting blood glucose 
(mmol/L) 
4.0±0.1a 4.0±0.2a 5.1±0.2b 4.2±0.1a <0.0001* 0.0037* 0.0037* 
Glucose AUC (mmol/L/min) 651±13a 712±16a 831±28b 705±10a <0.0001* 0.0781 <0.0001* 
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Table 3.12 Plasma biochemistry and C-reactive protein of male Wistar rats following a dietary intervention of β-glucan powder 
Values are mean ± S.E.M. and n = 8 - 10 per group. Means without a common superscript letter differ, * indicates P < 0.05 
C = cornstarch; CO = C + wholegrain oat groats; CB = C + oat bran; CG = C + β-glucan powder; H = high carbohydrate high fat; 
HO = H + wholegrain oat groats; HB = H + oat bran; HG = H + β-glucan powder  
  *** C & H are the same for all 3 intervention groups*** 
      P-value  
variable C CG H HG diet intervention interaction 
Plasma total cholesterol 
(mmol/L) 
1.5±0.1a 1.6±0.1a 1.6±0.1a 1.7±0.1a 0.3441 0.3441 >0.9999 
Plasma triglycerides 
(mmol/L) 
0.3±0.0a 0.7±0.1ab 2.0±0.3c 1.3±0.3b <0.0001* 0.5242 0.0239* 
Plasma NEFA (mmol/L) 1.1±0.2a 4.1±0.6bc 5.1±0.5c 3.1±0.8b 0.0068* <0.0001* 0.3448 
Plasma C-reactive Protein 
(ng/ml) 
356±14a 317±18a 305±21a 342±15a 0.0416* 0.8707 <0.0001* 
Fasting blood glucose 
(mmol/L) 
4.0±0.1a 4.1±0.2a 5.1±0.2b 4.4±0.1a 0.0001* 0.0772 0.0204* 
Glucose AUC (mmol/L/min) 651±13a 740±10c 831±28b 727±25c 0.0005* 0.7345 <0.0001* 
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3.3.5 Gastrointestinal parameters  
3.3.5.1 Gastrointestinal length 
 
Small intestine length was similar in C and H and interventions were not significantly 
different to their respective controls (Figure 3.7a, 3.8a and 3.9a). Colon length was 
similar for both C and H and none of the interventions were different to the respective 
controls (Figure 3.7b, 3.8b and 3.9b).  
 
 
a) b)  
 
 
Figure 3.7 Gastrointestinal length of male Wistar rats following a dietary 
intervention of wholegrain oat groats.  a) small intestine – pyloric sphincter to 
caeco-ileal junction and b) colon – caeco-colonic junction to rectum 
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  P- value  
 diet intervention interaction 
small intestine 0.1550 0.0777 >0.9999 
colon 0.0320* 0.0273* 0.8698 
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Figure 3.8 Gastrointestinal length of male Wistar rats following a dietary 
intervention of oat bran a) small intestine - pyloric sphincter to caeco-ileal 
junction and b) colon – caeco-colonic junction to rectum 
  
  P- value  
 diet intervention interaction 
small intestine 0.0035* 0.8550 0.0505 
colon 0.0467* 0.4065 0.8201 
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Figure 3.9 Gastrointestinal length of male Wistar rats following a dietary 
intervention of β-glucan powder a) small intestine -pyloric sphincter to caeco-ileal 
junction and b) colon – caeco-colonic junction to rectum 
Values are mean ± S.E.M. n = 8 - 10 per group.  Means without a common superscript 
letter differ, * indicates P < 0.05  
C = cornstarch; CO = C + wholegrain oat groats; CB = C + oat bran;  
CG = C + β-glucan powder; H = high carbohydrate high fat; HO = H + wholegrain oat 
groats; HB = H + oat bran; HG = H + β-glucan powder  
  *** C & H are the same for all 3 intervention groups*** 
 
 
3.3.5.2 Gastrointestinal structure 
3.3.5.2.1 Villi height 
Duodenal villi height was decreased in H than C, while CO, CB CG and HO, HB, HG 
were similar to C (Tables 3.13, 3.14 and 3.15).  
Jejunal villi height was similar for all groups (Tables 3.13, 3.14 and 3.15). Ileal villi 
height was statistically similar in H and C; CB, CG and HO were similar to both 
controls; CO was longer than C; HG was greater than C but similar to H and CG 
(Tables 3.13, 3.14 and 3.15). 
  P- value  
 diet intervention interaction 
small intestine 0.5683 0.5683 0.0271* 
colon 0.4450 0.4450 0.0263* 
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Villi height profile along the small intestine was decreased in H diet compared to C 
and the three intervention diets. There were no changes in height between duodenum, 
jejunum and ileum in H (Figure 3.10). C duodenum villi height was increased 
compared to jejunum and ileum, and the jejunum villi height was increased compared 
to the ileum (Figure 3.10). CO duodenum villi height was increased compared to 
jejunum and ileum with no difference between jejunum and ileum (Figure 3.10). CB 
duodenum villi height was increased compared to the jejunum and ileum, and jejunum 
villi height increased compared to than ileum (Figure 3.10). CG duodenum villi height 
was greater than the ileum. Jejunum villi height was the same as duodenum and longer 
than ileum (Figure 3.10). 
 HO ileum villi height was decreased compared to both duodenum and jejunum. There 
was no difference between HO duodenum and jejunum (Figure 3.10). HB ileum villi 
height was less than both duodenum and jejunum. There was no difference between 
HB duodenum and jejunum (Figure 3.10). HG duodenum villi height was greater than 
jejunum and ileum while the jejunum villi height was greater than ileum (Figure 3.10). 
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Table 3.13 Villi height along small intestine of male Wistar rats following consumption of wholegrain oat groats 
 
 
 
 
 
 
 
Table 3.14 Villi height along small intestine of male Wistar rats following a dietary intervention of oat bran  
 
 
 
 
 
 
 
 
 
     P-value 
section C CO H HO diet intervention interaction 
Duodenum (µm) 735±55a 616±22a 352±81b 532±34a 0.0001* 0.5694 0.0087* 
Jejunum (µm) 403±31a 400±41a 380±98a 473±15a 0.6578 0.4271 0.3973 
Ileum (µm) 199±25a 304±5b 273±53ab 254±43ab 0.7443 0.2478 0.0998 
     P-value 
variable C CB H HB diet intervention interaction 
Duodenum (µm) 735±55a 709±68a 352±81b 599±49a 0.0007* 0.0974 0.0402* 
Jejunum (µm) 403±31a 371±45a 380±98a 515±52a 0.3362 0.4120 0.1877 
Ileum (µm) 199±25a 224±20a 273±53a 252±34a 0.1599 0.9552 0.5202 
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Table 3.15 Villi height along the small intestine of male Wistar rats following a dietary intervention of β-glucan powder  
  
Values are mean ± S.E.M. n = 8 - 10 per group.  Means without a common superscript letter differ, * indicates P < 0.05  
C = cornstarch; CO = C + wholegrain oat groats; CB = C + oat bran; CG = C + β-glucan powder; H = high carbohydrate high fat;  
HO = H + wholegrain oat groats; HB = H + oat bran; HG = H + β-glucan powder  
  *** C & H are the same for all 3 intervention groups*** 
 
     P-value 
section C CG H HG diet intervention interaction 
Duodenum (µm) 735±55a 509±53ab 352±81b 696±47a 0.3789 0.1.518 0.0004* 
Jejunum (µm) 403±31a 478±28a 380±98a 499±18a 0.9859 0.0995 0.6988 
Ileum (µm) 199±25a 268±19ab 273±53ab 340±15b 0.0322* 0.0444* 0.9751 
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Figure 3.10 Profile of villi height along small intestine of male Wistar rats following a dietary intervention of wholegrain oat groats, oat 
bran and β-glucan powder   
Number of * indicates number of groups that are significantly different. P < 0.05 is considered significant. 
C = cornstarch; CO = C + wholegrain oat groats; CB = C + oat bran; CG = C + β-glucan powder; H = high carbohydrate high fat;  
HO = H + wholegrain oat groats; HB = H + oat bran; HG = H + β-glucan powder   *** C & H are the same for all 3 intervention groups*** 
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3.3.5.2.2 Crypt depth 
Duodenal crypt depth in H was less than C, with CO, CB and HO, HB the same as C; 
CG and HG were not significantly different to H and C (Tables 3.16, 3.17 and 3.18). 
Jejunal and ileal crypt depths were unchanged in all diets (Tables 3.16, 3.17 and 3.18). 
Colonic crypt depth varied across proximal, mid and distal sections with crypts 
increasing in depth in the more distal portion of the colon (Tables 3.16, 3.17 and 3.18). 
However, within each section, there were no significant differences between diets 
(Tables 3.16, 3.17 and 3.18). 
 
Crypt depth profile along the entire gastrointestinal tract was similar in H with no 
difference between duodenum, jejunum, ileum, proximal colon, mid colon or distal 
colon (Figure 3.11). C crypt depth decreased from duodenum, jejunum to ileum. C 
crypt depth increased from ileum through to the distal colon (Figure 3.11). CO mid-
colon and distal colon were deeper than duodenum, jejunum, ileum and proximal colon 
(Figure 3.11). CB distal colon crypts were deeper than duodenum and jejunum but 
similar to ileum, proximal and mid colon (Figure 3.11). CG mid colon depth was 
deeper than all sections of the small intestine as well as the proximal colon. Distal 
colon crypts were deeper than jejunum and ileum but similar to duodenum, proximal 
and mid colon (Figure 3.11). HO had deeper crypt depths in mid colon and distal colon 
compared to proximal colon. HO ileum crypt depth was shorter than duodenum, mid 
colon and distal colon (Figure 3.11). HB had deeper crypt depths in mid colon and 
distal colon compared to jejunum and ileum with all other sections similar (Figure 
3.11). HG had deeper crypt depths in the distal colon compared to all other sections 
which were similar depths (Figure 3.11). 
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Table 3.16 Crypt depth along small intestine and colon of male Wistar rats following a dietary intervention of wholegrain oat groats 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
      P-value  
section C CO H HO diet intervention interaction 
Duodenum (µm) 151±8a 121±10ab 103±10b 137±23a 0.2654 0.8881 0.0309* 
Jejunum (µm) 112±9a 110±2a 127±9a 136±11a 0.0223 0.6826 0.5214 
Ileum (µm) 93±9a 98±5a 108±14a 98±8a 0.4396 0.7957 0.4396 
Proximal colon (µm) 116±17a 117±13a 85±20a 113±5a 0.2488 0.3375 0.3713 
Mid colon (µm) 158±34a 219±2a 154±39a 188±25a 0.5284 0.0941 0.6262 
Distal colon (µm) 189±22a 211±10a 147±26a 181±18a 0.0812 0.1704 0.7653 
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Table 3.17 Crypt depth along small intestine and colon of male Wistar rats following a dietary intervention of oat bran 
 
 
 
  
      P-value  
section C CB H HB diet intervention interaction 
Duodenum (µm) 151±8a 134±9aB 103±10b 166±22a 0.5582 0.0995 0.0062* 
Jejunum (µm) 112±9a 116±9a 127±9a 125±8a 0.1816 0.9099 0.7346 
Ileum (µm) 93±9a 136±22a 108±14a 104±15a 0.5925 0.2245 0.1456 
Proximal colon (µm) 116±17ab 149±27ab 85±20a 165±20b 0.1031 0.3058 0.9789 
Mid colon (µm) 158±34a 156±29a 154±39a 199±16a 0.5307 0.4897 0.4506 
Distal colon (µm) 189±22a 206±19a 147±26a 179±22a 0.2831 0.1346 0.7401 
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Table 3.18 Crypt depth along small intestine and colon of male Wistar rats following a dietary intervention of β-glucan powder 
Number of * indicates number of groups that are significantly different. P < 0.05 is considered significant. 
C = cornstarch; CO = C + wholegrain oat groats; CB = C + oat bran; CG = C + β-glucan powder; H = high carbohydrate high fat;  
HO = H + wholegrain oat groats; HB = H + oat bran; HG = H + β-glucan powder  
  *** C & H are the same for all 3 intervention groups*** 
 
 
      P-value  
section C CG H HG diet intervention interaction 
Duodenum (µm) 151±8a 115±13a 103±10a 147±12a 0.4723 0.7180 0.0015* 
Jejunum (µm) 112±9a 105±5a 127±9a 124±9a 0.0509 0.5482 0.8095 
Ileum (µm) 93±9a 106±7a 108±14a 119±11a 0.2003 0.2697 0.9256 
Proximal colon (µm) 116±17a 118±3a 85±20a 104±13a 0.1421 0.4840 0.5701 
Mid. colon (µm) 158±34a 189±12a 154±39a 168±21a 0.6663 0.4400 0.7690 
Distal colon (µm) 189±22a 164±16a 147±26a 198±10a 0.8393 0.5119 0.0651 
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Figure 3.11 Profile of crypt depth along small intestine and colon of male Wistar rats following a dietary intervention of wholegrain oat 
groats, oat bran or β-glucan powder 
Number of * indicates number of groups that are significantly different. P-value <0.05 is considered significant. 
C = cornstarch; CO = C + wholegrain oat groats; CB = C + oat bran; CG = C + β-glucan powder; H = high carbohydrate high fat;  
HO = H + wholegrain oat groats; HB = H + oat bran; HG = H + β-glucan powder; *** C & H are the same for all 3 intervention groups*** 
d
u
o
d
e
n
u
m
 
je
ju
n
u
m
 
il
e
u
m
 
p
ro
x
im
a
l 
c
o
lo
n
 
m
id
 c
o
lo
n
 
d
is
ta
l 
c
o
lo
n
 
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
d
e
p
th
 (

m
)
H O
* *
* * *
* *
*
* *
 110 
3.3.5.2.3 Villi height to crypt depth ratio 
Duodenal villi height to crypt depth ratio was decreased in H compared to C; HO and 
HG increased compared to H and were not significantly different to C (Table 3.18, 
3.19 and 3.20). CO, CB, CG and HB were the same as there relevant controls. Jejunum 
and ileum villi height to crypt depth ratios were not significantly different between any 
of the diets (Table 3.18, 3.19 and 3.20).  
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Table 3.19 Villi height to crypt depth ratio along the small intestine of male Wistar rats following a dietary intervention of 
wholegrain oat groats 
 
Table 3.20 Villi height to crypt depth ratio along the small intestine of male Wistar rats following a dietary intervention of oat 
bran 
 
      P-value  
section C CO H HO diet intervention interaction 
Duodenum (µm) 5.0±0.6a 5.2±0.3a 3.4±0.7b 4.4±0.8a 0.0498* 0.3140 0.4999 
Jejunum (µm) 3.6±0.1a 3.7±0.4a 2.6±1.0a 3.6±0.3a 0.3355 0.3355 0.4294 
Ileum(µm) 2.1±0.2a 3.1±0.2a 2.7±0.6a 2.8±0.6a 0.7398 0.2290 0.3229 
      P-value  
section C CB H HB diet intervention interaction 
Duodenum (µm) 5.0±0.6a 5.3±0.5a 3.4±0.7b 3.2±0.3b 0.0001* 0.9064 0.5577 
Jejunum (µm) 3.6±0.1a 3.3±0.6a 2.6±1.0a 4.1±0.1a 0.8660 0.3158 0.1367 
Ileum (µm) 2.1±0.2a 1.9±0.5a 2.7±0.6a 2.1±0.2a 0.3437 0.3437 0.6339 
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Table 3.21 Villi height to crypt depth ratio along small intestine of male Wistar rats following a dietary intervention of β-glucan 
powder 
Values are mean ± S.E.M. n = 8 - 10 per group.  Means without a common superscript letter differ, * indicates P < 0.05  
C = cornstarch; CO = C + wholegrain oat groats; CB = C + oat bran; CG = C + β-glucan powder; H = high carbohydrate high fat;  
HO = H + wholegrain oat groats; HB = H + oat bran; HG = H + β-glucan powder  
  *** C & H are the same for all 3 intervention groups*** 
      P-value  
section C CG H HG diet intervention interaction 
Duodenum (µm) 5.0±0.6a 4.5±0.4a 3.4±0.7b 5.3±0.4a 0.4681 0.2103 0.0382* 
Jejunum (µm) 3.6±0.1a 4.6±0.5a 2.6±1.0a 4.1±0.4a 0.2226 0.0488* 0.6793 
Ileum (µm) 2.1±0.2a 2.5±0.1a 2.7±0.6a 3.0±0.4a 0.1606 0.3649 0.8959 
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3.3.5.2.3 Mucosal thickness  
Duodenal mucosal thickness was decreased in H compared to C while CO, CB, CG, 
HO, HB and HG were not significantly different to C (Table 3.20, 3.21 and 3.22). 
Jejunal, ileal, proximal and mid colon mucosal thickness were not significantly 
different in any of the diets (Table 3.20, 3.21 and 3.22). Distal colon mucosal thickness 
was decreased in H compared to C, and CO, CB, CG, HO, HB and HG were not 
significantly different from to their respective controls (Table 3.20, 3.21 and 3.22). 
 
The profile of the mucosa was not uniform along the length of the gastrointestinal tract 
in all diets and there was large variability within sections (Figure 3.20). The mucosa 
of the small intestine was greater than the colon in all diets. H mucosal thickness was 
similar in the duodenum, jejunum and ileum and less in the colon with no difference 
between the proximal, mid and distal colon. C duodenal mucosa was greater than all 
other sections. C jejunum was greater than all sections except the duodenum and ileum; 
proximal colon, mid colon and distal colon were all similar thickness (Figure 3.20). In 
CO, all gastrointestinal sections were different with duodenum thickest and proximal 
colon thinnest. Mucosa became thinner from duodenum to proximal colon and became 
thicker from proximal colon to distal colon (Figure 3.20). In CB, all gastrointestinal 
sections were different with duodenum thickest and proximal colon thinnest. Mucosa 
became thinner from duodenum to proximal colon was a similar thickness from 
proximal colon to distal colon (Figure 3.20). CG mucosal thickness was the most 
variable with the duodenum the highest and proximal colon the lowest values. Mucosal 
thickness reduced from duodenum to proximal colon and was similar from proximal 
colon to distal colon (Figure 3.20). In HO, all gastrointestinal sections were different 
with duodenum thickest and proximal colon thinnest. Mucosa became thinner from 
duodenum to proximal colon and thicker in mid colon and distal colon (Figure 3.20). 
HB duodenal mucosa was thicker than all other sections except jejunum. HB ileum 
and all colon sections were similar thickness (Figure 3.20). HG duodenal mucosa was 
thicker than all other sections except jejunum. HG ileum was a different thickness to 
all other sections and all colon sections were similar thickness (Figure 3.20).  
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Table 3.22 Mucosal thickness along small intestine and colon of male Wistar rats following a dietary intervention of wholegrain 
oat groats 
 
Table 3.23 Mucosal thickness along small intestine and colon of male Wistar rats following a dietary intervention of oat bran 
 
      P-value  
section C CB H HB diet intervention interaction 
Duodenum (µm) 897±81a 874±60a 528±99b 848±32a 0.0109* 0.0498* 0.0250* 
Jejunum (µm) 518±57a 543±38a 670±137a 799±41a 0.0135* 0.3279 0.5068 
Ileum (µm) 300±33a 301±33a 427±63a 414±43a 0.0121* 0.8942 0.8767 
Proximal colon (µm) 234±26a 226±31a 231±57a 232±26a 0.9682 0.9259 0.9048 
Mid colon (µm) 221±23a 277±7a 268±41a 293±15a 0.2166 0.1153 0.5390 
Distal colon (µm) 314±39a 254±12a 234±20b 249±16ab 0.0886 0.3583 0.1308 
      P-value  
section C CO H HO diet intervention interaction 
Duodenum (µm) 897±81a 861±45a 528±99b 919±28a 0.0328* 0.0160* 0.0046* 
Jejunum (µm) 518±57a 613±90a 670±137a 588±26a 0.4663 0.9403 0.3121 
Ileum (µm) 300±33a 433±3a 427±63a 401±21a 0.2110 0.1605 0.0410* 
Proximal colon (µm) 234±26a 213±13a 231±57a 166±5a 0.4425 0.1910 0.4986 
Mid colon (µm) 221±23a 302±9a 268±41a 270±10a 0.7613 0.1007 0.1174 
Distal colon (µm)  314±39a 362±5a 234±20b 246±10b 0.0002* 0.1954 0.4328 
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Table 3.24 Mucosal thickness along small intestine and colon of male Wistar rats following a dietary intervention of β-glucan powder. 
Values are mean ± S.E.M. n = 8 - 10 per group.  Means without a common superscript letter differ, * indicates P < 0.05  
C = cornstarch; CO = C + wholegrain oat groats; CB = C + oat bran; CG = C + β-glucan powder; H = high carbohydrate high fat;  
HO = H + wholegrain oat groats; HB = H + oat bran; HG = H + β-glucan powder  
  *** C & H are the same for all 3 intervention groups*** 
 
 
      P-value  
section C CG H HG diet intervention interaction 
Duodenum (µm) 897±81a 729±65a 528±99b 920±58a 0.2636 0.1633 0.0017* 
Jejunum (µm) 518±57a 554±55a 670±137a 669±24a 0.1109 0.8291 0.8195 
Ileum (µm) 300±33a 363±30a 427±63a 441±11a 0.0161* 0.3352 0.5368 
Proximal Colon (µm) 234±26a 216±17a 231±57a 212±21a 0.9200 0.5968 0.9886 
Mid colon (µm) 221±23a 294±8a 268±41a 276±16a 0.5707 0.1230 0.2110 
Distal colon (µm) 314±39ab 260±20ab 234±20b 258±13b 0.1142 0.5525 0.1319 
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Figure 3.12 Profile of mucosal thickness along small intestine and colon of male Wistar rats following a dietary intervention of β-glucan 
powder    
Number of * indicates number of groups that are significantly different. P < 0.05 is considered significant.   C = cornstarch; CO = C + 
wholegrain oat groats; CB = C + oat bran; CG = C + β-glucan powder; H = high carbohydrate high fat; HO = H + wholegrain oat groats; HB = H 
+ oat bran; HG = H + β-glucan powder; *** C & H are the same for all 3 intervention groups***
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3.3.5.2.4 Goblet Cells  
 
Duodenal goblet cell numbers were not significantly different in H, C, CO, CB and 
HG with an increased number in CG, HO and HB compared to H and C (Tables 3.23, 
3.24 and 3.25). Jejunal goblet cell numbers were increased in H and HO, HB compared 
to C, with CO, CB, CG and HG having similar numbers all other diets (Tables 3.23, 
3.24 and 3.25). Ileal goblet cell numbers were greater in H than C, with all 
interventions having similar numbers to both controls (Table 3.23, 3.24 and 3.25).  
Colonic goblet cell numbers were unchanged between diets in proximal, mid and distal 
sections. However, there were more goblet cells in mid and distal colon than the 
proximal colon in all diets (Table 3.23, 3.24 and 3.25). However, as n = 4/group, 
further studies will need to be undertaken to determine any significance in goblet cell 
number changes in this model. 
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Table 3.25 Goblet cell number along small intestine and colon of male Wistar rats following a dietary intervention of wholegrain 
oat groats 
 
 
 
 
 
 
 
 
 
 
 
      P-value  
section C CO H HO diet intervention interaction 
Duodenum (µm) 4±1ab 5±1ab 1±0b 12±5a 0.4479 0.0285* 0.0645 
Jejunum (µm) 8±1a 13±3ab 17±2b 16±2b 0.0085* 0.3538 0.1683 
Ileum (µm) 9±2a 14±3ab 15±4b 13±6ab 0.5402 0.7126 0.3926 
Proximal colon (µm) 5±2a 5±1a 7±2a 6±2a 0.4124 0.7835 0.7835 
Mid colon (µm) 9±3a 17±5a 17±4a 10±2a 0.8927 0.8927 0.0508 
Distal colon (µm) 10±3a 12±3a 12±1a 11±3a 0.8515 0.8515 0.5753 
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Table 3.26 Goblet cell numbers along the small intestine and colon tract of male Wistar rats following a dietary intervention of 
oat bran 
 
 
  
      P-value  
section C CB H HB diet intervention interaction 
Duodenum (µm) 4±1a 8±1a 1±0a 16±3b 0.1429 <0.0001* 0.0025* 
Jejunum (µm) 8±1b 13±2ab 17±2a 18±4a 0.0092* 0.2402 0.4304 
Ileum (µm) 9±2a 11±1a 15±4a 13±1a 0.0553 0.6922 0.6922 
Proximal colon (µm) 5±2a 8±0a 7±2a 9±3a 0.4729 0.2354 0.8101 
Mid colon (µm) 9±3a 11±1a 17±4a 15±2a 0.0369* >0.9999 0.4713 
Distal colon (µm) 10±3a 14±1a 12±1a 15±1a 0.3938 0.0530 0.7750 
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Table 3.27 Goblet cell number along small intestine and colon of male Wistar rats following a dietary intervention of β-glucan 
powder 
Values are mean ± S.E.M. n = 8 - 10 per group.  Means without a common superscript letter differ, * indicates P < 0.05  
C = cornstarch; CO = C + wholegrain oat groats; CB = C + oat bran; CG = C + β-glucan powder; H = high carbohydrate high fat;  
HO = H + wholegrain oat groats; HB = H + oat bran; HG = H + β-glucan powder  
  *** C & H are the same for all 3 intervention groups*** 
      P-value  
section C CG H HG diet intervention interaction 
Duodenum (µm) 4±1ab 7±2a 1±0b 5±1b 0.0639 0.0144* 0.6903 
Jejunum (µm) 8±1b 10±1b 17±2a 7±1b 0.0426* 0.0106* 0.0007* 
Ileum (µm) 9±2a 11±1a 15±4a 7±0a 0.6703 0.2149 0.0497* 
Proximal colon (µm) 5±2a 11±1a 7±2a 9±0a >0.9999 0.0205* 0.2072 
Mid colon (µm) 9±3a 10±1a 17±4a 13±1a 0.0558 0.5744 0.3549 
Distal colon (µm) 10±3a 12±1a 12±1a 12±1a 0.5744 0.5744 0.5744 
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3.3.5.3 Gastrointestinal histology 
This section (Figures 3.13 to 3.18) is a visual representation of the data in the previous 
section (3.3.5.2 Gastrointestinal structure). Duodenum, jejunum and ileum show villi 
(V), crypts (C), mucosa (MT) and muscularis (M). Proximal, mid and distal colon 
show crypts (C), mucosa (MT), muscularis (M) and submucosal folds (S). 
Gastrointestinal morphology was changed by the addition of wholegrain oat groats, 
oat bran or β-glucan powder to the high carbohydrate, high fat diet. There were also 
differences between C and H diets.  
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Duodenum 
CS    CO    COB    CBGE 
 
HCHF    HO     HOB     HBGE 
  
Figure 3.13 Effects of oat supplemented diets on the morphology of the duodenum showing variations between control 
diets and Haematoxylin & Eosin Staining 4x magnification. 
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Jejunum 
CS     CO    COB    CBGE 
 
HCHF     HO    HOB    HBGE 
 
Figure 3.14. Effects of a variety of oat supplemented diets on the morphology of the jejunum, showing variations 
between control diets and intervention groups. Haematoxylin & Eosin Staining, 4x magnification. 
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Ileum 
CS     CO    COB    CBGE 
 
HCHF     HO    HOB    HBGE 
 
Figure 3.15. Effects of a variety of oat supplemented diets on the morphology of the ileum, showing variations between control diets and 
intervention groups. Haematoxylin & Eosin Staining, 4x magnification. 
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Proximal Colon 
CS     CO    COB    CBGE 
 
HCHF     HO    HOB    HBGE 
 
Figure 3.16. Effects of a variety of oat supplemented diets on the morphology of the proximal colon showing variations between control 
and intervention groups Haematoxylin & Eosin Staining, 4x magnification. 
 127 
 
Mid colon 
CS    CO    COB    CBGE 
 
HCHF    HO    HOB    HBGE 
 
Figure 3.17. Effects of a variety of oat supplemented diets on the morphology of the mid colon, showing variations between control diets 
and intervention groups Haematoxylin & Eosin Staining, 4x magnification. 
 
 128 
 
Distal colon 
CS     CO    COB   CBGE 
 
HCHF    HO    HOB    HBGE 
 
Figure 3.18. Effects of a variety of oat supplemented diets on the morphology of the distal colon, showing variations between control 
diets and intervention groups. Haematoxylin & Eosin Staining, 4x magnification. 
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3.3.5.4 Gastrointestinal contractility 
 
Ileal contractility in the H and C diets were the same. There was no difference with the 
addition of wholegrain oat groats or oat bran (Figure 3.19 and 3.20) β-glucan powder 
increased ileal contractility compared to both H and C (Figure 3.21). Colon 
contractility was the same for all diets (Figure 3.19, 3.20 and 3.21) . 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19 Effect of acetylcholine on the contractility of ileum and mid colon of 
male Wistar rats following a dietary intervention of wholegrain oat groats 
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  P-value  
 diet intervention interaction 
Ileum 0.3963 0.4743 0.0363* 
Colon  0.3314 0.0152* 0.3045 
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Figure 3.20 Effect of acetylcholine on the contractility of ileum and mid colon of 
male Wistar rats following a dietary intervention of oat bran 
  
  P-value  
 diet intervention interaction 
Ileum 0.0760 0.9220 0.8084 
Colon  0.0172* 0.0449* 0.9893 
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Figure 3.21 Effect of acetylcholine on the contractility of ileum and mid colon of 
male Wistar rats following a dietary intervention of β-glucan powder 
Values are mean ± S.E.M. n = 8 - 10 per group.  Means without a common superscript 
letter differ, * indicates P < 0.05  
C = cornstarch; CO = C + wholegrain oat groats; CB = C + oat bran; 
 CG = C + β-glucan powder; H = high carbohydrate high fat;  
HO = H + wholegrain oat groats; HB = H + oat bran; HG = H + β-glucan powder  
  *** C & H are the same for all 3 intervention groups*** 
 
 
  P-Value  
 diet intervention interaction 
Ileum 0.2216 0.0008* 0.8712 
Colon  0.6454 0.9499 0.1940 
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3.3.5.5 Faecal short-chain fatty acid (SCFA) analysis 
Total SCFA, acetate, propionate and butyrate concentrations were lower in H, HO, CG 
and HG compared to C, CO and CB with no difference between respective controls 
and interventions (Tables 3.26, 3.27 and 3.28). Total acetate concentrations were lower 
in HB compared to C and not significantly different to H (Table 3.27). Total SCFA 
and acetate concentrations of HG were increased compared to H (Table 3.28). 
Propionate concentrations were lower in H compared to C with HO, CO and CG 
unchanged compared to respective control (Table 3.26).  HG was increased compared 
to H and not significantly different from C (Table 3.28).  Butyrate concentrations were 
similar in all groups (Tables 3.26, 3.27 and 3.28)  
Propionate and butyrate concentrations as a percentage of the total faecal SCFA were 
greater in H, HO, HB and HG compared to C, CO, CB and CG which in turn decreased 
the percentage of acetate (Tables 3.26, 3.27 and 3.28) 
Acetate to propionate ratio was lower in H and HO than C and CO. HO, HB and HG 
were not significantly different to H (Tables 3.26, 3.27 and 3.28); CO was higher than 
C (Table 3.28), however, CB and CG were decreased compared to C (Table 3.29 and 
3.30).  
Acetate percentage of total faecal SCFA was greatest in C (92%) and lowest H (75%) 
with similar percentages in CO (77%), CB (86%), CG (83%) HO (85%), HB (75%) 
and HG (82%) compared to respective controls. Propionate percentage increased in 
CO (5%), CB (6%), CG (7%), HO (5%), HB (6%) and HG (6%) compared to C (3%) 
and H (4%). The highest percentage of butyrate was found in H (21%) with least in C 
(5%) CO (9%), CB (8%), HO (17%) and HB (19%) were not significantly different to 
C and H. HG (12%) decreased compared to H and CG (10%) increased compared to 
C.   
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Table 3.28 Average total SCFA, acetate, propionate and butyrate and acetate to propionate ratio in faecal samples of male Wistar 
rats following a dietary intervention of wholegrain oat groats 
 
Table 3.29 Average total SCFA, acetate, propionate and butyrate and acetate to propionate ratio in faecal samples of male Wistar 
rats following a dietary intervention of oat bran 
      P-value  
SCFA (µmol/g) C CO H HO diet intervention interaction 
Total SCFA 246±55a 212±14a 48±4c 76±3b <0.0001* 0.9172 0.2894 
Acetate 227±50a 181±14a 36±4c 59±3b <0.0001* 0.6640 0.2008 
Propionate 7±1b 12±1a 2±0.4d 4±0.5c <0.0001* 0.0002* 0.0676 
Butyrate 12±4a 19±3a 10±1b 13±2b 0.1597 0.0829 0.4737 
Acetate: Propionate 32.1±2.9a 15.1±0.1b 18.3±3.4b 14.8±1.1b 0.0061* 0.0002* 0.0082* 
      P-value  
SCFA (µmol/g) C CB H HB diet intervention interaction 
Total  246±55a 133±23b 48±4b 36±9b <0.0001* 0.0517 0.1102 
Acetate 227±50a 114±23b 36±4b 27±3b <0.0001* 0.0391* 0.0745 
Propionate 7±1a 8±1a 2±0.4b 2±0.5b <0.0001* 0.5268 0.5268 
Butyrate 12±4a 11±1a 10±1a 7±2a 0.2155 0.4039 0.6744 
Acetate: Propionate 32.1±2.9a 14.5±1.3b 18.3±3.4b 13.5±1.5b 0.0080* 0.0001* 0.0138* 
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Table 3.30 Average total SCFA, acetate, propionate and butyrate and acetate to propionate ratio in faecal samples of male Wistar 
rats following a dietary intervention of β-glucan powder 
Values are mean ± S.E.M. n = 8 - 10 per group.  Means without a common superscript letter differ, * indicates P < 0.05  
C = cornstarch; CO = C + wholegrain oat groats; CB = C + oat bran; CG = C + β-glucan powder; H = high carbohydrate high fat;  
HO = H + wholegrain oat groats; HB = H + oat bran; HG = H + β-glucan powder,  
  *** C & H are the same for all 3 intervention groups*** 
      P-value  
SCFA (µmol/g) C CG H HG diet intervention interaction 
Total  246±55a 120±8b 48±4d 89±2c 0.0005* 0.1431 0.0072* 
Acetate 227±50a 99±6b 36±4d 73±1c 0.0004* 0.0868 0.0039* 
Propionate 7±1ac 9±1a 2±0.4b 5±1c <0.0001* 0.0108* 0.5800 
Butyrate 12±4a 12±3a 10±1a 11±3a 0.6176 0.8675 0.8675 
Acetate: Propionate 32.1±2.9a 11.1±0.5b 18.3±3.4b 15.3±3.0b 0.0660 0.0001* 0.0039* 
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3.4 Discussion 
 
Metabolic syndrome is a complex combination of abnormalities associated with 
cardiovascular disease and type 2 diabetes, with the major cause being a diet high in 
fat and simple sugars (Kaur, 2014). As metabolic syndrome includes diabetes, 
hypertension, dyslipidaemia, fatty liver, glucose intolerance and obesity, many studies 
are needed to determine the causes and find ways to attenuate the complexity of 
symptoms. This study supplemented a high carbohydrate, high fat diet in a rat model 
of metabolic syndrome that mimics the human condition with 5% wholegrain oat 
groats, oat bran or partially purified β-glucan powder.  
Wholegrains are an important source of calories, nutrients and phytochemicals 
(Belobrajdic and Bird, 2013). Wholegrains have been associated with prevention of 
type 2 diabetes (Li et al., 2016), cancer (Jacobs et al., 1998) and other chronic diseases 
(Johnston et al., 2010, Dixit et al., 2011, Aune et al., 2016). The consumption of 
wholegrain oats has been advocated in dietary guidelines and nutritional policies 
worldwide (Clemens and van Klinken, 2014a). The 2015 Dietary Guidelines for 
Americans suggests consuming at least half of all grains as wholegrains with 3 serves 
of 16 g/day to reduce the risk of developing chronic disease (U.S. Department of 
Health and Human Services and U.S. Department of Agriculture, 2015). Wholegrain 
is classified as ‘consisting of intact, ground, cracked or flaked caryopsis, whose 
principal anatomical components – the starchy endosperm, germ and bran, are present 
in the same relative proportions as they exist in the intact caryopsis’ (Rebello et al., 
2014). Most studies use wholegrain rolled oats, oat flakes or oatmeal (Aune et al., 
2016, Jonnalagadda et al., 2011); this study used intact oat groats for supplementation.  
Oat groats are the hulled kernels of the oat grain that includes the germ and fibre-rich 
bran portion of the grain as well as the endosperm. Limited processing means that the 
groat contain many nutrients, including β-glucans, arabinoxylans and dietary fibre as 
well as high concentrations of proteins and lipids (Connolly et al., 2012). When grain 
is refined, the bran layer is removed and many bioactive compounds are lost (Connolly 
et al., 2012). Oat groats still contain these components and can be classified as a 
functional food as they have a beneficial effect on human health (Rasane et al., 2013).  
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Oat bran is the outer coating of the oat groat, which is produced by grinding and 
separating from the groat. Oat bran has at least 5.5% β-glucan and a total dietary fibre 
content of at least 16% so that at least one-third of the total dietary fibre is soluble 
(Robert et al., 1985). Bran is a good source of fructans and resistant starch (Bernstein 
et al., 2013) as well has containing vitamins, minerals (Peterson et al., 1975, Frølich 
and Nyman, 1988), phytates (Fulcher et al., 1981) and phenolics (Gray et al., 2000).  
Oat bran has been associated with prevention of hypercholesterolaemia (Kerckhoffs 
et al., 2003) and hypertension (Keenan et al., 2002). Bran provides many of the health 
benefits of the wholegrains (Slavin, 2003).   
Previous studies have focussed on individual components of the grain, such as 
β-glucans, dietary fibre, avenanthramides or lipids (Connolly et al., 2012). β-glucans 
have been classified as a potential prebiotic, meaning that they may selectively 
promote growth of beneficial microorganisms in the gastrointestinal tract (Connolly 
et al., 2012). These microbes produce SCFA’s through fermentation to be utilised as 
an energy source for bacteria and host and improvement of gastrointestinal structure 
and function. 
β-glucans are a soluble fibre found in oat grains and when ingested forms a gel inside 
the stomach and small intestine. This gel traps bile acids leading to reduced 
re-absorption. As cholesterol is a fundamental component of these bile acids, when 
concentrations decrease the body uses cholesterol to form bile acids, resulting in a 
lower LDL cholesterol and therefore an overall lower total cholesterol concentration 
(Queenan et al., 2007, Drozdowski et al., 2010). Randomised controlled trials with oat 
products and cardiovascular disease markers found that oat products produced a 3 - 6% 
decrease in total cholesterol and a 4 - 8% improvement in LDL cholesterol (Thies et 
al., 2014).  
Many studies have investigated cardiovascular disease, diabetes or dyslipidaemia but 
not metabolic syndrome in its complexity. Limited research exists characterising the 
gastrointestinal morphology of high carbohydrate, high fat diets when supplemented 
with wholegrain oat groats, oat bran or β-glucan powder. This study was warranted as 
it examined the physiological effects, gastrointestinal morphology and faecal SCFA 
production, after intervention with wholegrain oat groats, oat bran or β-glucan powder 
using a diet-induced rat model of metabolic syndrome. In part A of this study, C and 
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H were supplemented with 5% wholegrain oat groats. This translates to approximately 
25-30 g/day for the average 70 kg adult human using a relevant scaling equation 
(Bachmann et al., 1996). In part B of this study, C and H were supplemented with 5% 
oat bran. This translates to approximately 25 - 30 g/day for the average 70 kg adult 
human using a relevant scaling equation (Bachmann et al., 1996). In part C of this 
study, C and H were supplemented with 5% β-glucan powder. This translates to 
approximately 15-20 g/day for the average 70 kg adult human using a relevant scaling 
equation (Bachmann et al., 1996).  
The high carbohydrate, high fat diet in this study induced many parameters associated 
with metabolic syndrome, including central obesity, hypertension, dyslipidaemia and 
impaired glucose tolerance. Cardiovascular changes included increased inflammatory 
cell infiltration, ventricular fibrosis, cardiac hypertrophy and increased diastolic 
stiffness. Liver changes included steatosis, inflammatory cell infiltration and portal 
fibrosis. 
Wholegrain oat groats and oat bran both contain β-glucans at lower concentrations 
than in the β-glucan powder that was investigated. Therefore, it was expected that if 
β-glucans were the driver of physiological changes in metabolic syndrome, then 
increased concentrations would produce greater changes. 
 
3.4.1 Body composition and dietary intake 
Many studies into the impact of wholegrain oats and oat bran only record data of body 
composition as part of overall investigations into hypertension and hyperglycaemia. 
Human and rat intervention studies have given inconsistent results related to the 
decreased risk of obesity and weight gain (Li et al., 2016, Harland and Garton, 2008). 
Energy, food and water intake remained the same with the addition of wholegrain oat 
groats or oat bran to the diet. Many existing studies are human clinical trials; therefore, 
it is not possible to directly compare food and water intake with our rat studies. 
 
Rat studies have shown decreased body weight and epididymal fat over a period of 8 
weeks on an oatmeal diet (Dong et al., 2016) while humans on a 6 week wheat, corn 
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or rice diet showed no change in body weight, fat or lean mass (Cooper et al., 2017).  
Human studies have shown inconsistent results, possibly due to the use of hypocaloric 
diet programs rather than high carbohydrate, high fat diets (Katcher et al., 2008) or 
short-term studies which indicated no change in weight, BMI or body fat over 30 days 
(Li et al., 2016). Comparison of studies is difficult due to variations in the type of 
administered wholegrain, whether wholegrain was added or substituted into the diet 
and participant characteristics (age, gender, race) (McKeown and Jacobs, 2010, 
Rebello et al., 2014). However, overall studies suggest that wholegrains may alter fat 
distribution independently of body weight change. Human trials using oat bran 
indicated that body weight and abdominal circumference decreased with no change in 
lean or fat mass in a 2 - month intervention study (Guevara-Cruz et al., 2012). 
Abdominal circumference decreased in another trial (Devlin et al., 2016). Rat and mice 
studies, however, showed no decrease in body weight (Zhou et al., 2016, Jodayree et 
al., 2014). 
 Our study is consistent with this as abdominal circumference decreased in HO and 
HB rats with no change in body weight, total fat pads or fat mass. Lean mass was also 
unchanged in HO and HB compared to H, however increased when oat groats or bran 
was added to the CO or CB diet for 8 weeks. This suggests that the combination of 
resistant starch in the cornstarch diet with added oats causes an increase in fat 
oxidation and a decrease in carbohydrate and protein oxidation leading to increased 
lean mass (protein accretion) (Higgins, 2014). 
 
Increasing β-glucans in the diet did not alter body weight when added to a high 
carbohydrate, high fat diet. However, body weight increased when β-glucan powder 
was included in the cornstarch diet. Abdominal circumference decreased with a 
decline in fat mass corresponding to an increase in lean mass. β-glucans are fermented 
in the colon as a prebiotic that feeds the gut microbiota, increasing the production of 
acetate, propionate and butyrate (Morrison and Preston, 2016). SCFA mediated 
production of satiety hormones through FFA2 and FFA3 (GPR41/GPR43) receptors 
(Adam et al., 2014), decreasing food intake and energy intake, however this was not 
observed in this study. With improved structure of the gastrointestinal tract, nutrients 
can be absorbed and utilised by the organs more efficiently. Some studies suggest that 
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decreases in abdominal circumference (Maki et al., 2007, Zhang et al., 2012) and body 
weight (Anderson et al., 1990) occur, but most studies have found no effect on weight 
(Anderson et al., 1990, Jenkins et al., 2000, Judd and Truswell, 1981, Kerckhoffs et 
al., 2003, Kirby et al., 1981, Robitaille et al., 2005, Beck et al., 2010, Davy et al., 2002, 
Keenan et al., 2002, Kestin et al., 1990, Swain  et al., 1990), BMI (Saltzman et al., 
2001, Davy et al., 2002) or abdominal circumference (Beck et al., 2010, Davy et al., 
2002).  
Many human intervention studies (Maki et al., 2007, Bellisle et al., 2014, Robitaille et 
al., 2005, Keenan et al., 2002, Brownlee et al., 2010, Aune et al., 2016) have found no 
changes in these parameters even with increasing concentrations (2.3 g - 10.0 g/day) 
of β-glucans, while some display an increase in body weight (Davy et al., 2002). 
However, the anthropometric measurements were not the major component in many 
of these studies (Lefevre and Jonnalagadda, 2012).  Therefore, the addition of this 
study indicates that the effect of dietary β-glucans on these measures remains unclear. 
The molecular weight, dose, processing and the food matrix in which the β-glucans 
are found may influence any changes that occur (Wood et al., 2000, Decker et al., 
2014, Lyly et al., 2003).  
A possible mechanism of action to explain the β-glucans impact on central obesity 
could be the increased viscosity of the gastrointestinal chyme (Cloetens et al., 2010). 
The viscosity causes gel formation by the food bolus mixing with a layer of unstirred 
water adjacent to the mucosa, slowing the absorption of nutrients due to reduced 
enzymatic activity (Jenkins et al., 2000, Schneeman and Gallagher, 1985, Eastwood 
and Morris, 1992). The viscosity of β-glucans can give 79 - 96% changes in glucose 
and insulin responses to a 50 g glucose drink (Wood et al., 1994). The increased 
viscosity may send signals to the brain to stop eating sooner and therefore decrease 
energy intake. Oat β-glucans added to a liquid meal at 10.5 g/400 g portion increased 
the feeling of satiety in healthy volunteers compared to a meal free of β-glucans (Lyly 
et al., 2010). However, carrier food of the β-glucans is important in determining satiety 
as solid or semi-solid meals, which are known to increase satiety (El Khoury et al., 
2012), such as our experimental diet, may mask any satiating effect.  
As with previous studies, it is difficult to conclude that β-glucans are responsible for 
all the variations in the physiological changes that may be occurring. However, it is 
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possible that changing the food matrix and dosage of β-glucans may lead to the 
observed modifications. It may be that macronutrients such as proteins, carbohydrate 
or lipid concentrations are the drivers of the changes or the minor nutrients, such as 
the avenanthramides and other polyphenols. It is more likely that all these components 
are working synergistically. However, the investigation of these elements was outside 
the scope of this study but would be worthwhile investigating in the future. 
 
3.4.2 Cardiovascular effects 
Hypertension, dyslipidaemia and weight gain are major risk factors leading to 
cardiovascular disease and metabolic syndrome (Parikh and Mohan, 2012). Although 
this study did not decrease body weight, wholegrain oat groat, oat bran or β-glucan 
powder supplementation improved systolic blood pressure after 8 weeks. Diastolic 
stiffness was unchanged with wholegrain oat groats, oat bran or β-glucan powder 
consumption. Visual analysis of left ventricles indicated decreased inflammatory cells 
and collagen deposition after 8 weeks of wholegrain oat groats, oat bran or β-glucan 
powder consumption.  
The mechanisms behind the blood pressuring lowering effects of oats are still unclear, 
and therefore more investigation is needed, particularly in human trials as this will 
consider physical activity, energy intake and expenditure as well as the usual stresses 
of everyday life. Wholegrain oat and oat bran consumption have shown limited effect 
on blood pressure (Maki et al., 2007, Davy et al., 2002, Tighe et al., 2010, Wolever et 
al., 2010, Thies et al., 2014). Most studies have investigated oat β-glucan with 
inconsistent results indicating that systolic blood pressure can decrease by 4 to 8 %. 
However, these studies have been conducted after consumption of hypocaloric diets 
(Katcher et al., 2008, Saltzman et al., 2001) or in borderline hypertensive subjects 
(Keenan et al., 2002). Therefore, it cannot be ruled out that weight loss was the main 
reason behind the decrease in blood pressure. 
Elasticity of arteries and maintenance of vascular tone are important factors in the 
control of blood pressure. Nitric oxide (NO), prostacyclin and EDHF (endothelium-
derived hyperpolarizing factor) which are secreted from the endothelium are 
responsible for this maintenance (Burger and Touyz, 2012). Oats contain 
avenanthramides which help in the reduction of coronary heart disease. They possess 
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anti-inflammatory and anti-proliferative properties and cause vasodilation (Yang et 
al., 2014). Avenanthramides inhibit monocyte adhesion to endothelial cells, inhibit 
release of proinflammatory compounds from macrophages (Liu et al., 2004) and 
control blood pressure through increased production of NO and dilatation of blood 
vessels (Nie et al., 2006). Further investigation of endothelial function is necessary to 
confirm or repudiate that the avenanthramides are causing the improvement in blood 
pressure. 
 Oats also contain the highest fatty acid content of any cereal, and are a good source 
of linoleic acid and contain low amounts of saturated fats (Webster and Wood, 2011, 
Youngs, 1986) which may also be improving cardiovascular health. Further studies 
investigating the benefits of avenanthramides and oat lipids on cardiovascular disease 
would be worthwhile. 
Our studies contained 4%, 6% and 12% β-glucans and were consistent with those trials 
that decreased blood pressure. More investigation is needed, particularly in human 
trials as this will consider physical activity, energy intake and expenditure as well as 
the usual stresses of daily life. 
 
3.4.3 Liver effects 
Dyslipidaemia is a major factor in metabolic syndrome, increased cholesterol and 
triglycerides lead to cardiovascular dysfunction. The liver plays an important role in 
regulating plasma lipid concentrations through cholesterol clearance and recruitment, 
while lipid uptake affects hepatic fat composition. The cholesterol-lowering abilities 
of oat bran has been well studied in relation to β-glucans (Ho et al., 2016, Zhou et al., 
2016, Kestin et al., 1990, Wolever et al., 2010). 
The addition of wholegrain oat groats or oat bran to the diet for 8 weeks indicated no 
change to liver weight. Plasma alanine aminotransferase (ALT) and aspartate 
transaminase (AST) decreased with the addition of oat bran to the diet but not with the 
wholegrain oat groats. Total plasma cholesterol decreased, non-esterified fatty acids 
increased, and no change was found in triglyceride concentrations with the addition of 
the wholegrain oats. However, there was no alteration to these parameters with the 
addition of 5% oat bran to the diet.  Hepatic lipid deposition decreased with the 
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addition of wholegrain oats and oat bran. The addition of 7.5%, 15% and 30% 
wholegrain oat to a high fat diet decreased total cholesterol, triglycerides and free fatty 
acids as well as plasma ALT and AST activity and decreased hepatic lipid deposition 
(Peng et al., 2013). Our lower dose of 5% wholegrain oat was consistent with this 
study except for the free fatty acids; however, this may have been due to differences 
in wholegrain oat used, animal species or experimental design. These results are 
consistent with previous studies (El Rabey et al., 2013, Guo et al., 2014, Mosa et al., 
2015) that used 10% (El Rabey et al., 2013) and 20% (Mosa et al., 2015) oat bran to 
reduce the lipid profile and improved liver function indicating that lower amounts of 
oat bran also have an effect on hypercholesterolaemia. The inhibition of FAS, GPAT 
and HMG-CoA reductase preventing lipid synthesis and stimulation of PPARα, CPT-
1 and AMPK stimulating lipid oxidation has been demonstrated in a rat study with a 
high fat diet supplemented with either 7.5%, 15% or 30% oat (Peng et al., 2013). As 
our 5% dose of oat bran did not alter cholesterol, triglyceride or NEFA, it may be 
determined that it was too low to have an effect as the higher doses decreased each of 
those parameters. 
Many studies report the cholesterol lowering abilities of β-glucans (Ho et al., 2016, 
Varma et al., 2016, Queenan et al., 2007, Maki et al., 2007, Guo et al., 2014), covered 
in Part C of this thesis chapter, but other functional components that oats are rich in 
such as vitamins, minerals, antioxidants and phenolic compounds (Butt et al., 2008) 
may also contribute to the inhibition of lipid synthesis and stimulation of lipid 
oxidation (Peng et al., 2013).  
 
The reductions in plasma total cholesterol, triglycerides and NEFA concentrations by 
β-glucans have been investigated extensively (Kerckhoffs et al., 2003, Guo et al., 
2014, Queenan et al., 2007, Ho et al., 2016, van Bennekum et al., 2005, Pick et al., 
1996, Braaten et al., 1994, Anderson et al., 1990, Hara et al., 1999). However, this 
study showed no differences in total cholesterol or triglyceride concentrations. NEFA 
concentrations decreased in the high carbohydrate, high fat β-glucan powder 
supplemented diet, but also decreased in the C supplemented diet. Fat vacuole 
formation in the liver was increased in H which decreased with the addition of β-
glucan powder to the diet.  
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90% of bile acids synthesised from circulating cholesterol are absorbed by the ileum 
(Dawson, 2011). β-glucans decrease reabsorption of bile acids increasing their 
transport to the colon and microbial conversion to metabolites leading to increased 
excretion. This leads to the liver obtaining additional cholesterol by upregulation of 
low density lipoprotein (LDL) receptors, increasing LDL particle uptake which in turn 
reduces circulating LDL-cholesterol (Papathanasopoulos and Camilleri, 2010).  
Consumption of wholegrain oats have had a greater overall effect on LDL-cholesterol 
concentration than when specific components, such as β-glucans, are taken 
individually (Klose and Arendt, 2012, Einhorn et al., 2003). However, as our studies 
only investigated total cholesterol concentration rather than LDL-cholesterol and 
HDL-cholesterol, further studies would need to be completed to determine this. Oat 
bran increased the portion of total bile acid pool that was deoxycholic acid (Marlett et 
al., 1994), a microbial by-product of bile acid that decreased the absorption of 
exogenous cholesterol in humans (Hillman et al., 1986). The increased viscosity of β-
glucans in the small intestine which slows digestion and absorption is thought to play 
a role in this decreased reabsorption of bile acids (Wolever et al., 2010, Drozdowski 
et al., 2010).   
β-glucan powder increased fermentation of SCFA with acetate concentration 
increased with the addition of β-glucan powder to the high carbohydrate, high fat diet. 
SCFA are readily taken up from the colon and transported to the liver to serve as a 
substrate for cholesterol synthesis, while propionate has a hypocholesterolaemic 
action by inhibiting HMGT-CoA reductase and preventing the utilisation of acetate 
for cholesterol synthesis. Increased propionate is used in hepatic lipid metabolism 
which may have led to the improvements in the liver structure through decreased 
steatosis. 
 
3.4.4 Glycaemic effects  
Impaired glucose tolerance and fasting glycaemia are major risk factors for 
cardiovascular disease and Type 2 diabetes (International Diabetes Foundation, 2011). 
Hypertensive and hypercholesterolaemic subjects are used when examining glucose 
responses, as these studies did. 
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Wholegrain oat groats, oat bran or β-glucan powder in the diet improved glycaemic 
control with postprandial glucose area under the curve (AUC) and fasting glucose 
concentrations lower after 8 weeks. This may indicate that oat products have a role in 
normalising blood glucose concentrations. 
While there is plenty of information regarding the glycaemic response of gluten-
containing foods, studies on gluten-free foods, such as oat bran, are minimal, with 
those studies conducted on composite recipes rather than specific foods (Di Giacomo 
et al., 2013). Many studies focus on β-glucans rather than the bran itself, therefore not 
considering the synergistic effect of all the nutrients found in the wholegrain or bran.  
The addition of wholegrain oat to the diet increases viscosity of the food bolus through 
the gastrointestinal tract, caused by the β-glucans in the grain. The increased viscosity 
slows the absorption of carbohydrates and lowers postprandial glucose concentrations 
(Li et al., 2016). Results in previous β-glucans studies have been inconsistent with 
fasting plasma glucose decreasing in some human and animal trials with no changes 
in other randomised controlled trials (Cooper et al., 2017, Bao et al., 2014, Shen et al., 
2011). Postprandial blood glucose concentrations may be affected by the starch in oats 
which is slowly degradable due to high amounts of β-glucans (Rose, 2014). 
Inconsistent results in previous oat bran studies have shown plasma glucose 
concentrations decreasing in some human and animal trials while other trials have 
found no change (Bjorck et al., 1994, Tapola et al., 2005, Holm et al., 1992). As cell 
structure, particle size and food form are associated with low glucose responses 
(Björck et al., 1994), one human trial consisted of oat bran flour and oat bran crisp. 
The oat bran flour lowered glucose area under the curve (AUC) while the oat bran 
crisp gave no change to the control (Tapola et al., 2005). Another study incorporating 
oat bran into fettucine did not lower postprandial blood glucose in healthy subjects 
(Holm et al., 1992). Our study had oat bran that was a flaky consistency and results 
are similar to the oat bran flour results.   
Hypertensive and hypercholesterolaemic subjects are used when examining glucose 
responses, as this study did. These studies, however, display varying results in the 
lowering of blood pressure and cholesterol concentrations along with the 
improvements in glucose response. Indications from 12-week intervention studies on 
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hypertensive subjects consuming either 5.5 g/day or 7.7 g/day of oat β-glucans did not 
change fasting glucose concentrations (Davy et al., 2002, Maki et al., 2007). This study 
indicated an improvement in fasting glucose concentrations with the addition of 
14 g/day β-glucan powder.  
Consumption of soluble dietary fibre, such as β-glucans, improves postprandial 
glucose and insulin responses. Postprandial glucose concentrations were decreased in 
hypercholesterolaemic subjects after consumption of 4 g oat β-glucan as a beverage, 
while 10 g did not influence postprandial glucose concentrations (Biörklund et al., 
2008). In overweight women, improvements in postprandial plasma glucose followed 
the consumption of 0.26, 0.68, or 2.3 g β-glucan/100 g muffin (Behall et al., 2006). 
The improved glucose AUC with the addition of β-glucan powder suggests that higher 
concentrations of β-glucans lower the postprandial glucose concentrations possibly 
through the alteration of gastric emptying and transit time of glucose through the 
intestinal tract.   
These differing results may be due to the variation of the molecular weight of the 
β-glucans that are being used (Biörklund et al., 2008, Wolever et al., 2010). The 
molecular weights of the β-glucans play a major role in the viscosity of the gel that is 
delaying the gastric emptying and therefore the absorption of the glucose, as higher 
molecular weight oat β-glucans cause a more viscous gel (Wood et al., 2000). A more 
viscous gel delays glucose absorption and lowers postprandial glucose concentrations 
(Wolever et al., 2010), which may also account for limited changes occurring in 
glucose AUC as the absorption of the glucose is taking place over an extended period. 
There are limitations on studies utilising the molecular weight of β-glucan as there are 
currently no available β-glucan control standards with specific molecular weight and 
branches (Staka et al., 2015). Therefore, most research on β-glucans uses extracts 
rather than purified samples, and it is therefore not possible to exclude confounding 
factors (Staka et al., 2015).  
Another mechanism for improvements in the glucose AUC and fasting glucose may 
be the increased production of acetate and propionate, lowering the acetate to 
propionate ratio. By lowering this ratio, increased gluconeogenesis is possible. 
Propionate oxidising to propionyl-CoA and pyruvate leads to gluconeogenesis and 
with this improved hepatic function and maintenance of glucose concentrations 
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(Giacco et al., 2014). This study showed a lower acetate to propionate ratio with the 
addition of wholegrain oat groats which is consistent with previous studies.  
 
3.4.5 Inflammation 
Many inflammatory markers, such as interleukin-6 (IL-6) and intercellular adhesion 
molecule 1 (ICAM-1), are linked to cardiovascular disease, but only C-reactive protein 
(CRP) is currently considered an independent marker of cardiovascular disease risk 
(Pearson et al., 2003), which is why the current study only measured plasma CRP 
concentrations.  Limited studies have examined the effect that wholegrain oats, oat 
bran or β-glucans have on the inflammatory markers of cardiovascular disease. No 
change with increased consumption of oats  (Ajani et al., 2004, Ma et al., 2006) has 
been apparent, which these studies supports. This suggests that the modulation of these 
markers is not the mechanism for the benefits conferred by oats. However, further 
studies  investigating more specific inflammatory markers such as IL-6 or NF-κB 
which wholegrains decrease (Herder et al., 2009, Oliveira et al., 2009) may be 
warranted to confirm or repudiate these findings.  
Long term high fat diets can increase intestinal inflammation and oxidative stress 
(Gulhane et al., 2016).  Histological assessment of wholegrain oat groats, oat bran, 
and β-glucan powder showed limited inflammatory cells throughout the 
gastrointestinal tract including the high carbohydrate, high fat rats. Previous studies 
found similar results with limited inflammation (Luck et al., 2015, Gulhane et al., 
2016, Johnson et al., 2015). However, other studies have shown increases in pro-
inflammatory markers, such as NF-кB and TNF-α (Ding et al., 2010), indicating that 
these may be more relevant to the development of inflammatory-related diseases such 
as ulcerative colitis and obesity-associated colorectal cancer. These studies indicate 
that a high fat diet alone may not be the cause of inflammation in the gastrointestinal 
tract.  
As inflammatory marker results in both cardiovascular and gastrointestinal tissue and 
plasma samples were not as expected, further studies investigating other inflammatory 
markers such as IL-6 or NF-κB are needed to confirm or repudiate these findings. 
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3.4.6 Gastrointestinal parameters 
As a prebiotic, oat β-glucans are fermented by the gut microbiome to produce SCFA 
(Rose, 2014) which contribute to gastrointestinal structure and function. Limited 
studies exist focussing on the effects that metabolic syndrome has on the 
gastrointestinal tract with most studies instead examining the gut microbiome. Those 
studies that have been undertaken tend to focus on specific compounds, such as 
β-glucans, rather than the complete oat groat or oat bran. Therefore, a study on the 
changes to gut morphology caused by high carbohydrate, high fat diets and subsequent 
improvements with the addition of wholegrain oat groats and oat bran to the diet is 
warranted.  
As the healthy control, the C diet may be acting as a prebiotic, improving the 
gastrointestinal tract structure prior to the addition of the wholegrain oat. Cornstarch 
is approximately 25% amylose and 75% amylopectin (Takeda et al., 1988). Starch can 
be used by a wide range of microbiota to produce metabolites for health benefits. 
Studies have shown that cornstarch alters gut fermentation and bacterial communities 
(Kalmokoff et al., 2013). Therefore, with a healthy gut environment, any effect that 
wholegrain oat, oat bran or β-glucan powder may have will be limited as they are also 
predicted to improve the environment with fermentation by similar microbes. The CO, 
CB and CG groups may then give less overall improvement than is seen in the H 
groups. However, the focus of the study was on how wholegrain oat groats, oat bran 
or β-glucan powder can impact the gastrointestinal tract after a high carbohydrate, high 
fat diet.  
The effects of oat bran on overall health are derived from its effects in the 
gastrointestinal tract on digestion, absorption and fermentation (Dong et al., 2016). 
Previous studies have focused on β-glucans prebiotic effect on the gut microbiome 
(Delcour et al., 2016, Staka et al., 2015) rather than the gastrointestinal tract. Limited 
studies have investigated oat brans effect on the gastrointestinal morphology of a high 
carbohydrate, high fat fed rat model of metabolic syndrome.  
β-glucans have prebiotic potential, and may act as a substrate for gastrointestinal 
microbiota to use as an energy source to produce short chain fatty acids which are then 
utilised for providing health benefit to the host (Gibson et al., 2017).  
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The influence of high fat and high fructose diets inducing changes in the gut 
microbiota and its influences on intestinal permeability, inflammation and other 
metabolic complications have been well studied (Cani et al., 2009, ter Horst et al., 
2016, Panchal et al., 2011b, Jurgoński et al., 2014, Moreira et al., 2014, Catalioto et 
al., 2011). High fat diets contribute to a lack of intestinal barrier integrity with 
increased low-grade inflammation being caused by metabolic endotoxaemia (Cani et 
al., 2009) leading to a breakdown of the intestinal barrier and resulting in weight gain, 
NAFLD and insulin resistance (Cani et al., 2009). Serum endotoxin and TNF-α 
concentrations decreased with the addition of β-glucans to a high fat diet (Dong et al., 
2016). Although this study did not analyse LPS concentrations, by examining the 
morphology of the intestine, it may be possible to determine the integrity of the 
intestinal barrier through the overall structure of the various sections of both the small 
intestine and colon. While there is plenty of research regarding the benefits of β-
glucans on cholesterol concentrations and blood pressure, limited research exists on 
the effect of β-glucans on the gastrointestinal tract and whether it affects the 
gastrointestinal mucosa. The effects that β-glucans have depend on their molecular 
form and physicochemical properties. The degree of polymerisation and concentration 
of oat β-glucan depends on cultivar as well as growing, processing and storage 
conditions (Clemens and van Klinken, 2014a). Existing studies have used yeast wall 
β-glucans (Schwartz and Hadar, 2014) rather than grain-based ones for this reason 
(Handayani et al., 2012).  
Limited research has been found on the effects that metabolic syndrome has on the gut 
with most studies focused on the gut microbiome not the gastrointestinal tract. 
This study determined the overall impact of wholegrain oat groats, oat bran or β-
glucan powder on the contractility and morphology of the gastrointestinal tract. 
Further, faecal SCFAs were examined to determine if concentration changes occurred 
with the addition of these supplements to the diet.  
 
3.4.6 Gastrointestinal morphology 
The structure of the gastrointestinal tract is important when considering overall health 
as nutrient absorption is more efficient in those that are well formed compared to those 
that are structurally inadequate (Wells et al., 2017). Gastrointestinal health 
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maintenance is a complex, delicate balance between diet, commensal microbes and 
the mucosa, including the epithelium and mucus layers. The hypothesis for this section 
of my study was that morphology can be used to examine intestinal barrier integrity. 
The small intestine is the primary absorptive site of nutrients with absorptive cells the 
major cell type within the epithelial layer. The vast surface area of the small intestine 
is a result of villi and microvilli projecting from the mucosa (Helander and Fändriks, 
2014, Schulze, 2015). The crypt-villus unit is the functional unit of the small intestine 
(Marshman et al., 2002) with stem cells in the base of the crypt differentiating into 
various cell types including absorptive, enteroendocrine, Paneth and goblet cells 
(Marshman et al., 2002). In vitro studies have found that structures similar to villi have 
been produced when cell cultures are exposed to an intestinal chyme indicating that 
exposure to luminal content is important for development and structural integrity of 
the small intestine (Kim and Ingber, 2013). As the chyme passes through the small 
intestine, gut hormones, such as cholecystokinin (CCK), GLP-1 and PYY, are released 
increasing pancreatic secretions and bile from the bile duct of rodents and gall bladder 
in humans (West and Mercer, 2004). These hormones lead the digestive processes and 
possibly have roles in reducing gastric secretions and gut motility (Ellis et al., 2013, 
West and Mercer, 2004). The addition of β-glucans to the diet increased GLP-1 and 
PYY (Beck et al., 2010, Greenway et al., 2007). However, whether this is due to 
structural changes is unknown and was beyond the scope of this study. Goblet cells 
produce a protective mucus barrier for protection of the epithelial layer from 
pathogenic bacteria (Hino et al., 2012). SCFA production could mediate intestinal 
stem cell activity, however only small amounts of SCFA are produced in the small 
intestine and SCFA may be more significant to differentiation in the colon (Petersen 
et al., 2014).  
The duodenum as the entry point to the small intestine from the stomach receives bile 
through the rat’s bile duct, as they have no gall bladder, which emulsifies fat and 
digestive enzymes which break down protein from the gastric chyme. Most of the 
changes in the small intestine were found in the duodenum, particularly in the high 
carbohydrate, high fat diet with mucosal thickness decreased by approximately 50% 
primarily due to atrophy of villus height and crypt depth. The addition of wholegrain 
oat groats, oat bran or β-glucan powder to the high carbohydrate, high fat diet saw an 
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improved structure with villi, crypts and mucosa returning to similar measurements as 
the cornstarch diet. Longer villi may indicate increases in brush border hydrolases due 
to more mature enterocytes being produced (Picariello et al., 2016). Our results differ 
from previous studies that showed a diet low in fibre increased villi height in the need 
for absorptive capacity and decreased goblet cell production as well as atrophy in the 
mucosa (de Oliveira Belém et al., 2015). However, that study used dietary restriction 
rather than a high carbohydrate, high fat diet as well as 18-month-old rats compared 
to 6-month-old rats. Other studies have shown trophic effects on villi. Rats fed pectin 
at 25 g/kg for 14 days significantly increased villus height and crypt depth (Andoh et 
al., 1999).  
 This suggests dietary intake and possibly age are key components in the 
differentiation of intestinal stem cells. Increased villi heights were observed in mice 
fed a high fat diet, however this study sectioned the small intestine into 3 equal parts 
and called the first section the duodenum (de Wit et al., 2008). Due to this, the section 
that was analysed could have been at a further distance from the pyloric sphincter than 
in our study. 
Another mechanism that may be leading to the increased villi height is the high 
proportion of  medium-chain fatty acids, such as oleic and linoleic acids which are 
found in wholegrain oat groats which stimulate intestinal mucosal growth and increase 
villi height that can directly affect nutrient absorption by increasing the absorptive and 
surface area of the duodenum, jejunum and ileum (Chwen et al., 2013). 
The jejunum as the longest section of the small intestine is also the main region of 
absorption of sugars, amino acids and fatty acids. Our studies with wholegrain oat 
groats, oat bran or β-glucan powder found no morphological changes in the jejunum 
which was similar to previous studies (Mathers et al., 2007) that indicated longer 
crypts and shorter villi but no overall change to the structure of the jejunum. Pigs fed 
both high and low amounts of fermentable dietary fibre have shown no effect to villi 
height, crypt depth and epithelial layer of the small intestine (Glitsø et al., 1998). 
Goblet cell numbers were greater in the high carbohydrate, high fat diet than the 
cornstarch diet, but there was no difference with the addition of wholegrain oat groats, 
oat bran or β-glucan powder. As mucus provides physical and chemical protection 
against pathogenic gut microbiota (Peterson and Artis, 2014), it may also indicate that 
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a reduced level of protection is needed as the gut microbe population is balanced with 
the intestinal epithelium (de Oliveira Belém et al., 2015). Other studies have also 
found that adding dietary fibre, such as cellulose and arabinoxylan both of which are 
found in wholegrain oat groats, increased goblet cells in the mucosa (Hino et al., 2013, 
Hino et al., 2012, Ito et al., 2009, Chen et al., 2015). However, due to complexities in 
measuring the mucus barrier, relatively few studies have assessed this. 
Immunohistochemistry and other techniques have been used to determine mucin 
production (Morel et al., 2005, Tanabe et al., 2006, Morita et al., 2008). MUC2 mucin 
gives physical and chemical protection as well as immunomodulation contributing to 
intestinal homeostasis (Tadesse et al., 2017). Deficiencies in MUC2 are linked to low-
grade chronic inflammation in the small intestine and colon (Velcich A et al., 2002, 
Sluis et al., 2006). Our study did not determine mucin production as the aim was to 
determine number rather than functional aspects of goblet cells. However, future 
research may determine whether MUC2 production and therefore the intestinal mucus 
barrier is improved with the addition of wholegrain oat groats to the diet.  
The ileum is the final section of the small intestine and mainly absorbs vitamin B12 
and bile salts and any remaining unabsorbed nutrients from the jejunum. Our studies 
with wholegrain oat groats, oat bran or β-glucan powder found no changes to villi 
height, crypt depth, mucosal thickness and goblet cell numbers in the ileum. However, 
there was a large variability in results achieved, therefore further experiments would 
be beneficial to confirm or repudiate these findings. 
The overall profile along the length of the small intestine has been altered in the high 
carbohydrate, high fat diet with the villi height atrophied and similar along the entire 
length rather than longer in the duodenum and decreasing in length towards the ileum 
as in samples that were fed wholegrain oat groats. This profile decreases the surface 
area of the small intestine leading to reduced absorptive capacity. The addition of 
wholegrain oat β-glucans to the diet increases viscosity of the intestinal chyme and 
therefore slows transit time allowing increased absorption of nutrients and not as much 
stress is placed on the epithelial layer, and villi. Further rheological studies to 
determine the viscosity of the intestinal contents would be beneficial to make a 
correlation between viscosity and intestinal barrier integrity. Previous studies in mice 
have found that high fat diets lead to a shortening of the small intestine length 
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compared to a regular chow diet (Beyaz et al., 2016, Soares et al., 2015, de Wit et al., 
2008), but no studies have been found that compared intestinal length between high 
fat and cornstarch diets.  
β-glucans act differently in the small intestine compared to the colon. In the small 
intestine, β-glucans remain intact, as no enzymes are available that hydrolyse it and 
this increases the viscosity (Daou and Zhang, 2012). A study on pig digesta found that 
β-glucans were retained within the endosperm of oats until it reached the ileum but the 
cell wall structures were disrupted by the caecum (Johansen et al., 1997). In human 
ileostomy patients, 88.5% of ingested β-glucans could be recovered (Lia et al., 2007). 
In the colon, β-glucans are broken down by gut microbes and fermented into 
metabolites, such as acetate, propionate and butyrate (Bach Knudsen et al., 2007). Due 
to this, many of the changes that have been found in the small intestine may not be 
linked to β-glucans but to other bioactive compounds, such as avenanthramides within 
the β-glucan powder supplement or in the previous wholegrain oat groat or oat bran 
studies. As this study was focussed on β-glucans with 12% concentration in the 
supplement, other bioactive components which may have been present were not 
examined and future studies could be worthwhile to determine which components lead 
to the changes that are described below for the small intestine. It is likely that. although 
the viscosity of β-glucans was involved in the morphological changes, this may not 
have been the major cause of the observed changes.  
Between the small intestine and the colon lies the caecum, where much of the 
fermentation occurs in a rat. This explains the low concentrations of SCFA that were 
retrieved from the faecal samples as over 90% of SCFA are utilised either through 
absorption into the blood stream for use in the liver (acetate and propionate) or colon 
(butyrate) as an energy source (Ríos-Covián et al., 2016). Further analysis of the 
caecum should be undertaken by future researchers to determine SCFA 
concentrations.  
The colon was separated into three sections for this study, proximal, mid and distal. 
Although there were limited changes found in the crypt depth, histological analysis 
indicated more submucosal folds in the wholegrain oat groat, oat bran or β-glucan 
power, proximal and distal colon compared to the high carbohydrate, high fat diet fed 
group. This may be due to increased production of butyrate which is used as an energy 
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source for colonocytes allowing increased cell proliferation and differentiation (Wong 
et al., 2006). The increase in submucosal folds gives the colon a greater surface area 
and increased ability to extract any remaining water and nutrients before waste is then 
excreted. Histologically, the colon has a more intact epithelial layer and mucus layer 
in the HO, HB and HG groups compared to the high carbohydrate, high fat group. 
Limited changes were found in mucosal thickness with increases only in the distal 
colon of the wholegrain oat groat group. No changes in goblet cell number were noted. 
Long term high fat diets can increase intestinal inflammation and oxidative stress 
(Gulhane et al., 2016). However, my histological assessment showed limited 
inflammatory cells throughout the gastrointestinal tract including the high 
carbohydrate, high fat rats. Previous studies found similar results with limited 
inflammation (Luck et al., 2015, Gulhane et al., 2016). One study found that although 
there was limited inflammation, increased non-esterified fatty acids indicating 
oxidative stress was reversed by IL-22 (Gulhane et al., 2016). Another study on mice 
found T cells in the colon were limited after 3 weeks on a high fat diet, but after 
12 – 16 weeks numbers had increased (Luck et al., 2015). Therefore, our results may 
have been due to the protocol not being long enough for the inflammatory cells to 
infiltrate. A third study found that, unlike liver and adipose tissue, there was no 
evidence of intestinal inflammation by monocytes or macrophages from a high fat diet 
(Johnson et al., 2015). However, other studies have shown increases in pro-
inflammatory markers, such as NF-кB and TNF-α (Ding et al., 2010), indicating that 
these may be more relevant to the development of inflammatory-related diseases such 
as ulcerative colitis and obesity-associated colorectal cancer. These studies indicate 
that a high fat diet alone may not be the cause of inflammation in the gastrointestinal 
tract.  
There were limited changes in the colon length of any of the intervention groups. 
However, as in the small intestine, the diet and intervention both may have contributed 
to changes in the overall colonic length. No other rat studies have been found that 
measure intestinal lengths separately in relation to fibre or high fat diets. One study 
found overall rat intestinal length increased with oat bran compared to wheat bran and 
pea fibre and a low dietary fibre control (Hansen et al., 2007). Small intestine and 
colon length was unchanged by β-glucan powder but there was high variability in the 
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results. These results are the same as the previous wholegrain oat groats and the oat 
bran studies. This possibly indicates that increasing the concentration of β-glucans in 
the diet does not change the length of the intestine. However, as all three dietary 
interventions included compounds other than β-glucans, it is not possible to be 
definitive that it is the β-glucans.  
As our rats were from 16 - 24 weeks of age or equivalent to human young adults, 
morphological and functional abnormalities that are associated with an ageing 
population (de Oliveira Belém et al., 2015), such as reduced gastric emptying, slow 
intestinal transit, impaired digestion and absorption, lower production of digestive 
enzymes and changing composition of the gut microbiome have not been taken into 
account. Future research could include an ageing rat population or an extended study 
protocol. Another issue with this study was ensuring that samples were taken from the 
same points along the gastrointestinal tract. As can be seen from the data, differences 
exist between each section and therefore can be assumed to be changing along the 
entire length not just those sections measured. Although each sample was measured 
and taken from the same point, there may still have been changes within the sample 
collected during histological processing and sectioning. Variation between individuals 
also appears to be an issue as with all groups and parameters exhibiting differing 
results giving a wide range of data points. Therefore, it may be a useful study to 
examine numerous sections from a single sample per group to determine the complete 
profile of the gastrointestinal tract before examining other samples.  
Due to these limited gastrointestinal morphological changes, the use of morphology 
as a sign for intestinal barrier integrity is not viable. Molecular studies such as 
immunohistochemistry, Western blot and ELISA would be more appropriate to 
determine LPS, tight junction protein, such as occludin and claudin, and gut hormone 
concentrations. Overall, there was a large variability in gastrointestinal results 
achieved, therefore further experiments would be beneficial to confirm or repudiate 
these findings. 
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3.4.5 Gastrointestinal contractility 
Limited studies have been reported on ileal and colonic muscular contractility using 
diet-induced metabolic syndrome in rats or with wholegrain oat groats, oat bran or β-
glucan supplemented diets. This study found that ileal and colonic contractility were 
not changed between control and wholegrain oat, oat bran or β-glucan powder 
consumption, primarily due to large variability. 
One study found that elevated concentrations of butyrate reduced colonic contractility 
suggesting that the butyrate stimulates sodium and fluid absorption reducing 
contractility and motility (Bajka et al., 2010). Our study indicated that while faecal 
butyrate concentrations did not increase, total faecal short-chain fatty acid and acetate 
concentrations were higher in rats fed wholegrain oat groats or β-glucan powder. As 
acetate can be converted to butyrate in the colon (Ríos-Covián et al., 2016, Chassard 
and Bernalier-Donadille, 2006), it is possible that this is in part responsible for any 
decreased colonic contractility. However, unlike the wholegrain oat groats, oat bran 
consumption did not increase faecal short chain fatty acid production Therefore, it is 
not possible to say that the stimulation of sodium and fluid absorption by butyrate 
reduced contractility and motility. 
Another study examined wheat in rats fed a western diet found no changes to colonic 
contractility relative to effects of maize starch (Patten et al., 2015). Rat studies have 
indicated that SCFA inhibit peristaltic contractility above a physiological threshold of 
SCFA in the lumen (Cherbut, 2007). However, these effects may differ between 
species, as human trials using an intracolonic infusion of 100 mM SCFA solution did 
not modify transit in two healthy subjects (Kamath et al., 1990). As our study 
examined faecal SCFA and not luminal SCFA concentrations, this may be a 
worthwhile objective for future research.  
 
3.4.6 Faecal SCFA 
SCFAs are metabolites of gut fermentation produced by gut microbiota in the colon 
from food components that are unabsorbed and undigested in the small intestine. Each 
SCFA has distinct physiological effects including shaping the gut environment, 
influencing the physiology of the colon, providing energy sources for the host cells 
 156 
and gut microbiota and participating in different host-signalling mechanisms (Dong et 
al., 2016, Kasubuchi et al., 2015, Ríos-Covián et al., 2016). They are the main end-
products of carbohydrate catabolism (Ríos-Covián et al., 2016). Acetate and 
propionate both enter the bloodstream and in the liver they act as energy sources for 
gluconeogenesis (den Besten et al., 2013). Butyrate is used by the colonocytes for cell 
proliferation and differentiation (Pryde et al., 2002). Low concentrations of butyrate 
and propionate lead to inflammatory diseases, such as ulcerative colitis (low butyrate) 
and asthma (low propionate) (Machiels et al., 2014, Arrieta et al., 2015). As many of 
their functions and uses have been discussed throughout this chapter in relation to each 
of metabolic syndrome and gut health parameters, this section will only discuss the 
results as they were found in relation to each other.  
Studies have highlighted the influence of different foods and long-term diets on 
intestinal microbiota and specifically on the pattern of SCFA. However, although oat 
β-glucans are a prebiotic and known to produce SCFA, limited studies have 
specifically investigated the SCFA rather than the impact on the gut microbiome. 
Firstly, our study was a preliminary one to show that cornstarch and high carbohydrate 
high fat diets produce different proportions of SCFA and that the addition of 
wholegrain oat groats will also have an effect on the SCFA production. Secondly, as 
this is only a preliminary study, the sample size was limited to 6/group. Consequently, 
further research will need to be continued to confirm and consolidate any results from 
these experiments.  
90 - 95% of SCFA are utilised through rapid absorption from the colonic lumen, 
meaning faecal samples can only give a representative analysis of production and act 
as a biomarker as it does not represent epithelial cell exposure (Ríos-Covián et al., 
2016). Many studies utilise the addition of ‘pure’ acetate, propionate or butyrate to the 
diet to determine serum concentrations. Studies have highlighted the influence of 
different foods and long-term diets on intestinal microbiota and specifically on the 
pattern of SCFA (Yang and Rose, Costabile et al., 2015). Limited studies exist where 
wholegrain oat groats, oat bran or β-glucans as part of an overall diet has been 
investigated (Cloetens et al., 2012).  
Firstly, these studies are preliminary ones to show that cornstarch and high 
carbohydrate high fat diets produce different proportions of SCFA and that the 
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addition of wholegrain oat groats, oat bran or β-glucan powder would have an effect 
on the SCFA production. Secondly, as they were only preliminary studies, the sample 
size was limited to 6/group. Consequently, further research will need to be continued 
to confirm and consolidate any results from these experiments.  
This study indicated that acetate and propionate concentrations were increased by the 
addition of wholegrain oats while butyrate remained the same.  
Our study indicated that C and CO in the diet produced more faecal SCFA than high 
carbohydrate high fat diets. The addition of wholegrain oat groats to the high 
carbohydrate high fat diet also increased the overall faecal SCFA. The larger 
concentration of SCFA is likely to be due to β-glucans and other soluble fibres, 
including starch in the diet, that is then able to be fermented. However, it is interesting 
to note that faecal SCFA in the cornstarch wholegrain oat group contained less total 
SCFA than the cornstarch control. This may be due to more efficient absorption of 
SCFA by the epithelial cells of the caecum and colon. 
Our oat bran study indicates that high carbohydrate, high fat diets even when 
supplemented with oat bran produce less faecal SCFA than cornstarch and cornstarch 
supplemented with oat bran diets. However, unlike the wholegrain oat groat study, 
there was no change in concentration in total SCFA, acetate, propionate or butyrate 
concentrations between the control group and its oat bran supplemented group. This 
may mean that they are being transported across the epithelial layer into the 
colonocytes and blood stream more efficiently due to the limited inflammation and the 
gut barrier being intact.  
In faecal samples recovered from the H diet and the HO groups, an increased 
proportion of butyrate was produced compared to the C control. The faecal samples 
recovered from HG contained a greater proportion of acetate and lower proportion of 
butyrate than H control. Both of these outcomes may be  due to butyrate forming from 
two molecules of acetyl-CoA, and the liberation of butyrate from butyryl-CoA. The 
butyryl-CoA to acetyl-CoA transferase pathway is used by the majority of known 
butyrate-producing gut bacteria (Anastasovska et al., 2012, Louis et al., 2004, Louis 
et al., 2010). If this is occurring, then the acetate concentrations will be decreased, and 
butyrate concentrations increased as can be seen in our results.  
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The fermentation of wholegrain oats and subsequent SCFA production has an integral 
role at both colonic and systemic levels. As well as β-glucans, wholegrain oat groats 
and oat bran contain other compounds, such as arabinoxylans and cellulose that have 
the ability to stimulate the growth of beneficial gut microbiota. Further studies are 
needed to determine the role these compounds have in SCFA production.  
The increased percentage of β-glucans in the diet with the β-glucan powder made little 
difference to the overall concentration of the SCFA produced, indicating the possible 
involvement of other components of the wholegrain oat groats or oat bran such as 
arabinoxylans and cellulose that have the ability to stimulate the growth of beneficial 
gut microbiota. This study has not definitively answered the question of whether it is 
the β-glucans alone that has the impact, although they increase the viscosity of the 
food bolus, leading to slower gastric emptying and absorption of nutrients which all 
stimulate the growth of gut microbiota and therefore increase SCFA production. 
 
3.4 Conclusion 
This study demonstrate that the addition of 5% wholegrain oat groats, oat bran or 
partially purified β-glucan powder to a high carbohydrate, high fat diet can improve 
blood pressure, glucose tolerance and cholesterol. Heart, liver and gastrointestinal 
tract structure was also improved. This may have been due to the overall nutrient 
content with β-glucans, avenathramides and oat lipids and other compounds working 
synergistically to make these improvements.  β-glucans increase viscosity of the food 
bolus and slow transit time allowing greater absorption of the other nutrients, with 
further research on this area needed. Also leading the changes may be the increased 
production of SCFA which act as energy sources for hepatic and colonic cells and as 
signalling molecules. Many of the results reported in wholegrain oat groats have been 
repeated in the study on oat bran. This is unsurprising as the oat groat still contains an 
intact bran layer. However, it was expected that as the oat bran and β-glucan powder 
had a higher concentration of β-glucan that results would increase in a dose-related 
fashion and this was not found. This may have been due to different cultivars of oat 
grains being used or varying molecular weights of the β-glucans both of which lead to 
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differing results. As these were unknown in these studies, future work should consider 
these factors prior to the commencement of work. 
This study also indicated that production of SCFA was different between cornstarch 
and high carbohydrate, high fat diets but limited difference was made with the addition 
of wholegrain oat groats or oat bran. Further research is needed to determine whether 
this is due to improved gut integrity and therefore improved absorption rather than 
excretion of SCFA. Further research is needed to determine whether the consumption 
of wholegrain oat groats or oat bran also increase the expression of FFAR2, FFAR3, 
MUC2 and tight junction proteins, leading to improved gut repair, protection and 
integrity. Also, further study is necessary to determine the gut microbiome changes 
that have possibly caused the changes in SCFA production.  
The main limitation of this study was the limited sample size for the SCFA analysis 
which needs further exploration to confirm the results. Another limitation was in the 
gut morphology analysis where samples, although measured to collect tissue from 
exactly the same section, may have been out of alignment with each other between 
sample groups. These limitations could be ameliorated by only using the samples for 
one type of experiments rather than multiple ones that may impact results. It was also 
noted that in an uncompromised gastrointestinal tract, a high carbohydrate, high fat 
diet did not lead to increased inflammation. While this may be a good model for 
studying diet-induced metabolic syndrome, a different model may be necessary for 
gut studies.  
Overall, the addition of wholegrain oat groats, oat bran or β-glucan powder to the diet 
attenuated diet-induced metabolic syndrome, improved gastrointestinal tract structure 
Wholegrain oat groats altered SCFA production however, oat bran and β-glucan 
powder did not alter SCFA output.  
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 - Wholegrain oat groats improve 
cardiometabolic and gastrointestinal parameters in a high 
carbohydrate, high fat diet in male Wistar rats 
  
4.1 Introduction 
As the world gains access to diets that are high in fats and simple carbohydrates such 
as fructose (Moreira et al., 2014, ter Horst et al., 2016), rates of metabolic syndrome 
are increasing, with 20 to 40% of the adult population having at least one of the 
co-morbidities encompassed by this syndrome (Moreira et al., 2014, O'Neill and 
O'Driscoll, 2015). The World Health Organisation (WHO) classifies patients with 
metabolic syndrome as having decreased glucose tolerance and insulin resistance 
along with two of the following: hypertension, dyslipidaemia, visceral obesity and 
microalbuminuria (International Diabetes Foundation, 2011). In recent years, diet has 
become an integral therapeutic intervention to normalise the biomarkers of metabolic 
syndrome. Diets that include wholegrains such as oat groats may protect the body 
against cardiovascular disease and diabetes (Connolly et al., 2012, Zhou et al., 2015, 
Dixit et al., 2011) through the changes in short-chain fatty acid (SCFA) production 
and improved gastrointestinal morphology. Oats are a functional food that has been 
consumed for thousands of years (Ladizinsky, 1995), mostly as a wholegrain (van den 
Broeck et al., 2016). They do not contain gluten, which makes it suitable for coeliac 
disease patients if processed separately to gluten-containing grains (Moulton, 1959, 
Janatuinen et al., 2002). The WHO recommends increasing wholegrain consumption 
to reduce the risk of obesity, cardiovascular disease and diabetes (WHO/FAO, 2003). 
According to the 2015 American Dietary Guidelines, 16 g/day of wholegrains will 
reduce the risk of developing cardiovascular diseases and diabetes (U.S. Department 
of Health and Human Services and U.S. Department of Agriculture, 2015). 
Approximately 25% of the Western diet is composed of whole grains (Alexandratos 
and Bruinsma, 2012). By changing the composition of the diet in the previous study 
in Chapter 3 to incorporate 20% wholegrain oats, this study results should reflect any 
health effects that are achieved by wholegrain oats in the human diet. An increase in 
wholegrain oat consumption and consequently β-glucans and other dietary fibre 
should increase SCFA production leading to an overall improvement in 
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gastrointestinal physiology. Knowledge of dietary changes to the concentration of 
SCFA and subsequent physiological effects is currently limited.  
Firstly, this study was a pilot study to determine if modifying the previous model was 
feasible and secondly to analyse the effects of wholegrain oat groats on the 
physiological and metabolic parameters associated with metabolic syndrome and 
whether they were associated with changes in the SCFA produced in male Wistar rats 
fed a high carbohydrate, high fat diet. I hypothesise that addition of 20% wholegrain 
oat groats will improve metabolic changes, reverse changes in gastrointestinal 
structure and increase faecal SCFA concentrations when added to a high carbohydrate, 
high fat diet, reversing the signs of metabolic syndrome. 
 
4.2 Materials and Methods 
Please refer to Chapter 2 for the following methods: rat diets, cardiovascular, 
metabolic, hepatic and gastrointestinal studies.  This study was undertaken under AEC 
approval #15REA003 valid until 20/07/2018. Four groups of rats were used for this 
study: modified corn-starch (mC); modified high carbohydrate high fat (mH) controls 
(n = 8/group), modified corn-starch + wholegrain oat groats (mCO) and modified high 
carbohydrate high fat + wholegrain oat groats (mHO) (n = 8/group). They were fed 
the diets described in Chapter 2. 
The following parameters were measured in the control and intervention groups using 
the methods detailed in Chapter 2 of this thesis: body weight, food, water and energy 
intake, oral glucose tolerance test, body composition (DXA), systolic blood pressure, 
diastolic stiffness, aortic contractility, ileum and colon contractility, blood lipid 
analysis, liver enzyme analysis, gastrointestinal structural analysis, SCFA analysis and 
inflammatory marker analysis. 
The C and H diets used in Chapter 3 were modified so that interventions up to 20% 
w/w of the diet could be included. The modified corn starch-rich diet (mC) and the 
modified high-carbohydrate, high-fat diet (mH) are described in Chapter 2.  
To test an intervention in these modified diets, the mC and mH diets were 
supplemented with 20% wholegrain oat groats (mCO and mHO rats) with this 
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200-g/kg addition replacing 200 ml/kg of water as described in Chapter 2. 
Interventions were started after 8 weeks of the diet and continued for the remaining 8 
weeks with 8 rats in each intervention. The same batch of oat groats was used in the 
CO and HO groups in Chapter 3. 
 
4.3 Results 
4.3.1 Body composition and dietary intake 
The food intake of the mC rats was not different from the mH or mCO. Food intake 
was decreased for mHO rats compared to both control groups (Table 4.2). Water intake 
in the mC rats was increased compared to the mH rats, but this does not include the 
water (200-ml/kg) that was included in the mC diet. mCO water intake was similar to 
mC, while mHO was increased compared to mH (Table 4.2). Energy intake for mC 
was decreased compared to mH. mCO and mHO were increased over mC and 
decreased from mH (Table 4.2). mC had a negative feed conversion efficiency which 
correlates with the initial weight loss in weeks 1 - 3 followed by limited body weight 
gain for the remainder of the study, with mH higher. mCO and mHO had increased 
feed efficiency compared to their corresponding controls (Table 4.2). 
mC rats had the lowest final body weight (Table 4.1) due to weight loss over the 
16-weeks. Most of this was in the first 3 weeks followed by maintenance of weight 
for the following 14 weeks (Figure 4.1). mH rats were heavier than the mC rats after 
16-weeks of chronic H feeding (Table 4.1). BMI was lower in mC compared to mH 
and abdominal circumference was lower in mC compared to mH (Table 4.1). With the 
addition of 20% wholegrain oat groats at 8 weeks, these four parameters were 
increased in mCO compared to mC and mHO compared to mH (Table 4.1). 
Retroperitoneal, omental, epididymal and total fat pads were increased between 
controls (mC vs mH), between controls and interventions (mC vs mCO and mH vs 
mHO), and between interventions (mCO vs mHO) (Table 4.1), indicating that the 
addition of the wholegrain oat groats increased body weights (Table 4.1).  
DXA measurements showed limited fat mass in the mC compared to mH (Table 4.1) 
with no change between the fat mass of the controls and their corresponding 
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interventions (mC and mCO or mH and mHO) (Table 4.1). Lean mass was lower in 
the mC compared to mH. The consumption of wholegrain oat increased lean mass in 
both mCO and mHO groups, with mCO having the highest lean mass of all the groups 
(Table 4.1). Bone mineral density was similar in both mC and mH groups and was not 
altered in either mCO or mHO. Bone mineral content in the mC rats was lower  than 
in mH. mCO bone mineral content increased compared to the mC group, but no 
significant difference was found between the mH and mHO groups (Table 4.1). These 
parameters, except bone mineral density, indicate that the wholegrain oat has a 
different effect based on the basal diet (Table 4.1). 
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Figure 4.1 Weekly body weight of male Wistar rats fed a diet of cornstarch 
(mC) or high carbohydrate high fat (mH) supplemented with wholegrain oat 
groats (mCO/mHO) after 8 weeks 
Values are mean ± S.E.M. n = 8 - 10 per group. Means without a common letter 
differ, P < 0.05 
mC = modified cornstarch; mCO = mC + wholegrain oat groats; 
mH = modified high carbohydrate, high fat; mHO = mH + wholegrain oat groats. 
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Table 4.1 Body composition of male Wistar rats following a dietary intervention of 20% wholegrain oat groats  
Values are mean ± S.E.M. n = 8 per group.  Means without a common superscript letter differ, * indicate P < 0.05 
mC = modified cornstarch; mCO = mC + wholegrain oat groats; mH = modified high carbohydrate, high fat; mHO = mH + wholegrain 
oat groats. 
     P-value 
variable mC mCO mH mHO diet intervention interaction 
Initial body weight (g)  339±1a 335±1a 337±1a 334±1a 0.1448 ------- 0.6210 
8-week body weight (g) 305±5a 287±3a 417±11b 380±12c <0.0001* ------- 0.1676 
Final body weight (g) 304±3a 443±7b 511±15c 557±11d <0.0001* <0.0001* 0.0001* 
Body weight gain (%) 8-16 wk 1.0±0.5a 15.6±1.8b 12.3±1.3b 14.8±4.0b 0.0112* 0.0001* 0.0040* 
Abdominal circumference (cm) 16.7±0.2a 20.2±0.2b 21.8±0.4c 22.8±0.2d <0.0001* <0.0001* 0.0002* 
Body Mass Index (g/cm2) 0.54±0.01a 0.66±0.01c 0.73±0.03b 0.75±0.01c <0.0001* 0.0015* 0.0190* 
Retroperitoneal fat (mg/mm) 169±10d 224±22c 373±47a 504±31b <0.0001* 0.0019* 0.1732 
Omental fat (mg/mm) 99±7d 134±17a 199±14b 254±19c <0.0001* 0.0027* 0.4883 
Epididymal fat (mg/mm) 63±7a 139±21b 124±2b 271±30c <0.0001* <0.0001* 0.0734 
Total fat pads (mg/mm) 330±21a 497±55c 696±77b 1028±75d <0.0001* <0.0001* 0.1435 
Visceral Adiposity Index 4.6±0.2a 4.9±0.5a 6.5±0.6b 8.8±0.5c <0.0001* 0.0108* 0.0459* 
Fat mass (g) 42±6a 76±10a 160±17b 186±17b <0.0001* 0.0343* 0.7689 
Lean mass (g) 247±6a 349±6b 314±9c 341±12b 0.0027* <0.0001* 0.0003* 
Bone mineral content (g) 9.47±0.23a 11.55±0.2b 14.26±0.76c 15.35±0.64c <0.0001* 0.0050* 0.3490 
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Table 4.2 Food, water and energy intake and feed conversion efficiency of male Wistar rats following a dietary 
intervention of 20% wholegrain oat groats  
     P-Value 
variable mC mCO mH mHO diet intervention interaction 
Food intake (g/day) 35±1a 34±1a 32±1a 25±1b <0.0001* 0.0005* 0.0067* 
Water intake (g/day) 38±2a 37±2ac 22±1b 31±3c <0.0001* 0.0535* 0.0173* 
Energy intake (kJ/day) 8-16 wk 365±6a 448±9b 555±11c 511±16d <0.0001* 0.1013 <0.0001* 
Feed conversion efficiency (%) -0.3±0.3a 3.9±1b 1.8±0.5c 4.1±0.9b 0.0856 <0.0001* 0.1528 
Values are mean ± S.E.M. n = 8 per group. Means without a common superscript letter differ, * indicate P < 0.05 
mC = modified cornstarch; mCO = mC + wholegrain oat groats;  
mH = modified high carbohydrate, high fat; mHO = mH + wholegrain oat groats.
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4.3.2 Cardiovascular parameters  
Systolic blood pressure was not significantly different in mC or mH rats. The addition of 
wholegrain oat did not alter blood pressure in mHO. However, blood pressures in mCO 
were decreased compared to the remaining groups (Table 4.4).  
Left ventricular mass in mC was decreased compared to mH. Both mCO and mHO were 
increased compared to mC and similar to mH (Table 4.4). Right ventricular mass was 
lowest in mC compared to mH. mCO was not significantly different to both mC and mH 
groups, while mHO was significantly different to mH (Table 4.4). Left ventricular 
diastolic stiffness constant was similar in mC and mH, and was increased in mHO and 
mCO compared to both controls (Table 4.4).  
Echocardiographic results (Table 4.3) indicated a lower heart rate in mC compared to mH. 
Heart rate in mCO was similar to mC and mHO was not significantly different to mH. 
LVIDd was smaller in mC than mH, mCO and mHO were both larger than mC and the 
same as mH. However, LVIDs indicated no significant difference between mC and mH 
and was unchanged with the interventions. LVPWd was smaller in the mC compared to 
mH, with mCO the same as mH. mHO was larger than both controls and mCO. Systolic 
volume, relative wall thickness, ejection time, deceleration time and MCMO showed no 
significant differences between mC and mH or either of the interventions. The ascending 
and descending aorta diameters were smaller in the mC group compared to mH. Both 
mCO and mHO were the same as mH. Fractional shortening in mC was the same as mH 
and mCO. It was increased in mHO compared to the other groups. The ejection fraction 
was similar in mC and mH as well as mCO. mHO had an increased ejection fraction 
compared to mC but it was similar to mH and mCO.  
Histological evaluation supported the preceding results. Inflammatory cell infiltration 
marked as “IC” (Figure 4.2) was high in both mC rats and mH rats, and was limited in 
mHO and mCO. Collagen deposition is clearly seen in the left ventricles of mC and mH 
hearts with limited deposition in mCO and mHO hearts (Figure 4.3). 
The above results lead to the conclusion that the mC diet needs further refining to be a 
considered a suitable healthy control for examining cardiovascular function and structure. 
Limited protein in this diet could be a cause of the inconsistencies of this control diet. This 
concept will be expanded in the Discussion section of this chapter. 
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Table 4.3 Echocardiographic cardiovascular parameters of male Wistar rats following a dietary intervention of 20% 
wholegrain oat groats 
Values are mean ± S.E.M. n = 8 per group. Means without a common superscript letter differ, * indicate P-< 0.05 mC = modified cornstarch; 
mCO = mC + wholegrain oat groats; mH = modified high carbohydrate, high fat; mHO = mH + wholegrain oat groats; LV = left ventricle, 
RV = right ventricle, LVIDd = Left ventricular internal dimension end-diastole, LVIDs = Left ventricular internal dimension end-systole, 
LVPWd = left ventricular posterior wall thickness end-diastole, EM = peak velocity early diastolic transmitral flow, AM  =  peak velocity late 
diastolic transmitral flow, MCMO = mitral closing-mitral opening time  
      P-value  
variable mC mCO mH mHO diet intervention interaction 
Heart rate (bpm) 230±5a 231±5a 262±14b 271±15b 0.0027* 0.6573 0.7225 
LVIDd (mm) 6.94±0.15a 8.05±0.23b 8.09±0.21b 7.89±0.09b 0.0124* 0.0206* 0.0013* 
LVIDs (mm) 4.14±0.18a 4.54±0.19a 4.21±0.35a 3.89±0.24a 0.2946 0.8842 0.1951 
LVPWd (mm) 1.68±0.02a 1.84±0.02b 1.84±0.03b 1.99±0.04c <0.0001* <0.0001* 0.8624 
Systolic volume 
(ml) 
0.08±0.01a 0.09±0.01a 0.10±0.01a 0.07±0.01a 0.9394 0.3624 0.0595 
Relative wall 
thickness 
0.49±0.01a 0.46±0.02a 0.47±0.02a 0.51±0.01a 0.3691 0.7635 0.0408* 
Ascending aorta 
diameter (cm) 
0.25±0.01a 0.31±0.01b 0.29±0.01b 0.31±0.02b 0.1197 0.0030* 0.1197 
Descending aorta 
diameter (cm) 
0.24±0.00a 0.29±0.01b 0.27±0.01b 0.28±0.01b 0.2418 0.0010* 0.0227* 
Fractional shortening (%) 40.4±1.5a 43.8±1.5a 43.5±1.6a 50.8±2.6b 0.0086* 0.0056* 0.2900 
Ejection fraction 
(%) 
78.5±1.6a 83.8±2.1ab 81.6±1.5ab 87.5±2.1b 0.0749 0.0038* 0.8919 
Ejection time (ms) 86.7±2.1a 79.7±3.4a 82.1±2.3a 90.9±3.5a 0.0285* 0.1662 0.0843 
Deceleration time 
(ms) 
54.6±1.3a 58.8±1.9a 50.4±1.9a 55.4±2.0a 0.0405* 0.0144* 0.8243 
EM (m/s) 0.63±0.02
a 0.79±0.03b 0.70±0.02c 0.72±0.16abc >0.9999 0.1928 0.3089 
AM (m/s) 0.34±0.02
a 0.45±0.0bc 0.39±0.01ac 0.51±0.03b 0.0305* <0.0001* 0.8389 
MCMO (ms) 113±2a 114±2a 118±5a 113±5a 0.6176 0.6176 0.4550 
Estimated LV 
mass (g) 
0.71±0.00a 1.07±0.04b 1.05±0.03b 1.14±0.03b <0.0001* <0.0001* 0.0008* 
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Table 4.4 Cardiovascular parameters of male Wistar rats following a dietary intervention of  20% wholegrain oat 
groats  
Values are mean ± S.E.M. n = 8 per group. Means without a common letter differ, * indicate P < 0.05 
mC = modified cornstarch; mCO = mC + wholegrain oat groats;  
mH = modified high carbohydrate, high fat; mHO = mH + wholegrain oat groats.  
LV = left ventricle, RV = right ventricle
      P-value  
variable mC mCO mH mHO diet intervention interaction 
Left ventricular + 
septum wet weight 
(mg/mm) 
17.9±0.8a 23.4±0.8b 25.3±0.8b 24.9±1.6b 0.0001* 0.0145* 0.0067* 
Right ventricular weight 
(mg/mm) 
4.8±0.4a 5.7±0.3abc 6.8±0.4b 5.3±0.5ac 0.0600 0.5029 0.0040* 
Left ventricular diastolic 
stiffness constant κ 
25.5±0.3a 28.6±1.4ab 26.8±1.2a 31.5±1.9b 0.1036 0.0046* 0.5244 
Systolic Blood Pressure 
(mmHg) 
143±3a 130±1b 142±3a 142±4a 0.0848 0.0433* 0.0433* 
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a)  b)  
c)  d)  
Figure 4.2 Inflammatory cells (IC) in the left ventricle of the heart of male Wistar 
rats induced by high carbohydrate, high fat diet and following a dietary 
intervention of 20% wholegrain oat groats 
Haematoxylin & eosin staining, 20 x magnification 
a) mC = modified cornstarch b) mCO = mC + wholegrain oat groats 
c) mH = high carbohydrate high fat d) mHO = mH + wholegrain oat groats  
IC  
IC  
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a)  b)  
c)  d)  
Figure 4.3 Collagen deposition (CD) in the left ventricle of the heart of male Wistar 
rats induced by high carbohydrate, high fat diet and following a dietary 
intervention of 20% wholegrain oat groats 
Picrosirius red staining, 20 x magnification 
a) mC = modified cornstarch b) mCO = mC + wholegrain oat groats 
c) mH = modified high carbohydrate high fat d) mHO = mH + wholegrain oat groats  
CD  
CD  
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4.3.3 Liver parameters 
Liver wet weight in mC was lower compared to mH. mHO was greater than mCO but 
there was no significant difference between the interventions and mH; however, mCO 
and mHO were both heavier than mC (Table 4.5). Plasma alanine transaminase (ALT) 
was not significantly different in mC and mH, mHO was unchanged compared to the 
controls but increased in the mCO group while plasma aspartate transaminase (AST) was 
similar in mC and mH and unchanged in mCO and mHO. (Table 4.5).  
Histological evaluation indicated fat vacuoles in the liver in both mC rats and in mH ones, 
with limited macrovascular steatosis in mCO and mHO. Limited inflammation is seen in 
both control and intervention groups (Figure 4.4).  
As with the cardiovascular results, the liver results lead to the conclusion that the mC diet 
needs further refining to be a considered a suitable healthy control for examining liver 
structure and function. Limited protein in this diet may be a reason for the inconsistencies 
of this control diet. This will be discussed later in this chapter. 
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a)  b)  
c)  d)  
Figure 4.4 Fat deposition (FV) and inflammatory cells (IC) in male Wistar rat 
livers induced by high carbohydrate, high fat diet and following a dietary 
intervention of 20% wholegrain oat groats 
Haematoxylin & eosin staining, 20 x magnification 
a) mC = modified cornstarch b) mCO = mC + wholegrain oat groats 
c) mH = modified high carbohydrate high fat d) mHO = mH + wholegrain oat groats  
FV  
FV  
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Table 4.5 Liver weight and plasma ALT, AST of male Wistar rats following the a dietary intervention 20% wholegrain 
oat groats 
      P-value  
variable mC mCO mH mHO diet intervention interaction 
Liver wet weight (mg/mm) 194±7a 311±9b 334±12bc 352±13c <0.0001* <0.0001* <0.0001* 
Plasma ALT (U/L) 27±1a 35±3b 24±1a 27±2a 0.0130* 00102* 0.1754 
Plasma AST (U/L) 92±6a 80±8a 68±8a 81±12a 0.1917 0.9775 0.1577 
Values are mean ± S.E.M. n = 8 per group. Means without a common superscript letter differ, * indicate P < 0.05 
mC = modified cornstarch mCO = mC + wholegrain oat groats 
mH = modified high carbohydrate, high fat mHO = mH + wholegrain oat groats.  
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4.3.4 Plasma biochemistry and inflammatory markers 
Plasma total cholesterol concentrations were statistically similar in mC and mH with both 
mCO and mHO having elevated concentrations. Triglyceride concentrations were lowest 
in mC, while mH and mHO had similar concentrations. mCO concentrations were not 
significantly different from both mC and mH. Non-esterified fatty acid (NEFA) plasma 
concentrations were lower in mC compared to mH, with mCO and mHO indicating no 
significant differences to their relevant controls (Table 4.6). 
Fasting blood glucose concentrations in the mC group were lower than in the mH rats 
Similarly, the blood glucose response to oral glucose loading showed the glucose area 
under the curve (AUC) decreased in the mC group but elevated in the mH rats. Fasting 
blood glucose concentrations for mCO and mHO were similar to mC. The glucose AUC 
was decreased in mHO compared to mH and not significantly different in mCO compared 
to mC (Table 4.6). 
Plasma C-reactive protein (CRP) concentrations were similar in mC and mH. Both mCO 
and mHO had increased CRP concentration compared to the controls (Table 4.6). This 
may be due to the increased total fat pads (Table 4.1) present in both mCO and mHO as 
CRP is produced by adipocytes.  
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Table 4.6 Plasma biochemistry and CRP of male Wistar rats following a dietary intervention of 20% wholegrain oat 
groats  
Values are mean ± S.E.M. n = 8 per group. Means without a common superscript letter differ, * indicate P < 0.05 
mC = modified cornstarch; mCO = mC + wholegrain oat groats; 
mH = modified high carbohydrate, high fat; mHO = mH + wholegrain oat groats  
  P-value 
variable mC mCO mH mHO diet intervention interaction 
Fasting blood glucose 
(mmol/L) 
4.0±0.2a 4.3±0.1a 5.0±0.1b 4.4±0.1a 0.0003* 0.2665 0.0020* 
Blood glucose AUC 
(mmol/L/min) 
738±19a 743±21a 925±44b 767±24a 0.0038* 0.0307* 0.0219* 
Plasma total cholesterol 
(mmol/L) 
1.6±0.1a 2.0±0b 1.7±0.1a 2.0±0b 0.4853 <0.0001* 0.4853 
Plasma triglycerides 
(mmol/L) 
0.7±0.1a 1.2±0.1ab 1.8±0.2b 2.1±0.5b 0.0012* 0.1618 0.7221 
Plasma NEFA (mmol/L) 2.2±0.2a 2.6±0.6a 4.9±0.3b 4.8±0.7b <0.0001* 0.7641 0.6175 
Plasma C-reactive protein 
(ng/ml) 
319±14a 469±44b 340±54a 475±29b 0.7103 0.0005* 0.8364 
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4.3.5 Gastrointestinal parameters 
4.3.5.1 Intestinal length 
Small intestine length from pyloric sphincter to ileo-caecal junction (duodenum, 
jejunum and ileum) was longer in mH than mC. mCO and mHO were similar length 
to mC. There was no significant difference in colon length (proximal, mid, distal 
colon) between mC, mH, mCO or mHO (Figure 4.5). 
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  P-value  
 diet intervention interaction 
small intestine 0.0043* 0.1152 0.0562 
colon 0.1049 0.3129 0.2571 
Figure 4.5 Gastrointestinal length of male Wistar rats following the a dietary 
intervention of 20% wholegrain oat groats a) small intestine  pyloric sphincter 
to caeco-ileal junction and b) colon – caeco-colonic junction to rectum 
Values are mean ± S.E.M. n = 8 per group. Means without a common superscript letter 
differ, * indicate P < 0.05 
mC = modified cornstarch, mCO = mC + wholegrain oat groats, 
mH = modified high carbohydrate, high fat, mHO = mH + wholegrain oat groats.  
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4.3.5.2 Gastrointestinal morphology  
Morphological analysis indicated that crypt depth was not significantly different in 
mC and mH mid-colon. The addition of wholegrain oat groats led to deeper crypts in 
the mCO rats, but the mHO crypts were similar length to both mC and mH controls 
(Figure 4.6a). Morphological analysis indicated mC had increased mucosal thickness 
than mH. mCO and mHO had mucosal thickness similar to mC (Figure 4.6b). Goblet 
cell numbers were low in both mC and mH mid-colons. The addition of wholegrain 
oat increased goblet cell numbers in mCO, with mHO similar to mC, mH and mCO 
(Figure 4.6c).  
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Figure 4.6 Effect of a dietary intervention of 20% wholegrain oat groats on a) 
crypt depth b) mucosal thickness c) goblet cell number in the mid colon of male 
Wistar rats 
Values are mean ± S.E.M. n = 8 per group. Means without a common superscript 
letter differ, P < 0.05 
mC = modified cornstarch; mCO = mC + wholegrain oat groats; 
mH = modified high carbohydrate, high fat; mHO = mH + wholegrain oat groats 
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4.3.5.3 Gastrointestinal histology 
Visual examination of the mid-colon indicated an increased number of submucosal 
folds in mC compared to mH that had limited folds. mCO and mHO had more 
submucosal folds than mH and a similar visual aspect as the mC (Figure 4.7). Increased 
submucosal folds indicates a greater surface area of the mucosa in the mid-colon. 
Crypts are upright and have a more complete structure in mC, mCO and mHO 
compared to mH (Figure 4.7). The epithelial layer is more complete in mC, mCO and 
mHO compared to mH (Figure 4.7).  
Gastrointestinal morphology was changed by the addition of wholegrain oat to the 
high-carbohydrate, high-fat diet. There were differences between mC and mH diets. 
This section (Figure 4.7) is a visual representation of the data in the previous section 
(4.5.2 Gastrointestinal morphology). Duodenum, jejunum and ileum show villi (V), 
crypts (C), mucosa (MT) and muscularis (M). Proximal, mid and distal colon show 
crypts (C), mucosa (MT), muscularis (M) and submucosal folds (S). 
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a)  b)  
c)  d)  
Figure 4.7 Morphology of the mid colon of male Wistar rats following a dietary 
intervention of 20% wholegrain oat groats  
C = crypt, MT = mucosa, S = submucosal folds, M = muscularis 
Haematoxylin & eosin. 10 x magnification  
a) mC = modified cornstarch b) mCO = mC + wholegrain oat groats 
c) mH = modified high carbohydrate, high fat d) mHO = mH + wholegrain oat groats
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4.3.5.4 Gastrointestinal contractility 
Ileal reactivity was not significantly different in mC and mH. mCO and mHO 
gave similar responses as the controls (Figure 4.8a). There were no significant 
differences between mC and mH or mHO for acetylcholine-induced colonic 
contractility. mCO had an increased colonic contractility at maximum 
contraction compared mC (Figure 4.8b).  
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Figure 4.8 Effect of acetylcholine on the contractility of ileum and mid colon of 
male Wistar rats following a dietary intervention of 20%  wholegrain oat groats 
Values are mean ± S.E.M. n = 8 per group.  Means without a common superscript letter 
differ, P < 0.05  
mC = modified cornstarch; mCO = mC + wholegrain oat groats; 
mH = modified high carbohydrate, high fat; mHO = mH + wholegrain oat groats
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4.3.6 Faecal short chain fatty acid (SCFA) analysis 
4.3.6.1 Combined  
Total SCFA, acetate, propionate and butyrate concentrations when averaged across all 
rats (n = 6) in each group were higher (Table 4.7) than when each group of rats were 
separated into rats that could feed until termination (n = 3) (Table 4.8) compared to 
rats that were fasted for 2-3 hours prior to termination (n = 3) (Table 4.9). The 
percentage of acetate relative to mC increased in mH and decreased in mCO and mHO 
samples. Propionate increased in all groups compared to mC. Butyrate decreased 
compared to mC in mH, mHO and mCO (Table 4.7).  
When fed and fasted samples were combined, there was an overall effect on total 
SCFA, acetate, propionate or butyrate caused by the diet (Table 4.7). When separated 
out to fed and fasted samples (Tables 4.8 & 4.9), both wholegrain oat and diet 
influenced total SCFA. Acetate concentrations were decreased by the addition of 
wholegrain oat in the fed samples (Table 4.8), while the diet had an effect on acetate 
and propionate in the fasted samples (Table 4.7). Therefore, for further analysis, fed 
and fasted groups were analysed separately.  
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Table 4.7 Average total SCFA, acetate, propionate and butyrate and acetate to propionate ratio in faecal samples of male Wistar 
rats following a dietary intervention of wholegrain oat groats 
Values are mean ± S.E.M. n = 6 per group.  Means without a common superscript letter differ, P < 0.05 
 
Table 4.8 Average total SCFA, acetate, propionate and butyrate and acetate to propionate ratio in faecal samples of male Wistar 
rats following a dietary intervention of 20% wholegrain oat groats. Rats fed until termination. 
Values are mean ± S.E.M. n = 3 per group.  Means without a common superscript letter differ, P < 0.05 
      P-value  
SCFA (µmol/g) mC mCO mH mHO diet intervention interaction 
Total  118±13ab 107±9b 155±12a 126±6ab 0.0138* 0.0680 0.3957 
Acetate 96±11a 48±4a 127±13b 91±6a 0.0384* 0.0121* 0.2696 
Propionate 9±1a 13±1b 16±2b 16±1b 0.0012* 0.1462 0.1462 
Butyrate 13±1a 13±1a 12±1a 19±1b 0.0006* 0.0091* 0.0006* 
Acetate:Propionate 10.6±0.1a 3.7±0.1d 7.9±0.2b 5.7±0.1c 0.0155* <0.0001* <0.0001* 
      P-value  
SCFA (µmol/g) mC mCO mH mHO diet intervention interaction 
Total  80±3a 62±1b 105±3c 51±1b 0.0021* <0.0001* 0.0002* 
Acetate 67±15ab 48±1a 93±8b 39±7b 0.3828 0.0041* 0.0938 
Propionate 6±0.3a 7±1a 6±1a 8±1a 0.5850 0.1263 0.5850 
Butyrate 7±0.4a 7±0.4a 6±1a 10±2a 0.4111 0.1211 0.1211 
Acetate: Propionate 11.1±1.9b 6.9±0.8c 15.7±1.3a 4.8±0.3c 0.3384 0.0003* 0.0259* 
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Table 4.9 Average total SCFA, acetate, propionate and butyrate and acetate to propionate ratio in faecal samples of male Wistar 
rats following a dietary intervention of 20% wholegrain oat groats. Rats fasted for 2-3 hours prior to termination. 
Values are mean ± S.E.M. n = 3 per group.  Means without a common superscript letter differ, P < 0.05 
mC = modified cornstarch; mCO = mC + wholegrain oat groats;  
mH = modified high carbohydrate, high fat; mHO = mH + wholegrain oat groats. 
 
 
 
 
      P-value  
SCFA (µmol/g) mC mCO mH mHO diet intervention interaction 
Total  38±3a 45±3a 50±3a 69±3b 0.0003* 0.0025* 0.0805 
Acetate 29±7a 33±4a 34±7a 52±9a 0.1240* 0.1538 0.3454 
Propionate 3±1a 6±0.3a 10±3a 8±0.4a 0.0228* 0.7628 0.1570 
Butyrate 6±0.1a 6±1a 6±2a 9±2a 0.3468 0.3468 0.3468 
Acetate: Propionate 10±1a 5.5±0.3bc 3.4±0.3c 6.5±0.8b 0.0032* 0.3297 0.0005* 
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4.3.6.2 Fed vs fasted 
4.3.6.2.1 Combined SCFA 
Total combined (acetate, propionate and butyrate) SCFA concentrations were lower in 
mC compared to mH. The addition of wholegrain oats lowered the total SCFA 
concentration in mHO and mCO in the fed samples compared to both controls (Table 
4.7). Concentrations decreased in the mCO compared to mC and mHO concentrations 
which were decreased compared to mH (Table 4.7). In the fasted faecal samples, there 
was no difference between mC and mH. mCO was similar to the controls and mHO 
had an increased concentration of SCFA compared to the controls (Table 4.7). In both 
fed and fasted samples, acetate was the largest proportion of SCFA with limited 
propionate and butyrate; however, there was an increased proportion of propionate and 
butyrate present in mHO samples (Table 4.7).  
 
4.3.6.2.2 Acetate, propionate and butyrate concentrationsConcentrations 
of acetate in faecal samples of fed rats was lower in mC compared to mH (Table 4.8). 
Acetate did not change between mC and mCO, and decreased from mH to mHO (Table 
4.8). In the fasted samples, mC, mH and mCO had lower concentrations than in the 
fed groups while mHO had similar concentrations to fed mHO, but there was no 
difference between any of the fasted groups (Table 4.9). Propionate concentrations 
were similar for mC and mH. mCO and mHO were similar to the controls in the fed 
samples (Table 4.8). There was no difference between any of the groups in the fasted 
samples (Table 4.9).  
Butyrate concentrations were similar in all groups in the fed samples (Table 4.8). In 
the fasted samples, butyrate concentrations in all groups were similar (Table 4.9).  
 
 185 
 
4.4 Discussion 
Metabolic syndrome has a complex aetiology, with the major factor that leads to the 
disease being a diet high in fats and simple sugars (Kaur, 2014). Since metabolic 
syndrome involves cardiovascular disease, diabetes, glucose intolerance and obesity, 
many studies need to be undertaken to define the causes and discover ways to attenuate 
the complexity of symptoms in this syndrome.  
The present study has supplemented a high-carbohydrate, high-fat diet as a rat model 
of metabolic syndrome that mimics the human condition with 20% wholegrain oat 
groats.  
Limited research exists characterising the gut morphology of high-carbohydrate, high-
fat diets when supplemented with wholegrains. This study was warranted as it 
examined the physiological effects, gut morphology and SCFA production, after 
intervention with a similar amount of wholegrain oat as the average human cereal 
consumption using a diet-induced rat model of metabolic syndrome. In this study, mC 
and mH were supplemented with 20% wholegrain oat. This translates to 
approximately 100 – 120 g/day in the average 70 kg adult human using a relevant 
scaling equation (Bachmann et al., 1996).   
The American Association of Cereal Chemists International (AACCI) classifies a 
wholegrain as ‘consisting of intact, ground, cracked or flaked caryopsis, whose 
principal anatomical components – the starchy endosperm, germ and bran, are present 
in the same relative proportions as they exist in the intact caryopsis’ (Rebello et al., 
2014). This study used intact oat groats for supplementation.  
Wholegrains are an important source of calories and offer nutrients and other food 
components such as phytochemicals (Liu, 2007). Wholegrains have been associated 
with the prevention of type 2 diabetes (Venn and Mann, 2004, Murtaugh et al., 2003), 
cancer (Jacobs et al., 1998) and other chronic diseases (Dixit et al., 2011, Johnston et 
al., 2010, Opie et al., 2016). The consumption of wholegrain oats has been advocated 
in dietary guidelines and nutritional policies in many countries including the USA, 
Australia, Canada, Mexico and across South America, Europe and Asia (Clemens and 
van Klinken, 2014a). The 2015 American Dietary Guidelines suggest consuming at 
least half of all grains as wholegrains with 3 serves of 16 g/day to reduce the risk of 
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developing chronic diseases including CVD, diabetes, and possibly some cancers 
(U.S. Department of Health and Human Services and U.S. Department of Agriculture, 
2015).  
The modified high-carbohydrate high-fat diet in this study induced many parameters 
associated with metabolic syndrome, including central obesity, hypertension, 
dyslipidaemia and impaired glucose tolerance. Cardiovascular changes included 
fibrosis, cardiac hypertrophy and increased diastolic stiffness and liver changes 
included steatosis, inflammatory cell infiltration and portal fibrosis as well as changes 
in plasma ALT and AST activities. These are consistent with the earlier findings using 
the established H diet (Panchal et al., 2011b). The modified cornstarch diet also 
induced several unexpected results such as hypertension, cardiac fibrosis, increased 
diastolic stiffness and steatosis and increased plasma AST activity.  
 
4.4.1 Body composition and dietary intake 
Few studies focus specifically on the impact of wholegrain oats on body composition 
as many only record this data as part of studies into hypertension and hyperglycaemia. 
Many of the studies investigating wholegrains such as The Framingham Heart Study 
classify a serving as any 1 of breakfast cereal, oatmeal, brown rice or other grains, 
slice of dark bread, popcorn or added bran or added germ (McKeown et al., 2010). 
This makes it difficult to compare studies of individual wholegrains and gives 
inconsistent results.  
Cross-sectional and prospective epidemiological studies have shown a reduced risk of 
obesity and weight gain with wholegrain consumption (Harland and Garton, 2008, 
Jonnalagadda et al., 2011, Liu et al., 2003, Koh-Banerjee et al., 2004, Sahyoun et al., 
2006). Observational studies also lend credibility to this relationship between 
wholegrains and weight loss (Liu et al., 2003, Koh-Banerjee et al., 2004). A systematic 
review and analysis of 15 human trials indicated that, with higher wholegrain 
consumption, adiposity measured by waist circumference was reduced by 2.7 cm and 
BMI was 0.630 kg/m2 lower (Harland and Garton, 2008). The cross-sectional and 
epidemiological studies, The Framingham Offspring Study and the Baltimore 
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Longitudinal Study of Aging (BLSA), indicated an inverse association between 
wholegrain consumption and BMI, waist to hip ratio and waist circumference 
(McKeown et al., 2004, Newby et al., 2007). The BLSA has been ongoing since 1958 
with participants returning every 12-24 months for repeated measures. Low 
wholegrain consumption compared to high wholegrain consumption indicated lower 
BMI (25.5 vs 24.8 kg/m2), lower body weight (75 vs 72.4 kg) and smaller waist 
circumference (87.4 vs 85 cm) (Newby et al., 2007). As with other studies, multiple 
wholegrains were consumed therefore it is difficult to indicate if any one wholegrain 
provides greater benefits. 
Prospective cohort studies of healthy males and females who consumed wholegrains 
such as wheat, oats, corn, rice, barley, rye bulgur, buckwheat, popcorn, amaranth and 
psyllium over 8 years showed an inverse association between increased wholegrain 
consumption and long-term weight gain (Koh-Banerjee et al., 2004, Liu et al., 2003). 
These studies also indicated a dose-dependent response with an increase of 40 g/day 
wholegrain decreasing weight 0.49 kg in men and 1.52 kg in women and an increase 
of 20 g/day decreasing weight 0.36 kg, with no associated response in refined grain 
consumption (Dong et al., 2016, Koh-Banerjee et al., 2004, Liu et al., 2003). 
The Adelaide Male Aging Study while not investigating wholegrains noted that 
increased cereal fibre had an inverse association with BMI (27.3 vs 25.4 kg/m2), 
percentage body fat (34 vs 31.5%) and trunk fat mass (42.8 vs 37.8%). There was no 
association between vegetable or fruit fibre and these measures (Atlantis et al., 2008). 
Intervention studies have shown inconsistent results in humans, possibly due to the 
use of hypocaloric diet programs rather than high carbohydrate, high fat diets (Juvonen 
et al., 2009, Katcher et al., 2008). Also the type of wholegrain administered, whether 
wholegrains were added or substituted into the diet and various participant 
characteristics (age, gender, nationality, health status) (McKeown and Jacobs, 2010) 
could be confounding factors in these studies. When these intervention and 
observational studies are combined, there is an overall suggestion that wholegrains 
may alter body fat distribution independent of changes in overall body weight. Our 
study is consistent with these studies as total abdominal fat pads increased in the mHO 
intervention group. However, there was no difference in body weight or lean mass, so 
this may be due to redistribution of fat from subcutaneous to abdominal stores. 
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Energy intake increased with the addition of wholegrain oats to mC which is similar 
to these intervention studies (Juvonen et al., 2009, Katcher et al., 2008). However, 
with the addition of wholegrain oats to the mH hypercaloric diet, the energy intake 
decreased which was inconsistent with previous studies. As many of these existing 
studies have been human clinical trials, it is not possible to directly compare food and 
water intake with our rat study. With the addition of wholegrain oat to the diet, food 
intake decreased, and water intake increased. This may have been due to the changed 
consistency of the diet. The mH diet was a thick liquid prior to the addition of the oat 
possibly meaning that the animals needed less water but with the addition of oat they 
needed to consume more due to the diet becoming thicker and stickier as water was 
removed and replaced by the oat grains.  
4.4.2 Cardiovascular effects  
The current study highlighted issues with the control healthy diet in relation to 
cardiovascular results. I used a modification to previous studies using the high 
carbohydrate, high fat rat model (Panchal et.al., 2011b), so that up to 20% of 
wholegrains or other interventions could be administered in the diet. To enable this, 
the powdered food was removed and replaced with a vitamin mix and increased water 
content. The removal of the powdered food decreased protein content by 20%, which 
appears to have led to decreased muscle and cardiac mass. As such, this may not be a 
good healthy control. The results for the modified unhealthy H control are similar to 
previous studies using the H diet (Panchal et.al., 2011a, Bhaswant et al., 2017) and 
also to the 5% experiments in Chapter 3.  
Therefore, due to issues with the mC diet, results may be inconsistent with earlier 
studies relating to high-carbohydrate, high-fat diets and metabolic syndrome; 
however, they may be relevant to cardiovascular disease caused by low protein diets. 
In pigs, a low protein diet upregulated lipogenic gene expression while down-
regulating lipolytic gene expression (Wang et al., 2012). Pigs that were fed a low 
protein diet had lower lean muscle mass and higher intramuscular fat than those on a 
high protein diet (Wang et al., 2012). The current study demonstrated similar lower 
lean muscle mass in the modified controls compared to the controls of Chapter 3 but 
intramuscular fat was not determined. The increase in fat vacuoles in the mC liver is 
a possible indication that intramuscular fat may be increased in this study. 
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Alternatively, isocaloric high animal or plant protein diets reduced liver fat and 
inflammation in Type 2 diabetes (Markova et al., 2017). The current study indicated 
that, with the addition of wholegrain oats, and subsequent increase in protein content, 
liver fat and inflammation decreased. This will need further investigation. 
Previous studies specific to oats or other cereal fibres have provided mixed results in 
the benefits to cardiovascular health (Maki et al., 2007, Behall et al., 2006, Pins et al., 
2002, Keenan et al., 2002). Studies have found systolic blood pressure increased (Maki 
et al., 2007) or decreased (Behall et al., 2006, Pins et al., 2002, Keenan et al., 2002). 
It is likely that both fibre and micronutrient intakes explain results in reducing 
antihypertensive medication and leading to positive blood pressure changes (Pins et 
al., 2002). As with this rat study, a human study was designed to identify the 
hypotensive effects of whole food intervention rather than specific bioactive 
compounds (Pins et al., 2002). It suggested that wholegrain oats have a synergistic 
anti-inflammatory effect with the soluble fibre (β-glucans) fraction, minerals, 
antioxidants, polyphenols and other phytonutrients responsible for the lowering of 
blood pressure (Pins et al., 2002). These changes may be mediated by improvements 
in other risk factors, such as body weight, dyslipidaemia and insulin resistance (Harris 
and Kris-Etherton, 2010). The current study results are consistent with previous 
studies indicating lower blood pressure, less cardiac inflammation and collagen 
deposition with the addition of wholegrain oats to both the mH and mC diets.   
Epidemiological studies in North America and Europe have indicated that 
wholegrains, such as rye, oats, brown rice and barley reduced the risk of 
cardiovascular disease (Seal and Brownlee, 2015), had an inverse association with the 
risk of death from ischaemic heart disease (Jacobs et al., 1998) and lowered the risk 
of coronary artery disease (Lutsey et al., 2007, Steffen et al., 2003). Intervention 
studies, in humans and animals, raise important issues relating to compliance and the 
interaction of complex food-based systems where the benefits and interactions of all 
the components are not necessarily understood.  
Several mechanisms may be responsible for the improved cardiovascular function. 
These include β-glucans forming a gel-like substance in the intestine increasing faecal 
excretion of cholesterol and bile acids and slowing glucose absorption (Keenan et al., 
2002, Alminger and Eklund-Jonsson, 2008). Anti-oxidant and anti-inflammatory 
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properties of polyphenols and phytonutrients may also play a part; however, these 
were not examined as part of this study.  
The fermentation of polysaccharides in the rat cecum resulting in SCFA production 
may also modulate blood glucose and insulin responses improving vascular function, 
blood pressure and weight control which in turn improve cardiovascular health 
(Pereira et al., 2002). Increasing propionate concentrations by fermentation of 
wholegrain oats inhibited cholesterol synthesis leading to the improvements in 
cardiovascular health (Richards et al., 2016, Queenan et al., 2007  However, it is still 
unclear if the lowering of LDL-cholesterol is the sole mechanism of action of 
wholegrain oat with regards to reducing the risk factors leading to coronary heart 
disease (Kelly et al., 2007). As this study only investigated total cholesterol changes, 
we are unable to confirm that LDL-cholesterol is lower in the intervention groups. 
However, the efficacy of oat and barley β-glucans in lowering blood lipids is well 
substantiated (Jonnalagadda et al., 2011). 
The higher fibre content of wholegrain oats may be fermented by colonic bacteria 
producing acetate and propionate which enter the portal circulation and influence 
hepatic glucose oxidation, decrease fatty acid release and increase insulin clearance 
and improve insulin sensitivity (Pereira et al., 2002). This may be due to improved 
insulin receptor sensitivity and a lower overall dietary glycaemic index and related 
insulin secretion. 
While current scientific evidence suggests that wholegrain oats has a beneficial effect 
on cardiovascular risk reduction, further research is needed to better understand the 
mechanisms of action and the impact that various components of the oats have on 
cardiovascular risk factors.  
4.4.3 Liver effects 
As with the cardiovascular results with the healthy mC in this experiment, there were 
inconsistencies with the liver results. Both mC and mH controls showed indications 
of steatosis, inflammation and fat vacuole formation in the liver. This indicates that 
this model needs further refinements before it is used in future studies.   
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The addition of wholegrain oats to the diet showed no change in liver wet weight, or 
ALT/AST activities. However, wholegrain oat decreased fat vacuole formation and 
inflammation in the liver. Previous studies have attributed the beneficial effects on 
blood lipid concentrations and hypocholesterolaemic effects to β-glucans (Forsberg 
and Reeves, 1995, Morrison, 1978), yet others have shown only slight improvements 
(Ebringerova et al., 2005). Up to 90% of bile acids that enter the small intestine for fat 
absorption are reabsorbed by the ileum (Dawson, 2011). As a soluble fibre, β-glucans 
reduced bile acid reabsorption thereby increasing bile acid excretion, lowering bile 
acid concentrations in the liver and increasing the conversion rate of cholesterol to bile 
acids (Papathanasopoulos and Camilleri, 2010). The liver then obtains the additional 
cholesterol by upregulating LDL receptors and increasing LDL particle uptake 
reducing circulating LDL-cholesterol (Papathanasopoulos and Camilleri, 2010). 
Further studies have shown that when wholegrain oats are consumed, there is a greater 
overall effect than when specific components, such as β-glucans, are taken 
individually (Klose and Arendt, 2012, Einhorn et al., 2003). Increases in the 
proportion of propionate produced by fermentation of wholegrain oats, and used in the 
hepatic lipid metabolism, may also lead to the improvements seen in the structure of 
the liver. 
4.4.4 Glycaemic effects 
Wholegrain oats in the diet improved glycaemic control with the postprandial glucose 
AUC returning to normal while fasting glucose concentrations were lower than the 
mH. This indicates that the wholegrain oats were playing a role in normalising glucose 
concentrations in the blood. Previous studies have found that the addition of 
wholegrains to the diet increased viscosity in the intestines caused by β-glucans, thus 
slowing the absorption of carbohydrates and lowering postprandial glucose 
concentrations (Li et al., 2016). However, results have been inconsistent with fasting 
plasma glucose with some human and animal trials finding a decrease in fasting 
glucose (Shen et al., 2011, Shen et al., 2016, Pick et al., 1996) but other randomised 
controlled trials found no differences (Bao et al., 2014). 
Lower blood glucose concentrations and improved insulin response of wholegrains 
has been demonstrated previously (Liu, 2007). Human studies comparing wholegrain 
and refined cereals in subjects with metabolic syndrome have found that wholegrains 
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lower plasma insulin and triglyceride concentrations which may reduce pancreatic 
β-cell stress preserving the β-cell function and delaying the onset of diabetes (Giacco 
et al., 2014, Tosh, 2013). A 12 - week intervention study found that the mechanism of 
these changes was not mediated by changes to free fatty acid (FFA) or GLP-1 plasma 
concentrations (Giacco et al., 2014). The reduction of postprandial triglycerides acts 
on the synthesis and/or catabolism of triglyceride lipoproteins. This reduction leads to 
an increase in lipoprotein lipase activity possibly due to the modification of lipid 
composition in lipoprotein particles rather than a reduction in number due to fibre 
present in wholegrain which interferes with the fat absorption in small intestine 
leading to synthesis of lipoproteins that are less rich in triglycerides (Giacco et al., 
2014). 
The viscosifying properties of β-glucans in the wholegrain oat groat may be one 
mechanism of action by delaying glucose absorption in the upper gastrointestinal tract 
(Wood et al., 1994). Viscosity has been attributed to 79 - 96% of changes in plasma 
glucose and insulin response (Wood et al., 2000). β-glucan concentration and 
molecular weight control the overall viscosity of the chyme that is produced for 
digestion (Wood et al., 2000). A linear relationship is evident between AUC and 
viscosity, with each log10 increment in viscosity contributing to approximately 30 
mmol/min/L decrease in postprandial glucose AUC (Tosh, 2013). However, very few 
studies report viscosity or molecular weight in the products that have been tested, 
including this current study.  
Another mechanism linking wholegrain consumption, colonic events and insulin 
sensitivity may also be involved in glycaemic control. The fermentation of 
wholegrains may improve the composition of gut microbiota and decrease gut barrier 
permeability by reducing LPS endotoxin leakage into circulation. Lower LPS 
alleviated peripheral inflammation and insulin resistance (Boulangé et al., 2016). This 
may be assisted by the continuous supply and absorption of metabolites, including 
acetate, propionate and butyrate and ferulic acid derivatives through fermentation 
(Giacco et al., 2014). 
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4.4.5 Inflammation 
Obesity has been characterised as a low-grade inflammation with increased 
inflammatory markers (Pereira and Alvarez-Leite, 2014) such as C-reactive protein 
(CRP) in obese subjects compared to lean ones. CRP is an acute phase protein 
indicating inflammation and is not only associated with obesity but also with 
cardiovascular disease and Type 2 diabetes. CRP is synthesised mainly in hepatocytes 
but CRP is also synthesised and secreted by adipose tissue (Fantuzzi, 2005). Increases 
in the mass of adipose tissue associated with obesity lead to increases in blood serum 
CRP concentrations (Ouchi et al., 2003, Selvin et al., 2007). A 14 week study of male 
Wistar rats on a high fat diet similar to our protocol showed higher blood CRP in obese 
animals compared to the control, with no significant difference in CRP concentration 
in the adipose tissue and no correlation between CRP in blood serum, liver or adipose 
tissue (Dimitrov et al., 2014). Our study is consistent with these findings as blood 
plasma CRP concentrations increased in the mH control and in both intervention 
groups where adipose tissue was greater than in the controls. Further studies 
investigating more specific inflammatory markers such as IL-6 or NF-κB which 
wholegrains decrease (Herder et al., 2009, Al-Lahham et al., 2010, Oliveira et al., 
2009) may be warranted to determine inflammatory status. 
 
4.4.6 Gastrointestinal Effects  
Gut function and efficiency is the key to successful nutrient absorption with the 
mucosa balancing electrolytes, immune response and endocrine function. 
Consumption of wholegrains may benefit those with metabolic syndrome by altering 
the environment of the gut. Previously in this chapter, it has been noted that β-glucans 
change the viscosity of the chyme being passed through the gut. This alters the transit 
time and in turn the absorption that takes place.  
One further mechanism of action that may be involved in gut function is the production 
of SCFA, which act as metabolic substrates for the gut microbiota. Gut microbiota and 
SCFA changes are correlated with energy intake, glucose, insulin, satiety hormones 
and hepatic cholesterol and triglyceride accumulation (Parnell and Reimer, 2012, 
Boulangé et al., 2016, Cani et al., 2009, Gibson et al., 2017, Delcour et al., 2016, 
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Verbeke et al., 2015) Prebiotic fibre has been substantially studied in relation the 
changing microbial dysbiosis (Boulangé et al., 2016, Bindels et al., 2015). However, 
as this study shows, further research is needed to explore how these changes occur.  
Healthy colons have a more complicated microarchitectural structure (Cox et al., 
2010)  therefore giving a greater surface area for nutrient absorption with longer and 
straighter crypts of Lieberkühn as seen with this study. Feed efficiency conversion 
rates in this study correlate with improved gut morphology. Poor gut morphology 
leads to inefficient feed conversion rates, as seen in the mC and mH colons, as 
repairing damaged enterocytes is an energy-consuming activity and valuable resources 
are diverted from growth to tissue repair and maintenance. Mucins and glycoproteins 
are produced by goblet cells which account for most of the epithelial cells found in the 
crypts. The mucus produced offers a barrier protecting the absorptive surfaces from 
microbial challenges, while endogenous acids, digestive enzymes and bile decrease 
bacterial growth which leads to improvements in the gut microarchitecture (Cox et al., 
2010, Forder et al., 2007).  
Limited studies have been performed to determine physiological and histological 
changes in the colon of rats fed wholegrain oats. However, studies on poultry fed 
wholegrain wheat (15 - 22.5% of diet) and soybean (2.4% of diet) indicate that dietary 
fibre induced physiological and histological changes including increased feed 
efficiency, caecal and jejunal crypt depths, caecal butyrate and total SCFA 
concentrations, and increased thickness of muscularis externa (Zdunczyk et al., 2013, 
Jankowski et al., 2009). This study showed increased crypt depth that could possibly 
be due to changes in the fermentation of the wholegrains leading to increases in total 
SCFA concentration in the mHO compared to the control group.  
The proliferation of colonocytes is more effective with increased butyrate production 
compared to acetate or propionate (Topping and Clifton, 2001). In a chronically 
starved colon, SCFA cannot be easily replaced and diminished mucosal nutrition may 
lead to mucosal atrophy and diminished absorption (Roediger, 1990). However, 
whether this process begins in the short-term still needs further research. This study 
has given some clarity to this area with the improvement in the mCO mucosa 
following the addition of the wholegrain to the diet. 
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As one of the bioactive compounds in wholegrain oat, β-glucans are seen to be 
prebiotic compounds selectively fermented by groups of beneficial bacteria present in 
the gut (Roberfroid et al., 2010). The main by-products of this fermentation are the 
short-chain fatty acids: acetate, propionate and butyrate. Acetate is the most abundant 
while propionate and butyrate are usually found in roughly equal proportions 
(Roediger, 1990). This study agrees with previous research with high concentrations 
of acetate and similar concentrations of propionate and butyrate produced in these 
experiments (Jankowski et al., 2009).  
In vitro experiments have found that different SCFA profiles are produced by different 
non-digestible components. β-glucans produced a propionate-rich profile with 
51:32:17 acetate to propionate to butyrate ratio, while arabinoxylans have a 
butyrate-rich profile at 63:12:25 ratio. β-glucans also produce a higher total SCFA 
concentration than inulin (Hughes et al., 2007, Hughes et al., 2008). Differences in 
SCFA production will also occur with β-glucans of different molecular weights 
(Hughes et al., 2008). An in vitro study using human faecal microbiota for 
fermentation found propionate total and proportional concentrations increased from 
30% with 150 kDa oat β-glucans to 37% with barley 172 kDa β-glucans (Hughes et 
al., 2008). Therefore, it is necessary for further research to be completed to determine 
the differences that may have occurred due to this factor. Studies have highlighted the 
influence of different foods and long-term diets on intestinal microbiota and 
specifically on the pattern of SCFA (Yang and Rose, Costabile et al., 2015). Limited 
studies exist where β-glucans as part of an overall diet have been investigated 
(Cloetens et al., 2012). 
In humans, up to 99% of SCFA produced by bacterial fermentation are rapidly 
absorbed from the colonic lumen (Scheppach, 1994). However, as the rat 
gastrointestinal tract differs substantially from a human in terms of length and 
composition (Nyman et al., 2007), any results gained from studies using rat faecal 
samples need to take account of this difference in anatomy. Pigs and dogs which have 
similar bowels to humans appear to be better models (Topping and Clifton, 2001). 
Rats are coprophagic, re-ingesting faeces produced by caecal fermentation (Nyman et 
al., 2007), ensuring retention of liquid digesta while solids are voided. This has 
implications for digestion of resistant starch but not fibre. Insoluble fibre fermentation 
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differs little between rats that were allowed to perform coprophagy or not (Cree et al., 
1986, Jackson and Topping, 1993). Coprophagy is a very important variable to 
consider and limits the reliability of SCFA data from rats, therefore it would be best 
to use humans, pigs or dogs for SCFA experimentation.  
This study indicated that while the difference in healthy and unhealthy control diets 
change the total faecal excretion of SCFA as well as individual SCFA, limited changes 
exist when adding wholegrain oat to the diet when using all samples tested which were 
a combination of rats that were fed until termination and collection of faecal samples 
and those that were fasted for 2 - 3 hours prior to collection. Propionate and butyrate 
concentrations fell after starvation or restricted feeding in rats, with butyrate 
decreasing the most and being restored more slowly after feeding recommenced 
(Topping and Clifton, 2001). The current study saw a difference between SCFA 
concentrations from fed samples compared to fasted samples indicating that a larger 
proportion of the SCFA is being excreted possibly due to excess being produced.  
However, due to the small number of faecal samples (total n = 6/group, fed/fasted 
n = 3/group) that were tested, any results need to be observed with that restriction in 
place. Further research will be needed to consolidate these results taking into account 
the differences between human and rat gastrointestinal tracts.  
Many studies to determine SCFA concentrations using cell cultures produced 
conflicting results (Connolly et al., 2010, Connolly et al., 2012, Dass et al., 2007, 
Hernot et al., 2009). These studies establish the quantity and ratio of SCFA produced 
on fermentation of non-digestible carbohydrates in vitro. There are very few studies 
that examine the effect of wholegrain oat consumption on SCFA production, but these 
few studies do not support a positive effect on SCFA production. Two studies 
investigated impact of feeding wholegrain cereals (wheat and maize) on microbiota 
and SCFA production and did not detect any changes in faecal SCFA concentrations 
(Costabile et al., 2008, Carvalho-Wells et al., 2010) as they are readily absorbed in the 
colon and either transported to the liver to be utilized in cholesterol synthesis and 
gluconeogenesis (acetate and propionate) or used in the colon to produce and 
differentiate colonocytes (butyrate). This study is consistent with the very low 
concentrations in our faecal samples. Faecal SCFA concentrations are used as a 
surrogate marker for SCFA production, however, this does not represent epithelial cell 
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exposure (Thies et al., 2014). The production of SCFA is also highly variable not only 
between individuals but also within individuals with many confounding factors, such 
as recent dietary intake, colonic transit time and hydration status. Therefore, the 
interpretation of this data is greatly limited (Thies et al., 2014). 
In human studies, there is a lack of evidence to support the effect of oats on faecal 
SCFA excretion as often no effect is observed as 90% of SCFA are absorbed and 
utilized by the host (Connolly et al., 2012). No changes in faecal SCFA or butyric acid 
were shown in a 2 - week oat bran randomised control trial on humans with colorectal 
adenomas (Kashtan et al., 1992). A 4 - week human randomised controlled trial with 
an oat bran intervention compared to high amylose wheat diet indicated no change to 
the faecal excretion of acetate or propionate but butyrate was lower (Noakes et al., 
1996). Finally, a 12 - week trial on humans with ulcerative colitis indicated no change 
in faecal excretion of the variety of SCFA or sum of SCFA, however butyric acid was 
increased by 26% by week 4 (Hallert et al., 2003). While these studies used oat bran 
which was lower in β-glucans than wholegrain oat, it could be extrapolated that as the 
prebiotic effect of β-glucans is expected, then by lowering the content, SCFA 
production will be decreased and therefore less likely to be found in faecal samples. 
As this study indicated total increases of acetate, propionate and butyrate, as well as 
the proportion of propionate and butyrate in the fed mHO rather than the fed mCO 
compared to the controls, a possible mechanism may be that the increased total SCFA 
production is causing a lower pH resulting in a decreased solubility of free bile acids 
which in turn decreases secondary bile acids (van Bennekum et al., 2005, Wong et al., 
2006). SCFA-mediated modulation of gut hormones by free fatty acid receptor 2 
(FFAR2) and free fatty acid receptor 3 (FFAR3) may also regulate food intake and 
energy balance leading to a decrease in obesity (Lin et al., 2012). Cross-feeding may 
also occur between Bifidobacteria and butyrate-producing bacteria (De Vuyst and 
Leroy, 2011) which may explain the significant increase in acetate and butyrate 
production. As exploring the microbiota was outside of the scope of this study, further 
research is needed to confirm any changes and mechanisms of action that this may 
lead to. 
Increases of faecal SCFA have been correlated with increased adiposity (Fernandes et 
al., 2014, Rahat-Rozenbloom et al., 2014). While this study gives similar results, this 
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may be due to the minimal fat mass of both control diets prior to the addition of the 
wholegrain oats. As previously mentioned, further refinement of these diets is 
necessary prior to any further intervention studies.  
 
4.5 Conclusions  
Results from this study demonstrate that the addition of 20% wholegrain oats to a high 
carbohydrate, high fat diet improved blood pressure, glucose tolerance and plasma 
cholesterol concentrations. It also improved the structure of the heart, liver and 
gastrointestinal tract. These responses may be due to changes in the gut microbiome 
caused by fermentation of dietary fibre, resistant starch, β-glucans and other minor 
prebiotic components within the grain. The microbial metabolites (SCFA) act as 
energy sources for the colonic and hepatic cells leading to improved function. Further 
research determining whether wholegrain oat consumption leads to greater expression 
of FFAR2 and FFAR3, MUC2 and claudin-1 improving gut repair, protection and 
integrity is needed. 
The main limitation of this study was the low protein intake of the control diets which 
led to decreased lean mass and body weight, particularly in the mC or healthy control. 
Further refinements of these diets are necessary before future intervention studies are 
carried out.  Another limitation to this study was the difference between human and 
rat gastrointestinal tracts. The rat model is valuable for studying diet-induced 
metabolic syndrome. However, when studying how the gut is involved, a different 
mode of study, such as an artificial gut, may improve results.  
Overall, the addition of wholegrain oats is beneficial in attenuating diet-induced 
metabolic syndrome and improving the structure of the gastrointestinal tract, and could 
be a healthy replacement for other grains in the diet. 
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 - Coconut products improve signs of diet-
induced metabolic syndrome in rats 
 
5.1 Introduction  
Coconut (Cocos nucifera L.) has for many civilisations, particularly in tropical and 
subtropical regions, been seen as the ‘tree of life’ (DebMandal and Mandal, 2011) as 
all parts of the tree can be used for numerous purposes yet until recently the health 
benefits, have been anecdotal rather than scientifically proven, with many previous 
studies focusing on only on the coconut oil (Arunima and Rajamohan, 2012, Liau et 
al., 2011, Zakaria et al., 2011) and not the other components of coconut.   
The fruit components are used industrially and in-home cooking in many ways (Lima 
et al., 2015). Traditionally, parts of the coconut fruit (such as shell fibre, pulp and 
water) and tree root have been used in many countries for treatment of various diseases 
(Lima et al., 2015). While coconut fibre is rich in polyphenols, the oil is rich in 
medium-chain saturated fatty acids (~90% of the oil) (Lima et al., 2015). Saturated 
fatty acids have been debated as a class of fatty acids for their association with 
cardiovascular disease risk (Lecerf, 2009, de Souza et al., 2015, Hammad et al., 2015), 
although the roles of the individual fatty acids were not considered for such 
conclusions. A recently published article highlights the need to look for a biological 
classification in order to confirm the disease risk and prevention potential of fatty acids 
(Poudyal and Brown, 2015).  
Cold-pressed coconut oil (also called virgin coconut oil or VCO) is composed of 
~-50% lauric acid, ~ 20% myristic acid and ~ 6% capric acid, all medium-chain 
saturated fatty acids (Katragadda et al., 2010). The content of medium chain fatty acids 
in VCO can vary depending on geographical location and ecological conditions 
(Nevin and Rajamohan, 2008). Lauric acid as the major component of coconut oil has 
an advantage in its cellular metabolism. Lauric acid is highly oxidized in the cell while 
the longer chain saturated fatty acids are oxidized at a slower rate (DeLany et al., 2000, 
Göransson, 1965, St-Onge and Jones, 2002). Myristic acid is 2 carbons longer than 
lauric acid and can be expected to have intermediate oxidizability, so slower than 
palmitic acid and stearic acid (DeLany et al., 2000, Rioux et al., 2000, St-Onge and 
Jones, 2002). In a previous study, lauric acid showed HDL-cholesterol increases in 
200 
healthy subjects in a crossover design study after 6 weeks of high-lauric acid diet 
consumption (Temme et al., 1996). In coronary artery disease patients, a diet rich in 
extra virgin coconut oil helped in reducing waist circumference with increases in 
HDL-cholesterol (Cardoso et al., 2015). 
Metabolic syndrome is the cluster of risk factors for cardiovascular disease and type 2 
diabetes (O'Neill and O'Driscoll, 2015). These risk factors are correlated with higher 
intake of dietary fat (Golay and Bobbioni, 1997, Lee, 2013, Hariri and Thibault, 2010). 
Dietary intake of saturated fatty acids are proposed to be involved in the development 
of metabolic diseases including obesity and dyslipidaemia (Golay and Bobbioni, 1997, 
Hariri and Thibault, 2010). This study is investigating the role of coconut-derived 
commercial products, Banaban virgin coconut oil and Banaban coconut nourish, as 
sources of fats and fibre. We have developed a high carbohydrate, high fat diet-fed rat 
model for human metabolic syndrome with metabolic, cardiovascular and hepatic 
complications developed in these animals (Panchal et al., 2011b). 
ORIGINAL PAPER
Coconut Products Improve Signs of Diet-Induced Metabolic
Syndrome in Rats
Sunil K. Panchal1 & Sharyn Carnahan1,2 & Lindsay Brown1,2
Published online: 27 October 2017
# Springer Science+Business Media, LLC 2017
Abstract Increasing prevalence of obesity and metabolic
syndrome warrants identification of potential therapeutic op-
tions for intervention. This study tested commercially avail-
able Virgin Coconut Oil and Coconut Nourish, as coconuts are
rich sources of lauric andmyristic acids.MaleWistar rats were
fed either corn starch diet (C); high-carbohydrate, high-fat diet
(H); high-carbohydrate, high-virgin coconut oil diet (HV); or
high-carbohydrate, high-coconut Nourish diet (HN) for
16 weeks. Metabolic, liver, and cardiovascular health param-
eters were measured during and at the end of the study. Virgin
coconut oil lowered body weight (C 386±8g, H 516±13g, HV
459±10g), blood glucose concentrations (C 4.2±0.1 mmol/L,
H 5.4±0.2 mmol/L, HV 4.6±0.2 mmol/L), systolic blood pres-
sure (C 127±5mmHg, H 149±4mmHg, HV 133±3mmHg,)
and diastolic stiffness (C 25.0±1.7, H 31.4±1.2, HV 25.2
±2.3,) with improved structure and function of the heart and
liver. Coconut Nourish increased total body lean mass (C 255
±10g, H 270±16g, HN 303±15g) and lowered plasma total
cholesterol concentrations (C 1.6±0.2 mmol/L, H 1.7
±0.1 mmol/L, HN 1.0±0.0 mmol/L), systolic blood pressure
(C 127±5mmHg, H 149±4mmHg, HN 130±3mmHg) and
diastolic stiffness (C 25.0±1.7, H 31.4±1.2, HN 26.5±1.0),
improved structure and function of the heart and liver but
increased plasma concentrations of triglycerides (C 0.3
±0.1 mmol/L, H 1.1±0.4 mmol/L, HN 1.8±0.2 mmol/L) and
non-esterified fatty acids (C 1.2±0.3 mmol/L, H 3.3
±0.8 mmol/L, HN 5.6±0.4 mmol/L). Thus, the fiber and pro-
tein in coconut Nourish and the medium-chain saturated fatty
acids in virgin coconut oil may improve cardiovascular and
liver complications in obesity.
Keywords Metabolic syndrome . Obesity . Coconut .
Saturated fatty acids . Lauric acid
Introduction
Metabolic syndrome is a cluster of risk factors for cardiovas-
cular disease and type 2 diabetes including obesity, insulin
resistance, hypertension, dyslipidemia, and impaired glucose
tolerance [1]. The role of dietary saturated fatty acids as a risk
factor for cardiovascular andmetabolic disease has beenwide-
ly debated [2, 3]. Current results suggest that the biological
effects of saturated fatty acids depend on the source of the fat
and the chain length of individual fatty acids, supporting the
classification of these fatty acids based on biological effects
rather than chemical structure [3]. Lauric and myristic acids
are medium-chain saturated fatty acids found in large amounts
in coconuts [4]. The 12-carbon lauric acid is rapidly oxidized
in the cell, the 14-carbon myristic acid has an intermediate rate
of oxidation while the longer-chain saturated fatty acids such
as the 18-carbon stearic acid are oxidized at a slower rate [5].
Cold-pressed coconut oil, also referred to as virgin coconut oil
(VCO), is mainly composed of saturated fatty acids (~91%),
predominantly lauric and myristic acids [6].
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5.2 Coconut products improve signs of diet-induced metabolic syndrome in rats
Traditionally, components of coconuts such as shell fiber,
pulp, and water have been used to treat diseases including
diabetes, asthma, stomach pain, dermatitis, and diarrhea, as
well as for their antipyretic and diuretic responses [7]. The
husk from coconut fruit as a source of fiber has been associ-
ated with health effects including antimalarial, antibacterial,
and antidepressant responses [8, 9]. Further, our recent studies
showed that lauric acid prevented induction of obesity and
osteoarthritis in high-carbohydrate, high-fat diet-fed rats
[10]. A review of studies with coconut oil suggested that the
consumption of coconut oil did not improve lipid profile and
hence cardiovascular risk when compared to cis unsaturated
fatty acids [11].
Intakes of simple sugars (fructose and sucrose), long-chain
saturated fatty acids and trans fatty acids in the modern diet
are major predictors of the increase in metabolic syndrome [2,
3, 12]. Our previous studies have reported that the feeding of
high-carbohydrate, high-fat diet using fructose and sucrose as
simple sugars and beef tallow as the source of long-chain
saturated fatty acids and trans fatty acids induced metabolic,
cardiovascular, and hepatic complications in rats that are sim-
ilar to the metabolic syndrome in humans [10, 13, 14].
Further, foods can also prevent or reverse disease states, and
current research has focused on these functional foods for
metabolic diseases [15].
This study investigated two commercial coconut-derived
products, Banaban virgin coconut oil and Banaban coconut
Nourish, as sources of medium-chain saturated fatty acids and
fiber, respectively, replacing beef tallow in diet-induced met-
abolic syndrome in rats. Structural changes in the rat heart
were characterized by histology and echocardiography, while
heart function was assessed in vivo using echocardiography
and ex vivo in isolated perfused hearts. Systolic blood pressure
and responses of isolated thoracic aortic rings were measured
to identify vascular reactivity. Metabolic parameters (oral glu-
cose tolerance, body composition, and plasma lipid concen-
trations) were assessed. Changes in liver structure and func-
tion were defined by histology and plasma activities of liver
enzymes.
Materials and Methods
Rats and Diets 40 male Wistar rats aged 9–10 weeks old
(337 ± 1 g) were purchased from Animal Resource Centre
(Canning Vale, WA, Australia) and housed individually in a
temperature-controlled (21 ± 2 °C), 12-h light/dark cycle en-
vironment with free access to group-specific food and water at
the University of Southern Queensland Animal House. Rats
were randomly divided into four separate groups (n = 10 each)
and were fed with one of the following diets for 16 weeks:
corn starch diet (C); high-carbohydrate, high-fat diet (H);
high-carbohydrate, high-VCO diet (HV) and high-
carbohydrate, high-coconut Nourish diet (HN). The composi-
tion of C and H diets have been reported previously [13, 14].
In HVand HN diets, beef tallow in the H diet was replaced by
Banaban virgin coconut oil (200 g/kg) and Banaban coconut
Nourish powder (200 g/kg), respectively. The composition of
VCO and coconut Nourish powder are described in
Supplementary Table 1.
Physiological Measurements Body weight and intakes of
food and water were recorded daily for all rats. Energy intakes
and feed conversion efficiency were calculated [13].
Abdominal circumference was measured every eighth week
using a standard measuring tape under light anesthesia with
Zoletil (tiletamine 10 mg/kg, zolazepam 10 mg/kg, intraperi-
toneal; Virbac, Peakhurst, NSW, Australia) [13]. Oral glucose
tolerance tests were performed on rats at 0, 8, and 16 weeks
[13]. Dual-energy X-ray absorptiometric measurements were
performed on rats after 16 weeks of feeding using a Norland
XR36 DXA instrument (Norland, Fort Atkinson, WI, USA)
[13]. Systolic blood pressure and echocardiographic examina-
tion were measured [13]. After terminal euthanasia, left ven-
tricular function was assessed using isolated Langendorff
heart preparation [13]. Responses of thoracic aortic rings to
noradrenaline, acetylcholine, and sodium nitroprusside were
measured [13].
Euthanasia Euthanasia was induced by intraperitoneal injec-
tion of Lethabarb (pentobarbitone sodium; 100mg/kg; Virbac,
Peakhurst, NSW, Australia). Heparin (200 IU; Sigma-Aldrich
Australia, Sydney, NSW, Australia) was administered through
the right femoral vein followed by withdrawal of ~5mL blood
from the abdominal aorta. Blood was collected into heparin-
ized tubes and centrifuged at 5000 × g for 15 min within
30 min of collection. Plasma was collected and stored at
−20 °C.
Organ Weights and Histology Following perfusion experi-
ments, right ventricle and left ventricle (with septum) were
separated and weighed. Liver, kidney, and retroperitoneal, ep-
ididymal, and omental fat contents were removed and
weighed. Organ weights were normalized relative to tibial
length (mg/mm). Two rats per group were used exclusively
for histopathological analysis. Thin sections (5 μm) of tissue
were cut and stained with haematoxylin and eosin stain for
determination of inflammatory cell infiltration (heart and liver,
×20) and fat vacuole deposition (liver, ×20). Picrosirius red
staining was used to define collagen distribution in the left
ventricle (×20) [13].
Plasma Biochemistry Plasma activities of alanine transami-
nase and aspartate transaminase and plasma concentrations of
triglycerides, total cholesterol, and non-esterified fatty acids
were determined [13].
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Statistical Analysis Data are presented as mean ± SEM.
GraphPad Prism version 6.00 for Windows (San Diego, CA,
USA) was used for statistical analyses of differences between
the groups by one-way analysis of variance. Statistically sig-
nificant variables were treated with Neumann–Keuls post hoc
test to compare all groups of animals. P < 0.05 was considered
statistically significant.
Results and Discussion
Physiological and Metabolic Parameters with Virgin
Coconut Oil (VCO) VCO-fed HV rats had higher body
weight, body weight gain, and abdominal circumference com-
pared to C rats while these parameters were lower in HV rats
compared to H rats (Table 1). Energy intake and feed conver-
sion efficiency were higher in HV rats compared to C rats
while these parameters were lower than H rats (Table 1).
During oral glucose tolerance test, basal blood glucose con-
centration in HVrats was not different fromC rats while it was
lower than H rats (Table 1). Although VCO lowered basal
blood glucose concentrations, it failed to improve the overall
glucose tolerance as evident from the area under the curve
(Table 1). Retroperitoneal, epididymal, and omental fats were
higher in HV rats compared to C rats while they were not
different between H and HV rats (Table 1). Total body fat
and lean mass were similar in C and HV rats whereas both
these parameters were also similar in H and HV rats (Table 1).
Plasma total cholesterol concentrations were not different in C
and HV rats while HV rats had higher total cholesterol con-
centrations compared to H rats (Table 1). Plasma triglyceride
concentrations were higher in HV rats compared to C rats
while HV and H rats had similar triglyceride concentrations
(Table 1). Plasma non-esterified fatty acid concentrations were
higher in HV rats compared to C rats while H and HV rats had
no differences in plasma concentrations of non-esterified fatty
acids (Table 1).
The responses of diet supplementation with virgin coconut
oil may be due to replacement of longer-chain saturated fatty
acids with medium-chain fatty acids [16]. Virgin coconut oil
components may induce increased energy expenditure leading
to a lower weight gain than beef tallow. The major medium-
chain fatty acids in virgin coconut oil are lauric acid and
myristic acid [16], which are rapidly absorbed in the intestine
even without pancreatic lipase [17]. Lauric acid is more likely
to be oxidized by themitochondria than longer-chain saturated
fatty acids such as stearic and palmitic acids [18]. We have
also compared lauric, myristic, palmitic, and stearic acids for
their effects on obesity and osteoarthritis with lauric acid
markedly reducing both obesity and osteoarthritis compared
Table 1 Dietary intakes, body
composition, and plasma
biochemistry
Variables C H HV HN
Initial body weight (g) 340 ± 1 337 ± 1* 337 ± 1* 337 ± 2
Final body weight (g) 386 ± 8 516 ± 13a* 459 ± 10b* 512 ± 11a*
Body weight gain (%) 13.3 ± 2.3 52.2 ± 3.7a* 36.5 ± 4.1b* 51.7 ± 2.8a*
Food intake (g/day) 38.8 ± 1.4 24.4 ± 0.5a* 21.4 ± 0.8b* 24.5 ± 0.9a*
Water intake (g/day) 30.0 ± 1.5 25.9 ± 1.9b 21.7 ± 1.2b* 36.7 ± 1.5a*
Energy intake (kJ/day) 378 ± 16 524 ± 10a* 441 ± 14b* 458 ± 14b*
Feed conversion efficiency (g/kJ) 0.12 ± 0.02 0.34 ± 0.02a* 0.27 ± 0.03b* 0.38 ± 0.02a*
Abdominal circumference (cm) 18.5 ± 0.2 22.7 ± 0.5a* 20.7 ± 0.3b* 21.8 ± 0.2a*
Basal blood glucose (mmol/L) 4.2 ± 0.1 5.4 ± 0.2a* 4.6 ± 0.2b 5.2 ± 0.2a*
Area under the curve (mmol/L.minutes) 765 ± 26 866 ± 22* 862 ± 32* 893 ± 29*
Retroperitoneal fat (mg/mm) 177 ± 21 420 ± 43* 415 ± 50* 380 ± 47*
Epididymal fat (mg/mm) 120 ± 11 229 ± 15* 198 ± 20* 252 ± 19*
Omental fat (mg/mm) 134 ± 13 242 ± 24* 237 ± 19* 250 ± 22*
Total abdominal fat (mg/mm) 430 ± 41 892 ± 73* 850 ± 87* 881 ± 84*
Total body fat mass (g) 121 ± 12 235 ± 19* 176 ± 26 169 ± 15*
Total body lean mass (g) 255 ± 10 270 ± 16 256 ± 11 303 ± 15*
Fat:lean mass ratio 0.49 ± 0.07 0.81 ± 0.10* 0.71 ± 0.12 0.58 ± 0.08
Plasma total cholesterol (mmol/L) 1.6 ± 0.2 1.7 ± 0.1b 2.0 ± 0.0a 1.0 ± 0.0c*
Plasma triglyceride (mmol/L) 0.3 ± 0.1 1.1 ± 0.4 1.4 ± 0.3* 1.8 ± 0.2*
Plasma NEFA (mmol/L) 1.2 ± 0.3 3.3 ± 0.8* 4.8 ± 0.8* 5.6 ± 0.4*
All values are mean ± SEM. * indicates significantly different values compared to C. Means between H, HVand
HN without a common letter are significantly different, P < 0.05. C, corn starch diet-fed rats; H, high-carbohy-
drate, high-fat diet-fed rats; HV, high-carbohydrate, high-VCO diet-fed rats; HN, high-carbohydrate, high-
coconut Nourish diet-fed rats; NEFA, non-esterified fatty acids
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to H rats, in contrast to palmitic and stearic acids [10]. Other
studies with coconut oil have shown similar health benefits
[19–21]. Previous studies with palmitic and stearic acids con-
firmed their role in inducing insulin resistance [22, 23].
Although lauric and myristic acids are also saturated fatty
acids with similar chemical properties to palmitic and stearic
acids, all saturated fatty acids cannot be considered to produce
the same physiological responses [3]. Fat to lean mass ratio
can predict metabolic dysfunction [24]. In our study, fat to
lean mass ratio was higher in obese rats compared to healthy
lean rats reflecting the metabolic disturbances in obese rats.
Further, the improved fat to lean mass ratio in VCO and co-
conut Nourish supplemented rats suggests that these interven-
tions improve the metabolic status of rats.
Physiological and Metabolic Parameters with Coconut
Nourish HN rats had higher body weight, body weight gain,
and abdominal circumference compared to C rats while these
parameters were similar in HN and H rats (Table 1). Energy
intake was higher in HN rats compared to C rats while it was
lower than H rats (Table 1). Feed conversion efficiency was
higher in HN rats compared to C rats while it was similar in H
and HN rats (Table 1). During oral glucose tolerance test, basal
blood glucose concentrations in HN rats were higher than C
rats while it was similar to H rats (Table 1). Area under the
curve was unchanged between the groups (Table 1).
Retroperitoneal, epididymal, and omental fats were higher in
HN rats compared to C rats while they were not different
between H and HN rats (Table 1). Total body fat mass in
HN rats was higher than C rats while it was similar to H rats;
total body lean mass in HN rats was higher than C rats while it
was similar to H rats (Table 1). Plasma total cholesterol con-
centrations were lower in HN rats compared to C and H rats
(Table 1). Plasma triglyceride concentrations were higher in
HN rats compared to C rats while HN and H rats had similar
triglyceride concentrations (Table 1). Plasma non-esterified
fatty acid concentrations were higher in HN rats compared to
C rats while H and HN rats had no differences in plasma
concentrations of non-esterified fatty acids (Table 1). In sum-
mary, replacement of beef tallowwith coconut Nourish caused
no change in body weight while increasing total body lean
mass. Coconut Nourish contains nutrients including protein
and fiber in addition to saturated fatty acids. This high content
of protein may be responsible for the decreases in fat mass to
lean mass ratio [25]. Moreover, the increase in lean mass oc-
curred in the presence of lower energy intake compared to the
obese rats, thus increasing the feed efficiency. Coconut
Nourish is also the source of fiber that may also help in the
improvements seen in these rats.
Cardiovascular and Hepatic Structure and Function with
VCO Virgin coconut oil, a rich source of medium-chain fatty
acids, reduced blood pressure in Spontaneously Hypertensive
Rats and heated palm oil-induced hypertensive rats [26, 27].
Increased nitric oxide productionmay be a possible mechanism
for this decrease in blood pressure [26, 27]. Fructose-induced
hypertension in rodents is well-studied as this model has been
used for intervention trials throughout the world [28, 29].
HV rats showed similar systolic blood pressure to C rats
while it was lower in HV rats compared to H rats (Table 2).
LVIDs was higher while fractional shortening and ejection
fraction were lower in HV rats compared to C rats (Table 2).
HV rats showed similar left ventricular diastolic stiffness to C
rats while stiffness was lower in HV rats compared to H rats
(Table 2). Left ventricular wet weight was similar in C and HV
rats while it was lower in HV rats than H rats (Table 2). HV
rats showed inhibition of infiltration of inflammatory cells
(Fig. 1c) and collagen deposition (Fig. 1g) compared to H rats
(Fig. 1b and f).
Livers from HV rats showed inhibition of infiltration of
inflammatory cells and deposition of fat vacuoles (Fig. 1k)
compared to H rats (Fig. 1j). HV rats had higher liver wet
weight compared to C rats while it was not different compared
to H rats (Table 2). Plasma ALP activity was higher in HV rats
compared to C rats while it was unchanged compared to H rats
(Table 2).
In summary, replacement of beef tallow with VCO as a
source of saturated fatty acids lowered body weight, blood
glucose concentrations, systolic blood pressure, and diastolic
stiffness while improving structure and function of the heart
and liver but without decreasing central obesity. These chang-
es may be correlated to the lower inflammatory cell infiltration
and subsequent collagen deposition in the heart and liver of
virgin coconut oil-supplemented rats.
Previous studies reporting the impact of saturated fatty
acids on human health concluded that lauric andmyristic acids
raised plasma total cholesterol concentrations, with lauric acid
increasing LDL cholesterol and myristic acid increasing both
LDL and HDL cholesterol concentrations [30, 31]. Lauric
acid lowered the ratio of total cholesterol to HDL, while
myristic acid did not change this ratio [32]. The current study
found that total plasma cholesterol concentrations increased
with virgin coconut oil supplementation in rats, although it
cannot be confirmed if the changes were due to increases in
HDL-cholesterol or LDL-cholesterol.
Cardiovascular and Hepatic Structure and Function with
Coconut Nourish HN rats showed similar systolic blood
pressure to C rats while it was lower in HN rats compared to
H rats (Table 2). LVPWd, IVSd, and relative wall thickness
were higher while fractional shortening and ejection fraction
were lower in HN rats compared to C rats (Table 2). LVPWd,
IVSd, and relative wall thickness were higher in HN rats while
ejection time was lower compared to H rats (Table 2). HN rats
showed similar diastolic stiffness to C rats while it was lower
in HN rats compared to H rats (Table 2). Left ventricular wet
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Fig. 1 Effects of coconut products on inflammation and fibrosis in the
heart and inflammation and fat deposition in the liver. Haematoxylin and
eosin staining of left ventricle showing inflammatory cells (‘in’; ×20)
from C (a), H (b), HV (c) and HN (d) rats. Picrosirius red staining of
left ventricle showing fibrosis (‘fi’; ×40) fromC (e), H (f), HV (g) andHN
(h) rats. Haematoxylin and eosin staining of liver showing inflammatory
cells (‘in’) and fat deposition (‘fv’, ×20) from C (i), H (j), HV (k) and HN
(l) rats. C, corn starch diet-fed rats; H, high-carbohydrate, high-fat diet-
fed rats; HV, high-carbohydrate, high-VCO diet-fed rats; HN, high-car-
bohydrate, high-coconut Nourish diet-fed rats
Table 2 Cardiovascular and
hepatic structure and function Variables C H HV HN
Cardiovascular variables
Systolic blood pressure (mmHg) 127 ± 5 149 ± 4a* 133 ± 3b 130 ± 3b
LVIDd (mm) 7.63 ± 0.13 8.31 ± 0.30 7.94 ± 0.21 7.76 ± 0.26
LVPWd (mm) 1.73 ± 0.08 1.79 ± 0.04b 1.89 ± 0.05ab 1.97 ± 0.03a*
LVIDs (mm) 3.41 ± 0.22 4.34 ± 0.34* 4.40 ± 0.22* 4.00 ± 0.23
IVSd (mm) 1.71 ± 0.09 1.77 ± 0.03b 1.86 ± 0.06ab 1.94 ± 0.03a*
Relative wall thickness 0.45 ± 0.02 0.43 ± 0.02b 0.47 ± 0.02ab 0.51 ± 0.02a*
Fractional shortening (%) 55.6 ± 2.4 45.5 ± 3.4* 44.5 ± 1.7* 48.7 ± 1.6*
Ejection fraction (%) 90.5 ± 1.4 85.7 ± 3.0 82.8 ± 1.5* 86.3 ± 1.2*
Ejection time (ms) 83.8 ± 3.6 88.0 ± 2.3a 89.0 ± 1.5a 81.7 ± 2.3b
Left ventricle wet weight (mg/mm) 19.7 ± 0.4 22.3 ± 0.9a* 20.6 ± 0.3b 23.8 ± 1.0a*
Right ventricle wet weight (mg/mm) 4.28 ± 0.18 4.68 ± 0.35ab 3.84 ± 0.23b 5.66 ± 0.73a
Diastolic stiffness constant, κ 25.0 ± 1.7 31.4 ± 1.2a* 25.2 ± 2.3b 26.5 ± 1.0b
Hepatic variables
Liver wet weight (mg/mm tibial length) 205 ± 18 293 ± 13b* 301 ± 8b* 372 ± 21a*
Plasma ALP activity (U/L) 124 ± 15 196 ± 19a* 222 ± 9a* 152 ± 11b
All values are mean ± SEM. * indicates significantly different values compared to C. Means between H, HVand
HN without a common letter are significantly different, P < 0.05. C, corn starch diet-fed rats; H, high-carbohy-
drate, high-fat diet-fed rats; HV, high-carbohydrate, high-VCO diet-fed rats; HN, high-carbohydrate, high-
coconut Nourish diet-fed rats; LVIDd, left ventricular internal diameter during diastole; LVPWd, left ventricular
posterior wall thickness during diastole; LVIDs, left ventricular internal diameter during diastole; IVSd, interven-
tricular septal thickness during diastole; ALP, alkaline phosphatase
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weights were similar in H and HN rats but higher in HN rats
compared to C rats (Table 2). HN rats showed inhibition of
infiltration of inflammatory cells (Fig. 1d) with inhibition of
collagen deposition (Fig. 1h). HN rats showed improved aor-
tic responses to noradrenaline (Supplementary Figure 1A,
−logEC50 values – C = 6.89 ± 0.18; H = 6.42 ± 0.33;
HV = 6.31 ± 0.08; HN = 6.98 ± 0.17) with no change in
thoracic aortic responses to sodium nitroprusside and acetyl-
choline (Supplementary Figure 1B and 1C).
Livers from HN rats showed inhibition of infiltration of
inflammatory cells and decreased deposition of fat vacuoles
(Fig. 1l) compared to H rats (Fig. 1j). HN rats had higher liver
wet weight compared to C and H rats (Table 2). Plasma ALP
activity was similar in C and HN rats while it was lower in HN
rats compared to H rats (Table 2).
Thus, the physiological and metabolic changes with coco-
nut Nourish were accompanied by the prevention of increases
in systolic blood pressure and diastolic stiffness while improv-
ing structure and function of the heart and liver, but also by
increased plasma triglyceride and non-esterified fatty acids
concentrations with lowered plasma total cholesterol concen-
trations. Similar to virgin coconut oil, coconut Nourish was
able to normalize the systolic blood pressure and left ventric-
ular diastolic stiffness. While these changes were similar, co-
conut Nourish was also able to lower total cholesterol concen-
trations. This reduction may be attributed to the fiber content
of the coconut Nourish as shown in previous study with die-
tary fiber reducing blood pressure and total cholesterol [33].
Coconuts are known for their great versatility for commu-
nities in the tropical and subtropical areas of the world.
Coconut or coconut products as part of the regular diet along
with seafood decreased cardiovascular disease risk factors in
Samoan Islanders, including higher HDL-cholesterol concen-
trations and lower abdominal circumferences [34]. Similar
observations were seen in the Kitava population when com-
pared with the Swedish population. The regular diet of Kitava
people includes tubers, coconuts, and seafood and this Kitava
population is free from overweight, hypertension, cardiovas-
cular disease, and malnutrition [35]. It is important that the
extent of health benefits with coconut and coconut products is
explored further to establish the role of coconut as a functional
food. These results can then form the basis for controlled
human trials to identify translatable responses of coconuts.
Conclusions
Both virgin coconut oil and coconut Nourish contain high
amounts of lauric and myristic acids while coconut Nourish
also contains increased fiber and protein. When beef tallow
was replaced with virgin coconut oil or coconut Nourish in a
high-carbohydrate, high-fat diet, the increases in systolic
blood pressure and diastolic stiffness in the heart were
inhibited. Moreover, the coconut Nourish increased the lean
mass in rats even with decreased energy intake. Virgin coco-
nut oil reduced the fasting blood glucose concentrations while
Nourish was able to reduce the total cholesterol concentrations
in plasma. Both the virgin coconut oil- and Nourish-
supplemented diets were rich in fructose and sucrose content,
so these results are quite relevant to overweight and obese
individuals who consume diets rich in simple sugars.
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 – Conclusions and future directions 
 
6.1 Conclusions 
Obesity, hypertension, dyslipidaemia, hyperglycaemia and insulin resistance together 
are termed metabolic syndrome (as discussed in Chapter 1). This combination of 
metabolic abnormalities increases the risk of cardiovascular disease and type 2 
diabetes and contributes to increased mortality and morbidity (O'Neill and O'Driscoll, 
2015). An unhealthy lifestyle including an unhealthy diet and decreased physical 
activity are strong determinants of the increasing obesity epidemic in Australia. 
Promoting healthy lifestyles through diet, nutrition and exercise will decrease the 
burden of these metabolic diseases. A healthy diet with the addition of functional foods 
gives health benefits and improves disease-related biomarkers. Therefore, research is 
warranted in evaluating functional foods using appropriate animal models prior to 
translation to human clinical trials.  
Research into dietary interventions that can improve metabolic syndrome markers 
requires a well-established and well-designed animal model that mimics the human 
condition to provide a better understanding of physiology, biochemistry and 
pathogenesis of disease. This study used a model of diet-induced metabolic syndrome 
and cardiovascular complications. Young male Wistar rats were fed a high 
carbohydrate (simple sugars), high saturated/trans-fat diet for sixteen weeks 
developing abdominal obesity, hypertension, dyslipidaemia, impaired glucose 
tolerance, cardiovascular complications and liver steatosis (Panchal et al., 2011b). This 
diet-induced rat model of metabolic syndrome was used to determine the physiological 
effects of wholegrain oats (Chapters 3 and 4), oat bran (Chapter 3), oat β-glucan 
powder (Chapter 3), virgin coconut oil and coconut Nourish (Chapter 5).  
Traditional food products that have been consumed for thousands of years were 
examined in relation to their impact on metabolic syndrome. Through this focus on 
foods that have been in the human diet for a long time, it may be possible for the health 
benefits gained from them to be incorporated easily into daily consumption without 
the need for drastic changes to dietary intake. Wholegrain oats, oat bran, oat β-glucan, 
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virgin coconut oil and coconut nourish were investigated and indicated that they were 
beneficial in the attenuation of metabolic syndrome.  
Oats are widely grown in Northern Europe and Canada and have been consumed for 
over 5000 years (Ladizinsky, 1995, Akeret, 2005, Mariotti Lippi et al., 2015). The 
benefits of adding oats to the diet have been known for many years. Oat β-glucans 
improve cholesterol and glucose tolerance. The study in Chapter 3 compared 
wholegrain oat groats, oat bran and oat β-glucan powder added to a high carbohydrate, 
high fat diet to determine whether they gave similar physiological responses or if the 
increased processing changed the response given. The study indicated that each of the 
oat products improved glucose tolerance as well as blood pressure, liver structure and 
duodenal morphology. As responses were similar for the three interventions given it 
is concluded that nutritional components in the oats may be working synergistically 
and therefore consumption of wholegrain oats in the diet is preferred. The relatively 
low dose of oat product in the diet could have contributed to the limited changes in the 
remainder of the gastrointestinal tract.  
The overall nutrient content of wholegrains with β-glucans, avenanthramides, oat 
lipids as well as a wide range of amino acids makes oats a viable replacement for other 
cereals in the diet. As oats do not contain gluten or α-gliadin that makes wheat, barley 
and rye toxic to coeliac disease patients, the addition of oats to the diet is possible for 
these patients. Further testing needs to be undertaken with the avenin content as some 
coeliac disease patients may also be sensitive to this compound. Chapter 4 of this thesis 
determined that it is possible that oats could make a viable replacement as the 
biomarkers for metabolic syndrome were improved. It also gave indications that oats 
would be a viable nutritional source when protein is lacking in the diet to increase body 
weight, improve heart function and structure and liver function and structure. 
Increasing oat intake in the diet would be simple for the average person as it would 
require either substituting oats for other cereal grains or adding oats to the diet. There 
are many products available, such as breads, porridge, food bars, oat milk and 
breakfast cereals which come as wholegrains or bran, as well as β-glucan supplements 
that come as powders to add to drinks. Therefore, the wide variety of oat products 
available for consumption would enable people to make a healthy choice in their diet. 
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This study also looked at coconuts as another traditional food source from South East 
Asia and the Pacific Islands. Coconuts have a variety of health benefits, such as 
treatment of diabetes, asthma, dermatitis as well as having antibacterial and 
antidepressant responses (Babu et al., 2014, Marina et al., 2009a). Coconut oil contains 
saturated fatty acids, mainly myristic and lauric acids, with cardiovascular and 
metabolic responses unclear. In Chapter 5 of this thesis, virgin coconut oil and a high 
fibre coconut Nourish were examined for their health benefits. Both virgin coconut oil 
and coconut Nourish improved cardiovascular and liver structure and function. 
Coconut Nourish increased body lean mass, and virgin coconut oil decreased body 
weight. These changes lead to improved heart health and metabolic syndrome 
parameters.  
The addition of both oat and coconut products to the diet gave beneficial cardio-
metabolic effects in this rat model of metabolic syndrome. They are easily available 
sources of fibre, protein, fats, carbohydrates and micronutrients that can be included 
in the human diet as functional foods conferring health benefits. This thesis has 
achieved the aims set in Chapter 1, where the effects of oats and coconut on cardio-
metabolic health and on gut structure and function were hypothesised. 
The hypotheses of this study were that various oat products (wholegrain oat groats, oat 
bran and β-glucan powder) would induce metabolic changes and alter gastrointestinal 
structure and function when added to a high carbohydrate, high fat diet and that oats 
could be a viable alternative to other grains in the diet. Another hypothesis was that 
virgin coconut oil and coconut Nourish would also induce cardiometabolic changes 
when substituted into a high carbohydrate high fat diet.  
The first hypothesis is proven that oats in the form of wholegrain oat groats, oat bran 
and β-glucan powder induces metabolic changes and improves gastrointestinal 
structure and function.  However, the second part of the hypothesis that changes would 
be greater with more processing is disproven as no greater changes were observed with 
the increased processing. The second hypothesis is proven as wholegrain oat groats 
induced metabolic changes and altered gastrointestinal structure and function when 
added to a high carbohydrate, high fat diet. The third hypothesis is proven with virgin 
coconut oil and coconut Nourish improving cardio-metabolic function when added to 
a high carbohydrate, high fat diet in rats.   
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6.2 Limitations and future directions 
There are clear indications that oat products in the form of wholegrain oats, oat bran 
and β-glucan powder and coconut products in the form of virgin coconut oil and 
coconut Nourish improved most of the markers of metabolic syndrome in a rat model. 
However, the mechanisms of action of these foods remains unclear and the bioactive 
compounds remain to be clarified. While β-glucans are an important bioactive 
component, further studies need to determine how they work synergistically with other 
compounds to produce the improvements.  
Clinical trials using a variety of oat products and bioactive compounds would be 
beneficial to determine how they attenuate metabolic syndrome and to establish the 
relative benefits of whole foods vs extracts. It is currently suggested that 3 g/day of 
β-glucan is beneficial for lowering cholesterol (Shen et al., 2016) or 10 – 25 g/day fibre 
intake (National Health and Medical Research Council, 2013b) so these reports could 
be a good starting point for determining dosages. Individual bioactive compound 
dosages would need to be determined and this could possibly be done by starting with 
the wholegrain oat groat containing all compounds and gradually increase the 
processing until individual bioactive components are studied. This would need to be a 
long-term study over 12 - 24 months with washout periods between each intervention. 
However, compliance may be an issue if taste and texture of the food matrix is 
unpleasant for each participant.  
Limited morphological changes were found due to the structure of the rat 
gastrointestinal tract. While a rat model may be useful to examine the interaction of 
wholegrain oat, oat bran and β-glucans with the intestinal morphology and function, 
anatomical differences are important to note when translating to human studies.  While 
clinical trials can inform metabolic syndrome attenuation for gastrointestinal 
morphological examination, invasive techniques, such as endoscopy would need to be 
used to resect tissue samples from the gastrointestinal tract for morphological 
examination more than once throughout the study. Other options within a clinical trial 
setting could indirectly measure morphological changes by examining other markers 
of gastrointestinal health through blood and plasma samples for inflammatory markers, 
stool samples or intestinal permeability with urine samples. It may be possible to 
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develop in vitro and ex vivo techniques using cell culture to grow “mini-guts” or 
enteroids / colonoids (In et al., 2016), human organs on chips (Ingber, 2016, Kim and 
Ingber, 2013) or artificial guts (Van den Abbeele et al., 2013b, Barroso et al., 2015) to 
determine the changes to human gastrointestinal morphology.  
The investigations in this thesis raised further topics as valid targets for research. 
These topics include:  
• Further refinement of the modified high carbohydrate, high fat diet rat model of 
metabolic syndrome.  
As the modified diet was run as a pilot study, it is necessary to further refine it so that 
in future studies the healthy control is improved and not causing cardiovascular and 
liver issues. It is expected that by increasing the protein content in this diet that those 
issues could be alleviated. 
This diet could also be promoted as a protein-deficient, carbohydrate-loaded diet, as 
found in developing nations, this imbalance could be reversed with dietary 
interventions. 
 
• Investigation of other bioactive compounds found in oats, such as 
avenanthramides, avenins and arabinoxylans. 
The study of other bioactive compounds found it oats would enable a clearer picture 
of how the addition of oats to the diet attenuates metabolic syndrome biomarkers and 
whether the compounds work individually or synergistically. It would be expected that 
each of the compounds improves biomarkers, such as avenanthramides improving 
vasodilation for cardiovascular function. Arabinoxylans may have prebiotic effects in 
the gastrointestinal tract and they may improve glucose metabolism. A study on avenin 
is important due to gastrointestinal sensitivities in some coeliac disease patients, so 
that morphological studies would confirm or repudiate previous findings on the impact 
of avenin in the gastrointestinal tract.  
 
• Investigation of various molecular weight oat β-glucan products.  
Molecular weight plays an important role in the health benefits of β-glucans, therefore 
this study is important in examining low molecular weight β-glucans which would be 
expected to give limited changes compared to high molecular weight β-glucans which 
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would improve cardiovascular and metabolic markers, such as BMI, abdominal 
circumference, blood pressure and triglycerides. It would also be expected that the 
higher molecular weight β-glucans would lead to beneficial microbial changes in the 
gut. 
 
• Determining the molecular mechanisms for oat products to improve glucose and 
lipid metabolism and reduce inflammation.  
By understanding the molecular mechanisms that lead to oats improving glucose and 
lipid metabolism as well as those that reduce inflammation, the diet can then be 
targeted to improve those specific molecules. It would be expected that tight junction 
proteins, such as occludin and claudin, increase to improve intestinal permeability. 
Increases in MUC2 to improve the mucus layer of the gastrointestinal tract and 
increased gut hormone production of CCK, PYY and GLP-1 to improve satiety, 
decrease food intake, improve glucose and lipid metabolism would also be expected.  
 
• Quantifying the effects of oat products on the diversity of gut microbiota. 
As oats contain prebiotic compounds, it would be expected that increases in 
Bacteroides and decreases in Firmicutes would be found. By investigating various oat 
products, this quantification of microbial diversity could lead to more personalised 
dietary understanding. 
 
• Extending the fatty acid analysis to include caecal and plasma concentrations in 
the obese rat model used in the studies described in this thesis.  
Short chain fatty acids are recognised as a key process in gut and systemic health, 
Investigating the fatty acids found in the caecum and plasma it gives a more complete 
picture of what is occurring. Fermentation occurs in the caecum therefore it would be 
expected that higher concentrations of acetate, propionate and butyrate would be found 
compared to the faecal samples. Examination of the plasma concentrations would give 
an indication of how long the SCFA remain in the blood stream to be used. It would 
be expected that, with a single dose of oat, limited concentrations would remain. 
However, if consumed regularly, sustained concentrations should remain. 
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• Elucidating the effects of oat products on mucin production as the basis for the 
functional improvement of the gastrointestinal tract. 
MUC2 produces the mucus layer in the gastrointestinal tract, which prevents host-
pathogen interactions. It is expected that increased MUC2 would be produced leading 
to an increased mucus layer and improvements to the epithelial cell layer and tight 
junctions preventing ‘leaky gut’. 
 
• Investigate other cereals such as barley, spelt and rye, that could have similar 
bioactive compounds to oats. 
By investigating other cereals that have similar bioactive compounds, it is expected 
that similar results to the current study would be achieved. However, due to 
individual variety between cereals such as viscosity, molecular weight, 
fermentability and botanical structure, different metabolic responses could be 
measured. Another study could be undertaken that adds a number of different cereals 
to the diet to investigate the interactions between them.  
 
• The development of varieties of oats high in specific bioactive compounds to 
improve the availability of the active components. 
This would be an interesting study to undertake. However, it is outside the scope of 
this current research, as these varieties may not yet exist, but could be performed in 
collaboration with research groups studying crop health. 
 
These studies will provide novel insights in the knowledge gap and give a better 
understanding of the molecular mechanisms that will strengthen the results from the 
studies compiled in this thesis. As improving nutrition becomes a tool in individualised 
health plans, a better understanding of the functionality of foods such as oats and 
coconut will allow cost-effective ways to manage metabolic syndrome. 
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